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SUMMARY.
The inositol-lipid system has not been extensively 
characterised in insect central nervous system. Such 
systems with their multiple sequential enzyme cascades 
offer the potential of a number of key modulatory sites at 
which exogenous agents could act to disrupt the system.
The results presented here show that 
phosphatidylinositol metabolism in locust (Schistocerca 
gregaria) ganglia is affected by treatment with muscarinic 
agonists. Incorporation of [3H]-inositol and [3 2P]-Pi into 
the phospholipids and into the acid soluble products of 
the inositol-lipid pathway was used to examine these 
effects. To show carbachol stimulation of 
phosphatidylinositol turnover, by measuring the 
accumulation of [3H]-inositol phosphates, required a
preincubation period and the presence of calcium, lithium
, , , . . ,
and [ H]-inositol in the incubation buffer. Atropine
inhibited this effect, suggesting that these muscarinic 
like receptors are coupled to the activation of 
phospholipase C. The phosphatidylinositol pool could be 
highly labelled with [3H]-inositol. It was found that 
there is a dose dependent breakdown of [ H]- 
phosphatidylinositol to give [3H]-inositol phosphates in 
the presence of carbachol and pilocarpine. H.p.l.c. 
analysis of the inositol phosphates showed the presence of 
at least two isomers of inositol trisphosphates: inositol
1,3,4-trisphosphate, which predominated, and inositol
1,4,5-trisphosphate.
Phosphorylation of phosphatidylinositol,
phosphatidylinositol phosphate and diacylglycerol resulted 
in the rapid incorporation of [32P]-Pi into 
phosphatidylinositol phosphate, phosphatidylinositol 4,5- 
bisphosphate and phosphatidic acid. Stimulation of 
phospholipase C activity in the presence of carbachol 
increased the rate of phosphatidic acid labelling and 
decreased the amount of label associated with the
polyphosphoinositides. This being consistent with the
, , , , •> , , 
production of inositol phosphates, seen m  [ H]-inositol
labelling experiments, and diacylglycerol from the
cleavage of polyphosphoinositides.
The muscarinic-like receptors in the locust ganglia 
were more fully characterised by inhibiting the binding of 
[3H]-quinuclidinyl benzilate using various muscarinic 
agonists and antagonists. [3H]-QNB bound to at least two 
classes of binding sites. The most potent of the 
muscarinic selective ligands for the [3H]-QNB labelled 
sites was 4-DAMP, an M3 selective muscarinic antagonist, 
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Although at least five million chemicals have been 
tested for useful effects on various pest species, only a 
few target sites have emerged to be of practical and 
economic value. Neuroactive insecticides provide the most 
reliable, effective and economic solutions to insect pest 
problems and account for upto 90% of the insect control 
market. The cholinergic system in insects has been and 
still is a major target site for pesticides. This is not 
altogether surprising as acetylcholine is the major 
excitatory transmitter in insect CNS; its concentration 
ranges from 7.6 nmol/mg protein in housefly brain to 50 
nmol/mg protein in locust thoracic ganglion (Clarke and 
Donnellan, 1982). Some elements of the cholinergic system 
have been well characterised and are known to be important 
targets for pesticide action, thus the nicotinic receptor 
is a target site for the nitromethylenes and cartap 
(Eldefrawi et al., 1982; Satelle, 1985) and the enzyme
acetylcholinesterase has long been known to be the site of 
action of the organophosphates and carbamates. Problems 
such as multiresistance and insecticide effects on non­
target organisms require the development of new more 
selective target sites. Muscarinic-like receptors have 
been demonstrated to be present in the insect CNS (Knipper 
and Breer, 1988; Knipper and Breer, 1989) but their 
potential as an insecticide target site has not been 
exploited to date. The insect muscarinic receptor, like 
its mammalian counterpart appears to be a member of the G-
2protein coupled, second messenger class of receptors. 
Such systems with their multiple sequential enzyme
cascades offer the potential of a number of key modulatory 
sites at which exogenous agents could act to perturb the 
system.
1.2). THE CNS OF THE LOCUST.
In insect embryos the body is segmented and each
segment contains a bilaterally symmetrical ganglion. These 
ganglia fuse, to some degree, during development to form
the central nervous system (CNS). The most anterior
ganglion in the insect after hatching is the
supraoesophageal ganglion (also known as the cerebral 
ganglion or brain), it includes ganglia fused together 
with the primitive, presegmental archecerebrum. The 
suboesophageal ganglion is connected, via the 
circumoesophageal connectives, either side of the 
oesophagus, to the brain. This ganglion is the first 
ganglion in the ventral nerve cord. The chain of ganglia, 
running the length of the body are linked to each other 
longitudinally by connectives made up only of axons and 
supporting cells, while extending from each ganglion to 
the peripheral sense organs and effectors are the
peripheral nerves (fig. 1).
The ganglia all have the same general structure. The
mass is surrounded by an acellular structure called the
neural lammella over a cellular layer, the perineurium..
3Under the perineurium are found the cell bodies of the 
neurones, supported by glial cells. The neuropile, a 
complex of axons and dendrites which is where all synapses 
are thought to occur, occupies the centre of the ganglion. 
In insects the axons are not myelinated and there are few 
glia in the neuropile. This localisation of function and 
the lack of axo-somatic synapses is in contrast with the 
vertebrates where cell bodies recieve many synaptic 
connections.
Structurally the supraoesophageal ganglion is 
composed of three parts, the protocerebrum, deutocerebrum 
and the tritocerebrum. The protocerebrum is the largest 
structure, and may be the seat of behavioural organisation 
(Chapman, 1982). The deutocerebrum contains the antennal 
lobes, containing the the cell bodies of the sensory 
neurones, and the tritocerebrum is the point of origin for 
the connectives to the suboesophageal and frontal ganglia 
(fig. 2 ).
4Figure 1.































61.3). THE MUSCARINIC RECEPTOR.
Cells in a multicellular organism need to be able to 
communicate, so that each cell population can call on the 
services of others, and respond to their requirements. This 
coordination is achieved by chemical signals. The central 
nervous system consists of highly specialised cells which 
can rapidly receive and respond to internal and external 
stimuli. Communication is achieved by propagation of 
electrical impulses along membranes of axons, which are 
elongated processes arising from cell bodies. Where nerve 
cells impinge on one another a synapse is formed. In 
cholinergic synapses , acetylcholine (ACh) is the chemical 
transmitter that is released from the synaptic terminal. 
Acetylcholine receptors (AChR), present on the post-synaptic 
membrane, receive the ACh. Binding of the ligand activates 
receptors which can open channels to allow potassium, sodium 
or calcium ions to pass through, or activate G-proteins. 
Existence of two superfamilies of receptors is confirmed 
from the genetic sequences of the ligand gated ion channels 
(nAChR, GABA, glutamate, 5-HT3 ) and the metabotropic 
receptors (mAChR, adrenergic receptors). Acetylcholine can 
activate receptors belonging to both superfamilies, but the 
receptors can be pharmacologically distinguished by the 
action of nicotine and muscarine. The nicotinic 
acetylcholine receptors open cation channels to cause 
excitatory post-synaptic potentials, whilst the muscarinic
7receptors via second messengers (cyclic GMP, cyclic AMP, 
inositol lipid pathway) activate protein kinases.
In mammals muscarinic receptors are found in all the 
effector cells stimulated by the postganglionic neurons of 
the parasympathetic nervous system, as well as those 
stimulated by the postganglionic cholinergic neurones of the 
sympathetic system (sweat glands, arterioles of the muscle), 
and also in the CNS (see Hoss and Ellis, 1985 for review) . 
Muscarinic receptors can also be found on the presynaptic 
membrane. These receptors can alter the reactivity of the 
synapse to incoming signals, and hence are called synaptic 
modulators. One mechanism by which transmitter release can 
be modulated is by the level of calcium in the presynaptic 
terminal, which can activate calcium dependent potassium 
channels to hyperpolarise the presynaptic membrane. This can 
be mimicked by a second messenger in the inositol lipid 
pathway, inositol trisphosphate (Higashida and Brown, 1986). 
Thus, presynaptic activation of muscarinic receptors may 
regulate calcium levels through the production of second 
messengers, and hence the membrane resting potential. 
Hyperpolarisation would increase, and a depolarisation would 
decrease neurotransmitter release on arrival of an action 
potential at the presynaptic membrane.
1.3.1). MUSCARINIC ANTAGONIST BINDING.
The extensive distribution of muscarinic receptors in 
the central nervous system of mammals led to the attempt to 
pharmacologically characterise these receptors. Development
of high specific activity, high affinity radioligands such
■» . . .  . as [JH]-quinuclidinylbenzilate (Yamamura and Snyder, 1974
a,b) and N-methylscopolamine for use in binding assays
resulted in the discovery of the complexity of the
muscarinic receptor system.
Earlier studies on the binding of antagonists suggested 
that the muscarinic receptor populations in different 
tissues were homogenous (Hulme et al., 1978). Binding 
capacities of various muscarinic [3H] antagonists; [3H]-QNB, 
[3H]-NMS, [3H] N-Methyl Atropine, [3H]-PrBch, in the rat
cerebral cortex (Hulme et al, 1978) was shown to be equal. 
In competition experiments with [3H]PrBch (N-(2,3 [3H2 ]
propyl) N, N-dimethyl-2-aminoethyl benzilate, a reversible 
muscarinic antagonist) , the Hill coefficients of all the 
antagonists tested were found to be close to unity, 
suggesting the reactions followed mass action principles at 
equilibrium.
The first real indication that there were subtypes of 
muscarinic receptors (table 1 ) came from competition studies 
against [3H]-NMS using a novel antagonist, pirenzepine 
(Hammer et al., 1980), which showed selectivity for the 
receptors in the cortex. These were termed muscarinic
9receptors. As well as binding selectivity, pirenzepine 
exhibited functional selectivity (Hammer and Giachetti,
1982) in blocking responses at the atria and the sympathetic 
ganglia. Use of [3H]-pirenzepine has shown high affinity 
binding in the rat cerebral cortex (Watson et al., 1982), 
whilst only a few [3H] -pirenzepine binding sites were 
demonstrated in cerebellar and heart homogenates. These high 
affinity binding sites for pirenzepine have been shown to be 
a subset of the available receptor binding sites as 
determined by [3H]-QNB (Watson et al., 1986). An analogue 
of pirenzepine, AFDX116, has been shown to have higher 
affinity for receptors in the heart, thought to be 
predominantly of the M2 subtype (Hammer et al., 1986). Other 
M2 selective antagonists such as the polymethylene 
tetramines (Melchiorre, 1988) can distinguish between' the 
glandular and cardiac types of muscarinic receptors. The 
glandular type of muscarinic receptors are termed M3 . 4-DAMP 
and hexahydrosiladifenidol have been shown to be selective 
for the M3 subtype (Waelbroeck et al, 1989). More recently, 
tritiated analogues of pirenzepine have been developed which 
show better selection for the muscarinic subtypes. These 
being telenzepine (Eveleigh et al., 1989) which has higher 
affinity for the M3 receptor than pirenzepine, and AFDX384 
which shows higher affinity for the M2 than the M3 
muscarinic receptor (Entzeroth and Mayer, 1990).
Heterogeneity of muscarinic binding sites can also be
10
demonstrated by kinetic studies using [3H]-NMS binding to 
rat CNS (Waelbroeck et al., 1986). First order dissociation 
kinetics of [3H]-NMS from striatum, cortex, hippocampus, 
cerebellum and heart differed markedly both in the extent of 
deviation from linearity and magnitude. These results 
suggested the existence of at least three classes of 
muscarinic receptors; type A having high affinity for 
pirenzepine and high affinity for NMS, type B having low 
affinity for pirenzepine and high affinity for NMS and type 
C having low affinity for both pirenzepine and NMS. A and B 
receptors were found in the hippocampus, cortex and 
striatum, whilst C receptors were localised in the heart. 
The deviations from linearity of the first order 
dissociation rate kinetics in the cerebral cortex were 
explained by the presence of at least three classes of 
receptors. This was postulated from the observation that 
[3H]-NMS dissociation was occupancy dependent. In these 
studies the proportion of rapidly dissociating receptors 
increased with receptor occupancy. Furthermore, the affinity 
of the unlabeled ligand, pirenzepine, for each receptor 
class could be deduced, from competition assays, by allowing 
the tracer to dissociate from the most rapidly dissociating 
receptors. The nature of selectivity of antagonists to 
various muscarinic receptors has not been conclusively 
demonstrated. This is due to small differences in antagonist 
affinity for each receptor subtype (10 fold selectivity = 
1.4Kcal/mole = Van der Waals energy for one methyl group)
11
(Hulme et al., 1990).
However, some experimental evidence is provided by the 
studies of Kubo et al, (1988). Chimaeric receptors made from 
transmembrane regions 1-5 of the ml receptor and 
transmembrane regions 6-7 of m2 expressed in Xenopus 
oocytes, showed that TM6-7 contributes to ml selectivity, 
whilst m2 selectivity resided in TM1-5.
Birdsall et al. (1989) have shown that the binding of 
antagonists can be inhibited by the protonation of groups in 
free receptors with pK*s in the range of 5.5-6.8 . Binding of 
non-selective antagonists to rat cardiac receptors can be 
inhibited at pK values 5.5-6.1. However, inhibition of 
binding of an m2 selective antagonist, AFDX116, requires the 
protonation of an ionizable group which has a pK of 6 .5-6.8 . 
Thus ligands may have a choice of negatively charged 
residues with which to interact. An interesting finding was 
that methoctramine, a cardiac selective antagonist, could 
bind simultaneously to two ionisable groups which can be 
allosterically regulated by yet another titratable group 
with a pK of approximately 7.5.
Binding of [3H]-atropine and [3H]-4NMPB (N-methyl-4- 
piperidyl benzilate) to different regions of the mouse brain 
(Kloog et al., 1979) indicated interaction of the ligand 
with a homogenous population of binding sites in each
12
region. There were small but consistent differences between 
the affinity constants in various regions. However, large 
differences in the kinetics of association and dissociation 
were demonstrated between the five regions of the brain 
investigated. The apparent half times of dissociation of 
[3H]-4NMPB from the binding sites in the cerebellum and 
medulla were 3 to 4 times faster than from the hippocampus, 
caudate and cortex. Determination of the association rate 
constants at different [3H]-NMPB concentrations showed 
biphasic behaviour at low ligand concentrations. This was 
indicative of receptor isomerisation. A binding mechanism 
involving receptor isomerisation was also suggested from the 
binding of 3-quinuclidinyl benzilate and N-methyl-4- 
piperidinyl benzilate to rat smooth muscle membranes from 
the small intestine (Jarv et al., 1979). Equilibrium studies 
showed binding to a single high affinity binding site, while 
the pseudo-first order rate constant of association showed a 
hyperbolic dependence on the concentration of antagonist.
Further complexities in the binding of muscarinic 
antagonists have been demonstrated by detailed analysis of 
the effects of a competing ligand, whose binding pattern is 
known, on the binding pattern of the primary labeled ligand. 
Such detailed kinetic analyses have been used to identify 
negative cooperativity in the rat adenohypophysis, to which 
the binding of antagonists ((-) 3QNB, 4NMPB, NMS) yields 
curvilinear Scatchard plots (Henis and Sokolovsky, 1983). On
13
the assumption that these antagonists bind to two sites, the 
affinity constants of the high and low affinity sites can be 
determined. From this, the effect of a constant
concentration of the unlabeled ligand on the binding pattern 
of the primary labeled ligand can be calculated for site 
heterogeneity without interactions. The inhibition of the 
binding of the primary ligand by the competing ligand showed 
significant deviations from that expected assuming
heterogeneity, suggesting site-site interactions. The 
presence of multiple allosteric regulatory sites associated 
with the muscarinic receptor has been postulated from the 
actions of gallamine, which has nicotinic blocking
properties, on the dissociation kinetics of [3H]-N- 
methylscopolamine (NMS) (Stockton et al., 1983) and [3H]- 
quinuclidinyl benzilate (QNB) (Ellis and Siedenberg, 1989). 
Both association and dissociation of [3H]-NMS showed a rapid 
then a slower phase of binding, and gallamine decreased the 
rates of these phases. The extent of decrease was greater 
for association than for dissociation. Gallamine had a 
biphasic effect on the dissociation of [3H]-QNB. At low 
concentrations (0.1/xM to lOO^M) , the dissociation rate of 
[ H]-QNB was accelerated. This effect was most pronounced in 
the rat cardiac membranes. Above 100/zM gallamine the 
disssociation rate was decelerated.
1.3.2) . MUSCARINIC AGONIST BINDING.
The diversity of muscarinic subtypes has come from 
antagonist binding. The agonist binding properties of 
muscarinic receptors have not turned out to be simple. 
Complications arose from the fact that agonist binding is 
mirrored by function.
Agonist binding on crude synaptosomal fractions from 
rat cerebral cortex (Birdsall et al., 1978) was found to 
deviate significantly from that predicted for a simple 1:1 
interaction with a uniform population of sites. Hill plots 
of [3H]-antagonist/agonist competition curves were found to 
be less than one suggesting binding site heterogeneity, 
negative cooperativity or receptor desensitisation. Exposure 
of membrane preparations to carbachol for up to 1000 sec did 
not result in any change in the inhibition of [3H]-PrBCh 
binding by carbachol. This suggested that the receptor did 
not desensitise.
The possibility that there were negatively cooperating 
sites was investigated by irreversibly blocking some of the 
receptors using propylbenzilylcholine mustard (PrBCM), and 
then competing [3H]-PrBCh with carbachol. This was based on 
the supposition that the receptors are organised as dimers, 
therefore by randomly alkylating a high proportion of the 
receptors the associations would be disrupted. The agonist 
inhibition curve would then be indistinguishable from a mass 
action curve. This was not found to be the case. Thus, the
15
low Hill coefficients of the agonists used (carbachol 0.33, 
acetylcholine 0.45, oxotremorine-M 0.25) suggested 
heterogeneity of binding sites. Also, by analysing the 
gradient of the occupying curve assessed by the inhibition 
of the specific binding of [3H]-PrBCh three sites were seen; 
super high (SH), high (H), low (L) (Birdsall and Hulme, 
1983). From the binding of [3H] labelled agonists such as 
[3H]-oxo-M the proportions of these sites were determined 
(Birdsall et al., 1980). Examination of the character of 
muscarinic receptors in the different areas of the rat brain 
has shown the binding curves for the agonists to be 
different, whilst the binding curves for the antagonists 
were shown to be similar. These differences in agonist 
binding were attributed to the different abundances of the 
three receptor subtypes distinguished by agonists. The 
binding parameters of the super high state were determined 
by the use of [3H]-oxotremorine-M, which almost exclusively 
binds to the highest affinity states. There was only a small 
variation in the absolute concentration of the SH sites 
between the six brain regions, whereas there were major 
differences in the absolute abundance of the low affinity 
states.
Comparisons of carbachol-stimulated turnover of 
phosphatidylinositol to the occupancy curve for carbachol, 
inferred from competition versus [3H]-NMS (Hoss and Ellis, 
1985), suggested that the phosphatidylinositol response of
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the rat brain slices may be associated with a single 
population of muscarinic receptors. Analysis of the binding 
data showed the presence of at least two sites, while the 
dose response curve was based on a one site model (EC50 = 
37/xM). This single site for activation had an affinity 
between the values for the high and low affinity binding 
sites, and was tentatively postulated to be related to the H 
site of the three site fit of Birdsall et al., (1980).
Agonist binding properties can be modulated by divalent 
ions and nucleotides. In the presence of GTP and magnesium 
ions the IC50 for carbachol, in competition experiments 
against [3H]-NMS, is increased and most of the binding sites 
are converted to the low affinity type. The effect of 
magnesium ions alone was to decrease the IC50 by converting 
high affinity sites to super high affinity sites (Birdsall 
et al, 1984). Divalent ions are thought to promote receptor 
G-protein coupling in the absence of GTP, in which the 
receptor attains a very high affinity state. When GTP is 
present, the coupling is disrupted and the G-protein 
activated. Micromolar concentrations of Gpp(NH)p, a stable 
analogue of GTP, will not reduce the affinity of agonist 
binding unless there are super high and high affinity sites 
present, and there is a sufficiently high concentration of 
magnesium ions to allow nucleotide binding (Hulme et al,
1983). Some studies have shown that populations of binding 
sites can be locked into the super high affinity state and
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cannot be affected by the addition of magnesium ions; and GTP 
(Hulme et al, 1983; Gillard et al, 1987).
1.3.3). MUSCARINIC RECEPTOR GENES.
Molecular cloning studies have led to the 
identification of at least five muscarinic receptor clones 
(table 1). Screening of cDNA libraries from porcine cerebral 
and cardiac tissues with oligonucleotide probes, based upon 
the the partial amino acid sequences from purified 
receptors, led to the discovery of the ml (cerebral) and m2 
(heart) receptors (Kubo et al., 1986a and b) . A different 
strategy led to the identification of the next two 
muscarinic receptor clones (m3 and m4). A region of sequence 
homology between the rat ml receptor and the hamster 82 
adrenergic receptor was used to construct the 
oligonucleotide, and was used to screen the rat cortex cDNA 
library (Bonner et al., 1987) to identify m3 and m4. As all 
these four clones lacked introns, screening of the genomic 
library led to the cloning and sequencing of the fifth 
receptor m5 (Bonner et al., 1988).
The presence of muscarinic receptors in insects has 
also been established from molecular cloning studies 
(Shapiro et al., 1988; Onai et al., 1989). Genomic and cDNA 
clones encoding a muscarinic receptor was isolated from 
Drosophila melanogaster in both studies. The receptor
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displayed greater than 60% homology with the mammalian 
muscarinic receptors. High level of identity to the ml, m3, 
and m5 sub-types in the membrane proximal portions of the 
third cytoplasmic loop was shown (Shapiro et a l . ,  1989). 
Expression of the receptor into mouse Y1 adrenal cells, 
showed that it could stimulate phospholipase C activity. 
Thus, this gene was structurally and functionally most 
similar to the mammalian ml, m3, m5 subtypes. The insect 
receptor contains a longer intracellular loop between 
putative transmembrane segments V and VI. It has also been 
found that the locust muscarinic receptor is more 
susceptible to the action of disulphide reducing agents and 
arsenicals (Fonseca et a l . ,  1991). This could arise from 
weaker hydrophobic interactions between the transmembrane 
segments III and IV, which are thought to contain the 
residues involved in ligand binding. The receptor cloned 
from Drosophila melanogaster was found to be less 
hydrophobic in transmembrane region IV than the mammalian 
receptor. Assuming this is found to be the case in the 
locust, it could explain the differences observed in thermal 
stability and sensitivity to the action of reducing agents 
by Fonseca et a l .  (1991).
These muscarinic clones can be stably transfected into 
the Chinese hamster ovary cell line (CHO-K1). Thus, the 
characteristics of pure receptor subtypes can be assessed 
(Buckley et al., 1989). Pharmacological characterisation
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using pirenzepine, methoctramine, AFDX116, hexocyclium and 
silahexocyclium showed that the binding profiles derived 
from displacement curves against competitions with [3H]-NMS, 
of ml, m2 and m3 were similar to that of M^, cardiac M2 and 
glandular M3 . That is, pirenzepine had a high affinity for 
the ml receptor, AFDX116 and methoctramine expressed a 
graded profile with the highest affinity for the m2 , and 
hexocyclium was the most selective agent for the m3 
receptor. A number of binding isotherms exhibited low hill 
numbers suggesting heterogeneity or negative cooperativity. 
This question of whether the sites are interacting in these 
pure populations of cells is currently being investigated 
(Buckley et al., 1989).
A report that the the M4 sites in rabbit lung, chicken 
heart and NG108-15 cells can be pharmacologically 
characterised has appeared in the literature (Lazareno et 
al., 1990). This study measured the inhibitory potency, 
against [3H]-NMS labelled sites, of 28 antagonists, and 
found that the binding profile was unlike that of M^, M2 and 
M3 sites. These receptors had a moderate to high affinity 
for [3H]-pirenzepine, but they were not M^ sites, as the 
cardioselective antagonist himbacine had a 10 fold higher 
affinity at these sites than at the M^ sites in rat rabbit 
cortex. The chicken heart receptor has been cloned and 
sequenced (Tietje et al., 1990), and shows greatest homology 
with the mammalian m4 receptor (hence designated cm4). The
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pharmacological characterisation of M4 may be related to the 
cm4 molecular characterisation.
The differences in structure of the binding sites for 
the antagonists must be very subtle as no antagonist 
exhibits more than five fold selectivity for one subtype 
over all the other subtypes. This is expected, due to strong 
conservation of the relevant amino acids.
1.3.4). RESIDUES INVOLVED IN LIGAND BINDING.
Propylbenzilylcholine mustard (PrBCM) being a 
muscarinic selective covalent affinity label (Burgen and 
Hiley, 1974; Burgen et al., 1974), has been used to identify 
the residues involved in the ground state binding of 
antagonists (Kurtenbach et al., 1990). The covalently 
labelled receptors from the rat forebrain were cleaved with 
a specific protease, lys C, yielding two glycosylated 
peptides of 34 and 28KDa. This difference was sufficient to 
differentially enrich these two peptides using high 
resolution FPLC gel filtration. Subcleavage of the 28KDa 
[3H]-PrBCM labelled peptide, with cyanogen bromide (CNBr), 
yielding primarily a 2.4KDa labelled product. Fractions 
enriched in the 34KDa peptide yielded a 3.9KDa labelled 
product after digestion with CNBr. The populations of 
polypeptides could be explained by the presence of more than 
one subtype of muscarinic receptor, as cleavage of a
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preparation of cloned ml mAChR purified from CH0-K1 cells 
gave primarily a 2.4KDa labelled peptide. This shorter 
peptide contains 26 residues which arise from ml, m3 and m5 
sequences that contain an additional methionine residue (Met 
88 between Met 79 and Met 114)•
An Edman degradation of the [3H]-PrBCM labelled CNBr 
peptides identified a conserved aspartate residue at 
position 105 (on the ml sequence) to be the binding site. A 
PrBCM binding site also exists in the head and thoracic 
ganglia of locusts (Knipper and Breer, 1988). Incubation of 
neuronal membrane preparations with [3H]-PrBCM, followed by 
SDS-polyacrylamide gel electrophoresis and autoradiography 
showed that a polypeptide with a molecular mass of 75KDa was 
labelled.
A considerable advance in the understanding of receptor 
structure-function relationships has occurred from the use 
of immortalised cell lines to express pure receptors. Site 
directed mutagenesis of these receptors has been performed 
to test which residues are important for function and 
binding. There are a number of highly conserved aspartate 
residues in the second and third segments of all the 
muscarinic receptors (Hulme et al., 1990). This conservation 
extends to other members of this multigene family including 
the B-adrenergic receptors (Venter et al., 1989). There are 
four conserved aspartate residues in the muscarinic
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receptors occurring at positions 71, 99, 105 and 122 in the 
ml sequence. Point mutations of these residues to neutral 
asparagine (Asn) in the ml receptor have been used to 
determine their importance to binding and function (Fraser 
et al., 1989). Mutation of Aspl05 abolished binding of QNB, 
thus characterisation of the Asnl05 mutant could not be 
performed. Mutation of the corresponding residue in the B- 
receptor reduced the level of binding for iodocyanopindolol 
to very low levels (Strader et al, 1987). Thus the aspartate 
113 in the B-receptor and the aspartate 105 in the ml
sequence suggests that this residue forms a part of the
binding site.
The Asn99 mutant of the ml receptor showed reduced
affinity for the muscarinic antagonist QNB, atropine, 
pirenzepine and PrBCM and the agonists carbachol and
oxotremorine. This mutant showed maximal carbachol 
stimulated PI hydrolysis, but higher concentrations of 
agonist were required for the response, reflected in the 
lower affinity for the agonists. Submaximal levels of 
covalent receptor labelling with PrBCM were observed, which 
implied that this Asp99 residue could also form part of the 
binding site. Thus both Aspl05 and Asp99 may be required for 
stable ligand binding conformation.
Substitution of Asp71 or Aspl22 with Asn produced 
mutant receptors that displayed high affinity for carbachol
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(in fact the Asn71 mutant showed a higher affinity than the 
wild type receptor for carbachol), but decreased the 
efficacy and the potency of activation of PI hydrolysis. 
Asn71 and Asnl22 mutants showed maximal PrBCM incorporation, 
thus suggesting that the Asp71 and Aspl22 residues were not 
involved in antagonist binding. However, Asnl22 reduced the 
affinity of the receptor to PrBCM indicating some 
interaction between Aspl05 and Aspl22 in the native 
receptor. Again, these findings were found to be similar for 
the B-adrenergic receptor in which the mutations of the 
corresponding aspartate residues effected agonist binding 
but not antagonist binding (see Venter et al., 1989 for 
review) .
Determination of the residues involved in agonist 
binding may be made possible from the advent of alkylating 
acetylcholine analogues (Hulme et al., 1991). Acety1-choline 
mustard, acetylethylcholine mustard, butyltrimethylammonium 
mustard and methylfurmethide mustard were all capable of 
blocking mAChR's in a manner which deviated significantly 
from the simple Langmuir isotherm. Binding of these mustards 
clearly showed the presence of low and high affinity sites 
typical of agonists.
There is also a tyrosine residue on TM7 (position 408 
in the ml sequence) which is specific to the cationic amine 
receptor sequences and thought to be involved in the
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formation of a hydrogen bond with the aspartate in TM3 
(Hulme et al, 1989). This tyrosine residue is precisely 
homologous to the lysine residue which forms the site of 
covalent attachment of the cis-retinal chromophore in the 
rhodopsin family of proteins (Findlay and Pappin, 1986). 
Site directed mutagenesis of this residue will help to 
determine the importance of tyrosine 408 in ligand binding.
1.3.5). STRUCTURE OF THE MUSCARINIC RECEPTOR.
A major goal in receptor research is to determine the 
relationship between the function of a receptor and its 
three dimensional structure. Progress in obtaining the 
crystal structure for the large membrane bound proteins has 
been hampered by the difficulty in generating crystals of 
sufficient quantity and quality to refract for X-ray 
analysis. This may be remedied by high density expression of 
cloned receptor genes. Fortunately, the existence of 
bacteriorhodopsin in high density in a periodic lattice in 
the bacterial purple membrane has enabled electron 
microscopy and low dose electron diffraction analysis 
(Henderson et al,, 1990), which resolved the structure of 
the 7 transmembrane helical bundle to a resolution of 0.35- 
0.6nM.
Hydropathy analysis of bacteriorhodopsin, rhodopsin, 
muscarinic receptors and adrenergic receptors show a
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strikingly similar pattern of seven strongly hydrophobic 
regions which are thought to correspond to the seven 
transmembrane helices observed in the bacteriorhodopsin 
diffraction maps (Venter et al., 1989). Analysis of the
primary sequences of these proteins exhibits significant 
similarity in these membrane spanning regions. These regions 
can be thought of as an everted version of the structure of 
water soluble proteins, in that the core residues tend to 
have polar side chains and the surface residues apolar ones. 
The surface residues are subject to fewer bonding 
constraints than the core residues, and are consequently 
more susceptible to genetic drift. Therefore, the helices 
should exhibit a conserved inward pointing face, whilst the 
outward pointing face should be less conserved. After 
alignment of the transmembrane regions of the twelve 
muscarinic receptors the number of different amino acid 
types occurring at each position in the aligned sequences 
can be determined, thus giving an index of variation at each 
position (Vj) (Hulme et al., 1991). The fourier transform 
power spectrum (P(w)) was calculated given Vj, the number of 
residues in the transmembrane sequence and the angular 
rotation per residue around the helix axis. In the case of a 
standard a-helix with a conserved face and a non-conserved 
face the P(w) is expected to peak at 100°. The results for 
the transmembrane sequences were found to be consistent with 
the predicted a-helical conformation, even when the 
calculations were repeated to derive the power spectrum for
amino acid polarity at each position. However, some 
variation in the power spectrum peaks were observed, and was 
thought to be due to tilting of the a-helix within the 
membrane, or to the dislocations in the helical wheel 
structure caused by the presence of proline residues.
In conclusion, by combining the three dimensional 
structure of bacteriorhodopsin, as a guide to protein 
folding, with fourier transform analysis of the residues, to 
search for periodicity, a working model of the intramembrane 
portion of receptor structure can be obtained (fig. 3). As 
this region contains the ligand binding site, the model 
allows interpretation of known features of the muscarinic 
receptor. More constraints for the model will come from 
studies in which the important residues involved in ligand 
binding are identified, to enable correlation between 
structure and function.
1.4). MUSCARINIC RECEPTORS COUPLED TO PI
TURNOVER.
Cells in a multicellular organism need to be able to 
communicate, so that each cell population can call on the 
services of some cell populations and respond to the 
requirements of others (Berridge, 1984). This coordination 
is achieved by chemical signals such as peptide hormones and 
neurotransmitters, the primary messengers. Thus,
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transduction of this signal occurs in the plasma membrane. 
On the outer surface of the membrane there are receptors 
which detect incoming signals. These activate proteins, by 
inducing conformational changes, to produce second
messengers, whose diffusion enables a signal to propagate 
rapidly throughout the cell. These internal signals 
ultimately regulate cellular processes such as secretion, 
contraction, metabolism and growth.-
Inositol compounds play a key role as regulators of 
calcium dependent metabolic processes. Phosphoinositides and 
inositol phosphates are involved in cellular signal
transduction mechanisms. Agonists which stimulate 
phosphoinositide turnover also increase intracellular 
calcium (Michell, 1975), which binds to a family of proteins 
including calmodulin and troponin which then activate other 
kinases (Berridge, 1987 for review). More recent studies 
have shown that carbachol stimulation of m3 muscarinic 
receptors expressed in SY-SY5Y human neuroblastoma cells, 
and ml receptors expressed in CHO cells leads to the 
biphasic production of inositol 1,4,5-tris phosphate, 
inositol 1,3,4,5-tetrakisphosphate and an increase in
internal calcium ion concentration (Lambert et al., 1992). 
As there are many steps in the cellular response, 
amplification and regulation can occur at many points.
The muscarinic receptor subtypes couple to multiple G-
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proteins (fig. 4) to modulate many signal transduction 
pathways including stimulation of phospholipases A2 , C and 
D, attenuation of cAMP synthesis, stimulation of cAMP 
degradation, stimulation of cGMP production and regulation 
of several ion channels (see Hosey, 1992 for review) . From 
the expression of cloned receptors in cell lines it has been 
possible to determine which receptor subtype couples to 
which effector protein. Generally, ml, m3 and m5 are coupled 
to PI turnover, whilst m2 and m4 are linked to adenylate 
cyclase inhibition (see Hulme et al., 1990 for review).
Analysis of the sequence data from ml-m5, revealed that 
a 16-17 amino acid segment at the amino terminal end of the 
third cytoplasmic loop (i3) is highly conserved between ml, 
m3, m5, but is different in m2 and m4 (Wess et al., 1989). 
Construction of cDNA encoding chimaeric m2/m3 receptors, in 
which the small fragment or the whole i3 loop have been 
exchanged between the human m2 and the rat m3 receptor, have 
showed that the wild type m2 with the i3 loop or the small 
fragment from the m3 can strongly couple PI turnover. The 
wild type m3 with the i3 loop or the small fragment from the 
m2 receptor reduced PI turnover. Hence, PI specificity has 
been localised more accurately to the N-terminal 17 amino 
acids of i3 of the m3 muscarinic receptor. Further research 
will be required to determine whether the discrimination 
between G-proteins is exclusively in the cytoplasmic 
domains, or whether other, as yet unknown factors are
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involved in functional selectivity.
Hydrolysis of phosphatidylinositol 4,5-bisphosphate by 
phospholipase C yields snl,2-diacylglycerol and inositol
1,4,5-trisphosphate. Diacylglycerol is required for the 
activation of protein kinase C (Nishizuka, 1986), and 
inositol 1,4,5-trisphosphate mobilises calcium from internal 
stores in the endoplasmic reticulum (see Berridge and 
Irvine, 1989 for review).
1.5). IMPORTANCE OF INOSITOL PHOSPHATES IN
CALCIUM HOMEOSTASIS.
Agonists which function through the inositol lipid 
pathway have been shown to mobilise intracellular calcium 
and to stimulate extracellular calcium entry. This process 
involves both Ins(l,4 ,5 )P3 and Ins(l,3 ,4 ,5 )P4 (see Downes 
and MacPhee, 1990 for review) . The dual action of these 
inositol phosphates provides an important mechanism for the 
control of the intracellular calcium ion concentration. The 
regulation of Ins(l,4 ,5 )P3 3-kinase by calcium ions may, in 
turn, regulate the relative levels of the two inositol 
phosphates, and thus control the calcium signal generated by 
the activation of the receptor.
One of the features of calcium entry and mobilisation 
is that it occurs in localised regions in the cell. This
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permits the cell to use calcium for different purposes in 
different places at the same time. (Harary and Brown, 1984). 
As inositol phosphates are freely diffusible through the 
cytoplasm and act at sites remote from the agonist receptor, 
they may serve as a second messenger for the calcium 
response. Rapid formation of inositol phosphates, and their 
ability to control calcium levels in the cytosol provide an 
important mechanism by which short and long-term regulatory 
functions of the cell can be controlled.
1.5.1). THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR.
Inositol 1,4,5-trisphosphate (Ins (1 ,4 ,5 )P3 ) injected 
into permeabilized cell preparations stimulates calcium 
release from non-mitchondrial stores thought to be part of 
the endoplasmic reticulum (Berridge & Irvine, 1989).
Spat et al. (1987) demonstrated high affinity binding 
of radiolabelled Ins (1 ,4 ,5 )P3 in liver cells and 
neutrophils. Furthermore, this binding correlated with 
release of 4 5Ca2+ from permeabilized cells. The binding site 
displays strict stereo selectivity with the D isomer of Ins 
(1 ,4 ,5 )P3 being greater than 3000 fold more potent than the 
L-isomer in the rat cerebellum, adrenal cortex and liver 
(Nunn et al., 1990). The receptor is not thought to 
densensitize as the inositol 1,4,5 trisphosphorothioate 
(Nahorski and Potter, 1989), shows a sustained release of
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calcium in human SY5Y neuroblastoma cells.
The abundance of the Ins(l/4 ,5 )P3 receptor in rat 
cerebellar purkinje neurons has enabled purification of the 
receptor and the raising of an antibody to it (Ross et al., 
1989)• This antibody recognises a single polypeptide of 
relative molecular mass of 260 KDa. Reconstitution of the 
IP3 binding protein into lipid vesicles (Ferris et al.,
1989) , shows the receptor to be functional, in that
Ins(1,4,5)P3 stimulated calcium flux. The IP3 receptor binds 
with high affinity to heparin and concanavalin A, thus
enabling the development of an effective purification scheme 
(Suppattapone et al., 1988). This protein is a major
substrate for cyclic AMP-dependent phosphorylation, which 
inhibits Ins(l,4 ,5 )P3 activated release of calcium 
(Suppattapone et al., 1988).
Availability of three monoclonal antibodies to the 
purified receptor IP3 protein (termed P400) enabled Furuichi 
et al (1989) to identify complementary DNA's within mouse 
cerebellum cDNA libraries that expressed the protein. The 
entire cDNA sequence, had an open reading frame encoding a 
protein of 2749 amino acids of theoretical molecular mass of 
313KDa. From hydropathy profiles, the protein may contain up 
to nine membrane spanning domains, but immunolocalisation 
studies showed the presence of a large N-terminal region on 
the cytoplasmic face of the endoplasmic reticulum. Hence, a
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cluster of up to seven transmembrane regions were proposed 
close to the C-terminus.
A similar clone was obtained by Mignery et al. (1989). 
It was noticed that a partial sequence of a major purkinje 
cell transcript named PCD6 (500 amino acids) was for a
protein containing several transmembrane domains. With the 
antibodies to the c-terminal peptide, the sequence of the 
part of a heparin binding protein was identified. The 500 
amino acid sequence differed by only one amino acid from the 
c-terminal sequence obtained by Furuichi et al., (1989). A 
region of 134 amino acids in the c-terminal of the IP3 
receptor closely resembled the c-terminal of the ryanodine 
receptor in skeletal muscle (64% homology including 
conservative changes)• Both of these receptors mediate 
calcium release into the cytosol and they form multimeric 
structures possibly in a square configuration (Furuichi et 
al., 1989). There is evidence that the IP3 receptor may 
function cooperatively, in which the opening of the calcium 
channel requires occupancy of three or more binding sites 
(Meyer et al., 1988).
Ins(1,4,5)P3 sensitive calcium stores were thought to 
exist within discrete calcium storage organelles, 
calsiosomes, based on observations by Volpe et al., (1988), 
who showed that calsequestrin-like protein in non muscle 
cells copurified with markers of the IP3 sensitive calcium
33
store. However, inmunohistochemical studies showed that the 
receptor is located in the endoplasmic reticulum and related 
membranes such as golgi and nuclear envelope (Furuichi et 
al., 1989; Mignery et al., 1989).
1.5.2). CALCIUM MOBILISATION AND ENTRY STIMULATED
BY INOSITOL 1,4,5-TRIPHOSPHATE AND INOSITOL
1,3,4,5-TETRAKISPHOSPHATE
Inositol 1,4,5-trisphosphate (IP3 ) induced calcium 
release from internal stores into the cytoplasm shows 
complexity in the way it occurs (Muallem et al., 1989; 
Taylor and Potter, 1989). A maximum concentration of IP3 is 
expected to rapidly mobilise all the calcium from the 
internal pool, further mobilisation will not occur until the 
pool is replenished. One might expect submaximal 
concentrations of IP3 to cause a submaximal opening of 
calcium channels, the result being a slower efflux of 
calcium, but on prolonged stimulation leading ultimately to 
the same net release. Studies on permeabilised pancreatic 
acinar cells (Muallem et al., 1989) and permeabilised 
hepatocytes (Taylor and Potter, 1989) have shown this type 
of continuous release using a calcium ionophore, ionomycin. 
This contrasts with the addition of IP3 , in which submaximal 
concentrations of IP3 release a small fraction of the 
calcium stored. Increasing the IP3 concentration increased 
the fraction of calcium mobilised. Prolonged stimulation
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with a calcium mobilising hormone or maintained levels of 
IP3 did not fully deplete the calcium store. This rapid 
release of a fraction of releasable calcium was termed 
•'quantal release” (Muallem et al., 1989). Taylor and Potter 
(1989) argued that the guantal release observed by Muallem 
et al., (1989) was probably due to IP3 regulating the size 
of the IP3-sensitive calcium pool, not to partial depletion 
of the total pool. This being an extension of the idea that 
GTP could augment calcium release by increasing the size of 
the IP3 sensitive pool through translocation of calcium ions 
between intacellular organelles (Ghosh et al., 1989). A 
mechanism to explain both of the above observations has been 
proposed by Irvine (1990). This hypothesis suggests a role 
for a calcium ion binding site on the intraluminal side of 
the IP3 receptor and also, that the binding of calcium to 
this site increases the affinity of the receptor for IP3 ; 
consequently binding of IP3 increases the affinity of the 
calcium site.
As well as calcium mobilisation, agonists which 
function through the inositol lipid pathway are able to 
stimulate influx of external calcium. This regulation of 
calcium entry is poorly understood (Putney et al., 1989). 
Direct stimulation of a plasma membrane calcium channel by 
ATP in smooth muscle cells has been shown (Benham and Tsien, 
1987). However, in most cells studied, calcium entry is 
triggered by a fall in the levels of internal stores
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(Takemura et al,, 1989). The two components of calcium 
mobilisation and calcium entry can be resolved by comparing 
the calcium signals when the cells are stimulated in calcium 
free or calcium containing media (Merritt and Rink, 1987). 
In the absence of calcium the response is transient, whilst 
in the presence of extracellular calcium the levels of 
intracellular calcium remain elevated. Lag times for influx 
and release seem to be indistinguishable, hence as soon as 
calcium is released more enters through the plasma membrane. 
The capacitance model, proposed by Putney (1986), argues 
that the empty state of the IP3 sensitive calcium store 
activates an influx pathway that refills the store.
A possible role for inositol 1,3,4,5-tetrakisphosphate 
(IP4 ) in regulating the calcium influx phase has been 
postulated. Irvine et al. (1988) proposed a mechanism 
analogous to that of GTP stimulated channels linking IP3 
dependent and IP3 independent calcium stores. The 
requirement for IP3 and IP4 for prolonged stimulation of 
calcium-dependent outward potassium current in lachrymal 
acinar cells (Morris et al., 1987) and activation of sea 
urchin oocytes (Irvine and Moor, 1986) suggests that IP4 
might serve some specific cellular function. IP4 binding 
sites have been shown in calf adrenal cortex (Enyedi and 
Williams, 1988) and Scatchard analysis of the binding data 
indicated that the population was heterogenous. This 
receptor was distinct from the IP3 receptor as IP3 was
36
unable to displace [32P]-IP4 from its binding site.
Irvine (1990) has suggested a mechanism by which the 
IP3 receptor and the IP4 receptor may interact to stimulate 
calcium entry. In this proposal, the calcium levels in the 
endoplasmic reticulum lumen influence calcium influx through 
the plasma membrane via the association with the IP3
receptor, with an intraluminal calcium binding site, and a 
plasma membrane associated IP4 receptor. In this model, low 
intraluminal calcium would reduce calcium release into the 
cytosol by reducing the affinity of the IP3 receptor, and on 
binding of IP3 and IP4 to their respective receptors would 
promote calcium entry. The role of IP4 binding would be to 
dissociate the IP3 and IP4 receptors to allow the entry of 
calcium.
1.5.3). METABOLISM OF INOSITOL PHOSPHATES.
Cells posess an ever increasing number of phosphatases 
and kinases which interconvert a bewildering array of
inositol phosphates (Shears, 1989). This complexity is more 
apparent than real, as the metabolism of inositol phosphates 
need to fulfill three basic functions:
1) . The rapid metabolism and hence control of cellular
concentrations of Ins(l,4 ,5 )P3 .
2). Recycling of inositol phosphates back to inositol, which 
is used for the regeneration of phosphatidylinositol.
37
3). The synthesis of higher inositol phosphates such as 
inositol tetrakisphosphates, inositol pentaphosphates and 
phytic acid. These may have distinctive functions in the 
cell.
Levels of inositol phosphates which change in response 
to agonist stimulation, and hence may be related to
intracellular signalling will be considered. Inositol-1,4,5 
trisphosphate (Ins(l,4 ,5 )p3 and inositol-1,3,4,5
tetrakisphosphate (Ins(l,3 ,4 ,5 )P4 ) are the principle second
messengers. The enzymes involved in the interconversions
between the two above mentioned inositol phosphates, and
their subsequent degradation back to inositol are 
Ins(l,4 ,5 )p3 3-kinase, inositol polyphosphate 3-phosphatase, 
inositol polyphosphate 5-phosphatase, inositol
polyphosphatase 4-phosphatase, inositol polyphosphate 1- 
phosphatase and inositol monophosphate phosphatase (see 
Shears, 1989 for review).
Inositol 1,4,5-trisphosphate is metabolised in cells 
via two routes. The first involving a 5-phosphatase cleavage 
to yield inositol 1,4-bisphosphate. Two distinct 5- 
phosphatases have been isolated from human platelets 
(Mitchell et al, 1989) and bovine brain (Erneux etal, 1989). 
The second involves a 3-kinase phosphorylation to yield a 
potential second messenger molecule inositol 1,3,4,5- 
tetrakisphosphate (Irvine etal, 1988). Calcium ions at
physiological concentrations (Johanson etal, 1988), and 
protein kinase C (King and Rittenhouse, 1989) stimulate the 
activity of the 3-kinase.
The metabolism of inositol phosphates is known to be 
affected by lithium ions, which non-competitively block 
inositol monophosphate phosphatase with an apparent Km of 
0.8mM (Hallcher and Sherman, 1980). This noncompetitive 
action of lithium is very important in selectively operating 
on receptors that are overactive, whilst the receptors that 
are working normally are less affected (Nahorski et al,
1991). In its action lithium is thought to bind to the 
enzyme-substrate complex and not to the free enzyme. 
Administration of lithium ions has been used for the 
treatment of manic depression. Research into the effects of 
lithium ions on inositol polyphosphate hydrolysis led to the 
inositol depletion hypothesis to explain the neural and 
developmental effects of lithium, on the basis that it 
inhibits signal transduction indirectly by slowing down the 
supply of PI. Evidence for this hypothesis has come from 
studies using blowfly salivary glands (Fain and Berridge, 
1979; Berridge and Fain, 1979), in which inositol depletion 
and the consequent PI loss could be associated with receptor 
desensitisation. The replenishment of inositol 
simultaneously restores the lipid and the response. 
Carbachol or electrical stimulation of CA1 hippocampal cells 
block the inhibitory effect of adenosine. Preincubation of
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the hippocampal slices with lithium resulted . in the 
restoration of the inhibitory effect of adenosine. On 
addition of phorbol 12,13 -diacetate, the inhibitory effect 
of adenosine is blocked, and the population spike from 
electrical stimulation of schaffer collaterals is restored 
(Worley et al, 1988). This suggests that the 
phosphoinositide derived diacylglycerol release was 
attenuated by lithium treatment.
1.6). PHOSPHOINOSITIDE SPECIFIC PHOSPHOLIPASE C.
1.6.1). SUBTYPES OF PLC.
Several distinct isoenzymes of phosphoinositide 
specific PLC have been identified which differ from one 
another with respect to their molecular mass, charge,
divalent cation requirements, substrate specificity and the
\
form of their released products (Rhee et al, 1989). Two 
distinct enzymes have been shown to be present in sheep 
seminal vesicles (Hofmann and Magerus, 1982), and antibodies 
to each of these isoenzymes did not react with the other. 
Three more PLC isoenzymes purified from bovine brain (Ryu et 
al., 1987), and a series of monoclonals prepared against 
these showed that these enzymes were immunologically 
distinct. Isolation of the cDNA clones encoding the 
structural genes of four distinct forms of PLC showed low 
overall homology, except for two regions in three of the
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forms; one of 150 amino acids and another of 120 amino acids 
(Suh et al., 1988). These regions designated X and Y, may 
constitute domains which are responsible for catalytic 
properties, such as recognition of polyphosphoinositides, 
hydrolysis of the diester bond, or interaction with G- 
proteins. The five isoenzymes of PI-PLC have been termed, 
PLCa, PLCB, PLCr, PLC£, PLCc (Rhee et al., 1989).
1.6.2). REGULATION OF PLC BY G-PROTEINS.
The Gq class of G-proteins are thought to stimulate the 
membrane bound form of phospholipase C (Shaw and Exton,
1992). This class of GTP-binding a-subunits lack the 
cysteine residue in the fourth position from the carboxyl 
terminus identified to be the ADP-ribosylation site for the 
pertussis toxin (Nakamura et al., 1991). Purification of 
phospholipase C isozymes from bovine liver, and their 
subsequent activation by GTPtS activated Gaq/Gall in 
reconstitution assays resulted in the specific activation of 
the B isoform of phospholipase C (Shaw and Exton, 1992) . 
Other members of the phospholipase C family; PLCr and PLCS, 
identified immunologically by the use of antisera against 
purified bovine brain PLCB1, PLCtI and PLCtfl, could also be 
resolved but not activated. There were two forms of 
activatable phospholipase C (150kDa PLC Ml and 140kDa PLC 
M2) identified by the anti-PLCBl immunoreactive protein. The 
150kDa enzyme was postulated to be the liver homologue of
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the brain PLC61 because of its comigration. This enzyme was 
found to preferentially hydrolyse phosphatidylinositol 
bisphosphate , and its calcium sensitivity was shown to 
increase in the presence of Gceg/11.
Transient transfections of various G-protein a-subunits 
into Cos 7 cells showed Gag/11 to be localised in the plasma 
membrane (Wu et al, 1992)• After prelabelling the cells with 
[3H]-inositol, the formation of inositol phosphates was 
shown to increase in cells transfected with Gag/11 and 
stimulated with aluminium fluoride. Further stimulation was 
observed when the cells were co-transfected PLC61, but there 
was no activity when the cells were transfected with PLC63, 
GaoA and Gaz. Moreover, membranes derived from Gag and Gall 
and not GaoA transfected cells showed GTPrS-stimulated 
phosphatidylinositol bisphosphate hydrolysis when added to 
purified PLC61 in a cell free system.
A second phospholipase C-fi subtype (PLCB2) has been 
cloned from cDNA library of HL-60 cells (Park et al., 1992). 
Its expression in HeLa cells and subseguent purification 
showed that this PLC isozyme could not be stimulated in the 
presence of aluminium fluoride or GTPtS when reconstituted 
with Gag. Lee et al. (1992) determined the relative 
specificities of the Gag's in their ability to stimulate 
PLCB1 or PLC&2. Cos-7 cells were transfected with Gag, Gall, 
Gal4 or Gal6 . The membrane preparations were reconstituted
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with purified PLCB1 or PLCB2 enzymes. All members of the Gq 
family stimulated GTPtS-dependent enzyme activity of PLCB1, 
with Gaq and Gall being the most active. However, Gal6 most 
stimulated PLCB2, whereas the other a-subunits showed little 
activation. Thus, there may be differences in the relative 
interactions of the Gaq subunits with specific members of 
the PLCB subfamily.
1.7). RECYCLING OF PHOSPHATIDYLINOSITOL.
Upon stimulation of the phosphoinositide-cycle
diacylglycerol kinase (DAG-kinase) rapidly converts
diacylglycerol released to phosphatidic acid (PA).In resting 
cells the activity of this enzyme must be suppressed, as the 
supply of DAG is required for the synthesis of major 
glycerolipids. A very important functional implication of 
this enzyme is that it controls the intracellular
concentration of the second messenger, DAG, which as a 
regulator of protein kinase C (Nishizuka, 1986).
To date only one form of the enzyme has been purified 
from animal sources, that being a 80kDa protein found in pig 
brain and thymus cytosol. Rabbit antibodies have been raised 
to the 80kDa enzyme from pig brain. Using this antibody, the 
enzyme was found to be distributed in both the membrane and 
cytosol fractions. Enzymological studies have shown the 
enzyme to be relatively inactive without the addition of
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various activators such as deoxycholate, phosphatidyl 
choline , phosphatidylserine or sphingosine (see Kanoh et 
al., 1990 for review). The cytosolic 80kDa enzyme is thought 
to become membrane associated upon phosphorylation, possibly 
by a protein kinase C (Maroney and Macara, 1989). This 
enzyme translocation is analogous to that of protein kinase 
C (Nishizuka, 1986), thus suggesting a functional 
interrelationship between DAG kinase and protein kinase C. 
Phosphorylation of DAG kinase by PKC does not alter its 
activity.
Phosphatidic acid is converted to phosphatidylinositol, 
via CDP-diacylglycerol, by a CTP-dependent inositol 
transferase (phosphatidylinositol synthetase), whose 
activity has been found in both the plasma membrane and the 
endoplasmic reticulum of the rat GH3 pituitary cell (Imai 
and Gershengorn, 1987). Phosphatidylinositol is the 
precursor for the synthesis of the polyphosphoinositides and 
comprises between 5 and 20% of the total phospholipids in 
eukaryotic cells (Maccallum et al, 1989). It is present in 
several of the membrane systems of the cell. The highest 
concentrations of PI are found in the endoplasmic reticulum 
(Paulus and Kennedy, 1960). Given this and the differential 
distribution of the polyphosphoinositides, cells face a 
potential problem in regulating the local supply of PI to 
support phospholipase C mediated transmembrane signalling. 
All of the PI in the cell might serve as a substrate for
polyphosphoinositide synthesis (Maccallum et al., 1989), in 
which case PI from the endoplasmic reticulum would have to 
be efficiently delivered to the plasma membrane when needed. 
Alternatively, there might be a metabolically discrete pool 
of PI used for receptor mediated hydrolysis, which remains 
associated with the plasma membrane over long periods and is 
phosphorylated to PIP2 on demand (Imai and Gershengorn, 
1987) .
The phosphorylation of PI to phosphatidylinositol 4- 
phosphate (PI(4)P) is catalysed by phosphatidylinositol 4- 
kinase. Several isozymes of PI 4-kinase are known to exist, 
although the possible roles of each remain to be elucidated, 
there are at least two distinct forms in bovine brain 
(Endemann et al, 1987). PI 4-kinase activity has been found 
in the nuclear envelope of hepatocytes (Smith and Wells, 
1984), the plasma membrane (Imai et al., 1986) and low 
density membranes (Lundberg and Jergil, 1988). From a 
functional point of view this kinase should reside in the 
plasma membrane, but Lundberg and Jergil (1988) found that 
in the rat hepatocytes synthesis of PI takes place in the 
endoplasmic reticulum, and its phosphorylation to PI(4)P 
occurs intracellularly in the low density membranes before 
translocation to the plasma membrane. PI(4)P-5 kinase 
phosphorylates PI(4)P to PI(4 ,5 )P2 « Its activity is found in 
a membrane bound form (Imai et al.,1986), and is located in 
the plasma membrane where it needs to be in order to
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contribute to receptor mediated PI metabolism (Jergil and 
Sundler, 1983; Seyfred and Wells, 1984) (see fig. 5 for PI 
cycle.).
Discovery of the phosphatidylinositol 3-kinase (Whitman 
et al., 1985), which phosphorylates the D-3 positiion of the 
myoinositol moiety, indicated the existence of a new 
signalling pathway not involving the inositol phosphates. 
The 3-kinase phosphorylates PI, PI(4)P, PI(4 ,5 )P2 to yield 
PI(3)P, PI(3 ,4P2 and PI(3 ,4 ,5 )P3 . Although these novel 
phosphoinositides were discovered in transformed cells, 3- 
phosphate containing phospholipids have been found in normal 
cells and in growing cells such as neutrophils (Stephens, 
1991), platelets, and brain cells. Thus these lipids may 
serve a function other than or in addition to stimulating 
cell proliferation (Bansal and Majerus, 1990). PI(3)P is not 
hydrolysed by phospholipase C, but by a 3-phosphatase (Lips 
et al., 1989).
Duggan (1987) showed that both adenylate cyclase and 
phosphatidylinositol turnover were coupled to a muscarinic - 
like receptor in locust supraoesophageal ganglia. We have 
attempted to more fully investigate the coupling of 
muscarinic-like receptors to PI turnover in these ganglia. 
There are many enzymic steps involved in the inositol-lipid 
pathway, the characterisation of which in the insect may 
reveal important differences from the mammalian system, and 










Model of the muscarinic receptor.
The positions of the seven transmembrane helices (1-7), 
the extracellular loops (ol-3) and the intracellular loops 
(il-3) are shown. Residues conserved across the G-protein 
coupled receptor family are shown as capitals, and the 
receptor specific residues are shown in boxes (in TM3 and 









>- LR.a.py - LR.a-GTP.py
GDP/GTP SEQUENTIAL EXCHANGE REACTION
Figure 4.
The GTPase cycle.
Agonist binding to the receptor forms an agonist-receptor 
complex (LR). The complex catalyses the release of bound 
GDP from the G-protein a-subunit. The LR complex is 
displaced on binding of GTP to the a-subunit, and the a- 
GTP complex forms the activated state of the G-protein. 
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Table 1 . Muscarinic receptor nomenclature as recommended by the proceedings of the fourth 
international symposium on subtypes of muscarinic receptors.
HHHSiD - Hexahydrosiladifenidol. AFDX116 - (11-2((-((diethylamino)methyl)-1-piperidinyl)- 
acetyl)-5,11 -dihydro-6H-pyrido(2,3-b) (1,4)-benzodiazepine-6-one). AFDX384 - (5,11-dihydro- 
11 — (((2—(2—((dipropylamino)methyl)-1-piperidinyl)ethyl)amino)carbonyl)-6H-pyrido(2,3- 




In insects PI metabolism has been shown to be 
important in peripheral tissues (Fain and Berridge, 1979); 
the addition of 5-hydroxytryptamine to isolated blowfly 
salivary glands (Calliphora erythrocephala) stimulates the 
breakdown of radiolabelled PI, transepithelial calcium 
transport and fluid secretion. More recent studies on the 
isolated tick (Amlyomma americanum) salivary glands have 
shown that calcium is mobilised from microsomal 
intracellular stores in response to agonists which 
increase inositol trisphosphate levels (Roddy et al., 
1989). Interaction between the cAMP pathway and the 
inositol lipid pathway has been suggested in the tick 
salivary gland during changes in feeding stages (McSwain 
et al., 1989). Later stages of feeding produce higher 
levels of inositol phosphates mediated by an unknown brain 
factor. However, the inositol-lipid pathway has not been 
extensively characterised in the insect CNS. It has been 
shown that muscarinic-like acetylcholine receptors are 
linked to both the cAMP pathway and the inositol lipid 
pathway in locust (Schistocerca gregaria) supraoesophageal 
ganglia (Duggan, 1987). Carbachol caused an increase in PI 
turnover which was blocked by atropine and a selective M^ 
muscarinic antagonist, pirenzepine. Other studies using 
locust metathoracic ganglia (Trimmer and Berridge, 1985) 
could not establish an increase in the levels of inositol 
phosphates in the presence of many cholinergic agonists, 
including carbachol. A muscarinic antagonist, atropine,
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however, decreased the levels of inositol phosphates 
suggesting that the ganglia were already maximally 
stimulated before the addition of agonist, probably due to 
the trauma of dissection. One of the primary aims of this 
study was to reduce these control values by experimenting 
with incubation conditions. Here we show the effects of 
carbachol on [32P]-Pi incorporation into the 
polyphosphoinositides, and the effect of several doses of 
pilocarpine and carbachol on the incorporation of 
[3H]-Inositol into PI and inositol phosphates.
2.2). GENERAL METHODS
2.2.1). DISSECTION.
Adult locusts (Shistocerca gregaria) supplied by 
Blades Chemicals were used in all experiments. The insects 
were anaesthetised by cooling and gassing with carbon 
dioxide, and then decapitated. On shaving the cuticle from 
the front of the head, the supraoesophageal ganglion was 
exposed and removed using metal forceps. The optic lobes 
were routinely removed. Dissection of 100 ganglia provided 
approximately 300mg wet weight of ganglia.
2.2.2). INCUBATION OF LOCUST GANGLIA IN
[3H]-INOSITOL
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Initial experiments were performed under varying 
conditions, both with regards to time of incubation and 
the saline used. It was found that low basal levels of 
incorporation were obtained when a preincubation was 
introduced under calcium free conditions. Then the effects 
of reintroducing calcium in the incubation saline could be 
determined. The final procedure adopted was as follows.
2.2.3). PREINCUBATION
Freshly dissected ganglia were immediately rinsed in 
ice cold buffer A (see below) . Groups of 10 to 20 ganglia 
were placed in 5mls of buffer A previously gassed with 
9 5%0 2 /5%C0 2 , in 10 ml beakers covered with parafilm. To 
this buffer, 5/iCi of [3H]-inositol (84Ci/mmol, Amersham) 
was added to preload the ganglia with radiolabelled lipids 











Groups of 20 ganglia were subdivided into groups of 
10, The level of [3H]-inositol incorporation into the 
inositol phosphates during the preincubation period was 
determined.
The 10 ganglia were equally divided into 5 Eppendorf 
tubes (1.5ml), each of which contained 0.5 mis of buffer 
and 1/iCi of [3H]-inositol. All these tubes were incubated 
for 20min at 25°C in a water bath which was gently 
agitated. The incubation conditions were manipulated to
investigate the effects of calcium, lithium and muscarinic 
drugs. In agonist treated experiments, the agonist was 
added 4min after the addition of lithium chloride.
2.2.5). EXTRACTION OF ACID SOLUBLE INOSITOL
PHOSPHATES.
Incubations were terminated by placing the ganglia on 
dry ice after which they were homogenised in acidified 
chloroform/methanol (1ml chloroform/methanol (1:2 by 
vol.), 0.2ml 0.5M hydrochloric acid). On addition of 0.2ml 
distilled water and 0 .2ml chloroform the phases were 
separated by centrifugation (2000g, 20min). The upper
phase contained the acid soluble inositol phosphates and 
the lower phase contained the phospholipids.
2.2.6 .1). SEPARATION OF INOSITOL PHOSPHATES USING
ANION EXCHANGE
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Anion exchange columns were prepared using. Dowex-1 
chloride resin (8% crosslinked, dry mesh 200-400, Sigma) 
converted to formate form. Approximately lg of Dowex resin 
was washed 4 times with 4ml of 1M sodium hydroxide in a 
5ml beaker. The resin was neutralised by washing with 
distilled water, and converted to formate form by adding 
1M ammonium formate to the resin. After mixing the large 
particles were allowed to settle, and the remaining small 
particles discarded. The Dowex-1 formate resin was 
neutralised with distilled water and packed by pouring the 
slurry into a pasteur pipette.
2.2.6 .2). CHARACTERISATION OF DOWEX-1 FORMATE COLUMNS
USING INOSITOL PHOSPHATE STANDARDS.
2.2.6.2.1). METHOD
A mixture of inositol polyphosphates (inositol 1- 
phosphate, inositol 1,4-bisphosphate and inositol 1,4,5- 
trisphosphate, 0.37 KBq//il, obtained from Amersham 
International) was added to Dowex-1 formate columns (see 
above for preparation). The inositol mono-, bis- and tris 
phosphates were separated by sequential batch elution with 
0.2M ammonium formate/0.1M formic acid, 0.5M ammonium 
formate/0.1M formic acid and 1M ammonium formate/0.1M 




The elution profile of the inositol phosphates (fig. 
6 ) showed that the inositol mono-, bis- and tris 
phosphates were well resolved using the elution protocol 
(81.1% +/- 3.4(s.d), n=3, 20 437 d.p.m. added to the
column).
2.2.6 .3). SEPARATION OF [3H]-INOSITOL LABELLED WATER
SOLUBLE PRODUCTS.
The upper phase of the chloroform/methanol extraction 
was added to 1ml of resin in a pasteur pipette. The 
inositol phosphates could then be sequentially eluted with 
distilled water (inositol), 5mM disodium tetraborate/ 60mM 
ammonium formate (glycerophosphoinositol); 0.1M formic
acid/ 0 .2M ammonium formate (inositol phosphates); 0 .1M 
formic acid/ 0.5M ammonium formate (inositol 
bisphosphates); 0 .1M formic acid/ 1 .0M ammonium formate
(inositol trisphosphates). The eluted fractions were 
collected in scintillation vials, to which 8mls of 
Optiphase Safe scintillant were added (LKB scintillation 
products). Radioactivity from each fraction could be 
determined using a scintillation counter (counting 
efficiency 35-40%). For each solvent mixture lOmls of 
eluant were collected to be counted (see fig. 7 for the 
separation of inositol phosphates).
2.3) . RESULTS
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2.3.1). EFFECT OF SINGLE INCUBATIONS.
Groups of 10 ganglia were incubated for 20 min at 
room temperature in 2 ml calcium free buffer A, to which 
3/xCi [3H]-inositol was added. To measure the effects of 
agonist stimulation on the accumulation of radiolabelled 
inositol phosphates, lithium (lOmM) and carbachol (ImM) 
were added to the treated incubation saline. Incorporation 
of [3H]-inositol into the inositol phosphates was 
determined as described in general methods. The percentage 
of each inositol phosphate fraction was expressed as a 
function of total radioactivity recovered (table 2) . This 
showed that carbachol increased the proportion of inositol 
incorporated into the inositol trisphosphate fraction. But 
there was no indication of any increase in total count.
On addition of ImM EGTA (ethyleneglycol-bis(B-amino 
ethylene ether)N,N,N',N'-tetra acetic acid), a calcium ion 
chelator, to the incubation buffer, the incorporation of 
[3H]-inositol into the inositol phosphates was reduced. 
Both counts recovered and percentage of incorporation 
showed low standard errors (S.E.M.). Low calcium levels in 
the incubation buffer may have either reduced 
phospholipase C activity or decreased the amount of 
endogenous neurotransmitter release to have this effect 
(see table 3).
2.3.2) . INTRODUCTION OF A PREINCUBATION.
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A preincubation period of 90 min at room temperature 
in calcium free, lithium free buffer A was introduced to 
investigate whether a carbachol enhanced accumulation of 
inositol phosphates could be obtained. Experiments were 
performed to determine the effects of adding 2mM EGTA, no 
calcium, 0.3mM calcium and 3mM calcium to the incubation 
buffer. At each of these concentrations of calcium, the 
effect of lOmM carbachol in the presence or absence of 
lOmM lithium on the incorporation of [3H]-inositol into 
the inositol phosphates was measured.
2.3.2.1). PREINCUBATIONS IN THE PRESENCE OF EGTA.
The requirement for calcium was highlighted by 
performing experiments in the presence of 2mM EGTA in both 
the preincubation and incubation conditions.
Groups of 10 ganglia were preincubated for 60min in 
lOmls of buffer (calcium free, lithium free, 2mM EGTA) at 
room temperature. In control experiments (n=6 ) the ganglia 
were placed in buffer A containing 1/xCi [3H]-inositol, 2mM 
EGTA and lOmM lithium, whilst in agonist treated 
experiments (n=6 ) lOmM carbachol was added. Incubations 
were performed at 25°C for 30mins. Carbachol had no effect 
on the incorporation of [3H]-inositol into the inositol 
phosphates in these conditions (fig. 8 ).
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2.3.2.2). EFFECT OF CALCIUM, LITHIUM AND CARBACHOL ON
THE INCORPORATION OF [3H]-INOSITOL INTO THE 
INOSITOL PHOSPHATES.
2.3.2.2.1). CONTROL INCUBATIONS IN THE ABSENCE OF 
CALCIUM.
In the preincubation buffer, groups of 20 ganglia 
were incubated in the presence of 5/iCi [3H]-inositol in 
buffer A. Incorporation of the radiolabel into the 
inositol phosphates was determined immediately after this 
90 min.preincubation period (fig. 9), and was taken to be 
the basal level of activity for 10 ganglia. The level of 
[3H]-inositol incorporation into the inositol phosphates 
after 110 min incubation in buffer A is also shown in fig. 
9. This shows that the radioactivity recovered after the 
110 min preincubation period was not significantly greater 
than the 90 min preincubation period. The remaining 10 
ganglia were transferred into incubation buffer (no added 
calcium or lithium), after being split into 5 groups of 2. 
Pooling the counts from 10 ganglia after the 20 min 
incubation period, showed significant increases in the 
inositol phosphate fraction (p< 0 .0 1 ), the inositol
bisphosphate fraction (p<0 .0 1), and the total counts 
(p<0.005) when compared to levels of incorporation after 
the preincubation period alone.
2.3.2.2.2). THE EFFECT OF LITHIUM AND CARBACHOL IN THE 
PRESENCE OF 0.3mM CALCIUM.
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Experiments were performed in which 0.3mM calcium was 
added to the incubation buffer. The effect of lOmM 
carbachol was investigated in the presence or absence of 
lOmM lithium, figs. 10 and 11). In the absence of lithium, 
carbachol had no effect on the incorporation of [3H]- 
inositol into the inositol phosphates (fig. 10) . However, 
in the presence of lOmM lithium and lOmM carbachol there 
was an agonist induced accumulation of radiolabelled 
inositol phosphates. Significant increases were observed 
in the inositol phosphate fraction (p<0 .0 2 ), inositol 
bisphosphate fraction (p<0.05) and total counts (p<0.05) 
between control (n=9) and treated (n=9) experiments (fig. 
11). When carbachol treated ganglia in the absence of 
lithium were compared with carbachol treated ganglia in 
the presence of lithium , there were significant increases 
in the inositol phosphate fraction (p<0 .0 1 ), inositol 
bisphosphate fraction (p<0.01) and total counts (p<0.05). 
Thus, in the presence of lithium carbachol enhanced the 
accumulation of radiolabelled inositol phosphates (1.6 
fold increase in the total amount of radioactivity 
recovered (see fig. 1 1)).
2. 3.2.2.3). THE EFFECT OF CARBACHOL AND LITHIUM IN THE 
PRESENCE OF 3mM CALCIUM.
Similar experiments were performed in the presence of 
higher concentrations of calcium (3mM) in the incubation 
buffer. Both in the presence and absence of lOmM lithium
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(figs. 12 and 13), carbachol stimulated the incorporation 
of [3H]-inositol into the inositol phosphates. There was a 
2.2 fold increase in the presence of 3mM calcium (p< 
0.01), and a 1.73 fold increase in the presence of 3mM 
calcium and lOmM lithium (p< 0.01). Results from these 
experiments showed that at this increased concentration of 
calcium, in the absence of carbachol and presence of lOmM 
lithium, there was an increase in the incorporation of 
[3H]-inositol into the inositol phosphates (significant 
differences (p<0 .0 1) were shown between control values in 
the presence of 0.3mM calcium (fig. 11) and 3mM calcium 
(fig. 13)).
To show that this carbachol induced increase in 
phosphatidylinositol turnover was due to a muscarinic-like 
receptor, experiments were performed in the presence of a 
muscarinic antagonist, atropine. Groups of 10 ganglia were 
incubated in the presence of 3mM calcium, lOmM lithium, 
lOmM carbachol and O.lmM atropine (n=5). When these 
results were compared with agonist treated experiments in 
the absence of atropine (fig. 13), there were significant 
decreases in [3H]-inositol incorporation into the inositol 
bisphosphate fraction (p<0.05) and total inositol 
phosphates (p<0.05).
2.4). DISCUSSION
The inositol phosphate standards were well resolved 
using anion exchange chromatography on Dowex-1 formate
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columns (fig. 6 ). The elution profile of the [3H]-inositol 
labelled water soluble products is shown in fig. 7. 
Initial experiments showed that the peak corresponding to 
inositol trisphosphates was the highest fraction recovered 
in both control and treated experiments (fig. 7). This 
implied phospholipase C activity even in the absence of 
the agonist, carbachol. This indication of 
phosphatidylinositol turnover in the control conditions 
could have been due to damage of the cells containing the 
relevent transmitters which activate phospholipase C, or 
it may have been the result of calcium-dependent release 
of endogenous transmitters triggered by the conditions of 
the experiments (Duggan, 1987).
The single incubation experiments (table 2) showed 
the immediate effects of removing the ganglia and placing 
them in buffer containing the label. To limit endogenous 
activity, the incubations were performed in the absence of 
calcium in the buffer. The results show that the 
appearance of label in the inositol phosphates was very 
variable (see total counts in table 2 ), and that carbachol 
had no detectable effect on total counts recovered. This 
suggested high endogenous activity, perhaps caused by the 
trauma of dissection. When the proportion of [3H]-inositol 
incorporated into the inositol phosphates was examined
(table 2 ), there were indications that in the presence of
carbachol the labelling of inositol trisphosphate
increased, whilst that of inositol monophosphate
decreased. This suggested that the production of inositol
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trisphosphate increased relative to its dephosphorylation 
to inositol phosphate. Adding a calcium chelator, EGTA, to 
the incubation buffer dramatically reduced the extent and 
variability of [3H]-inositol incorporation into the 
inositol phosphates, especially into the inositol 
trisphosphate fraction (table 3). The level of calcium in 
the incubation buffer profoundly affected
phosphatidylinositol turnover.
In an attempt to reduce the level of endogenous 
activity, experiments were performed in which a 
preincubation was introduced, and in which 2mM EGTA was 
added to both the incubation and preincubation buffers. 
There were no significant differences when the ganglia 
were incubated in the presence of carbachol and lithium. 
This lack of agonist induced enhancement of 
phosphatidylinositol turnover may have been due to the 
fact that calcium is required for phospholiase C activity 
(Rhee et al., 1989). The exposure of locust ganglia to 
EGTA may have sufficiently reduced the content of calcium 
in the cells to inactivate the phospholipase C.
Experiments were performed in which the EGTA was 
removed from buffers. Counts recovered after the 90 min 
preincubation showed low activity, much of it was 
accounted for as background (each scintillation vial with 
10 mis of scintillation fluid had an average count of 20 
c.p.m.). Transferring the ganglia into buffer A (no added 
calcium or lithium) and incubating for 20 min nearly
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doubled the incorporation of [3H]-inositol into the 
inositol phosphates. Hence, the act of placing the ganglia 
in the incubation buffer caused stimulation (fig. 9).
The effect of re-introducing calcium into the 
incubation buffer was determined. On addition of 0.3mM 
calcium (figs. 10 and 1 1), carbachol enhancement of 
phosphatidylinositol turnover was only observed in the 
presence of lOmM lithium (fig. 11) . The inhibition of
myo-inositol 1-phosphatase by lithium (Sherman et al., 
1981) is commonly used to identify receptors that function 
through the inositol lipid pathway. Increasing the calcium 
to 3mM (figs 12 and 13), in control conditions, also 
increased the incorporation of [3H]-inositol into the 
inositol phosphates (there was a significant difference 
between control+0.3mM calcium and control+3mM calcium (p< 
0.01) in the presence of lithium). This suggests that 
calcium enhances endogenous activity, probably by 
initiating transmitter release which activates receptors 
linked to the inositol lipid pathway. At this 
concentration of calcium (3mM), carbachol (lOmM) enhanced 
the accumulation of inositol phosphates both in the 
presence and absence of lOmM lithium (figs 12 and 13)•
The effects of intracellular calcium and the 
receptor-G-protein activation on the modulation of 
phospholipase C may be interrelated. The ability of 
muscarinic agonists to stimulate polyphosphoinositide 
turnover can be enhanced by a calcium ionophore in
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synaptosomes (Fisher and Agranoff, 1981). Synergy between 
calcium and guanine nucleotides in the activation of 
phospholipase C has been demonstrated in permeabilised 
cells (Valler et al., 1987). An increase in cytosolic 
calcium may, therefore, increase the sensitivity of 
phospholipase C to receptor activation. Thus, in neuronal 
cells, the entry of calcium through voltage gated or 
ligand gated channels may be involved in a positive 
feedback loop with inositol trisphosphate production. The 
results from these experiments showed that in general the 
levels of inositol phosphates were considerably higher in 
3mM calcium than 0.3mM calcium.
The action of inositol phosphates involve many 
biochemical steps, which makes it unlikely that they are 
responsible for rapid changes in calcium levels observed 
during depolarisations. The pathway is more likely to be 
involved in regulating cytosolic calcium in the 
presynaptic terminal, and therefore serve as a modulatory 
function for incoming signals. Many neurons respond to 
neurotransmitters that stimulate inositol phosphate 
turnover with a transient hyperpolarisation, which can be 
mimicked by the addition of inositol 1,4,5-trisphosphate 
(Higashida and Brown, 1986). This response has been shown 
to result from the opening of calcium gated potassium 
channels. Hyperpolarisations of the presynaptic terminals 
would modulate the amount of neurotransmitter released on 
arrival of a depolarisation signal. A physiological role 
for the muscarinic-like receptor in the insect central
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nervous system has been more clearly established in an 
identified motoneurone of the principle planata retractor 
muscle in the proleg of the tobacco hornworm, Manduca 
sexta (Trimmer and Weeks, 1991). this motoneurone forms a 
monosynaptic connection with a mechanosensory afferent at 
the tip of the proleg. The muscarinic-like receptor 
appears to regulate excitibility of the motoneurone. 
Microinjection of a muscarinic agonist, oxotremorine-M, 
into the neuropile increases the excitibility of the 
motoneurone by a slow depolarisation and by lowering its 
spike threshold. The muscarinic current underlying these 
effects is voltage sensitive and carried by sodium. The 
current requires the entry of extracellular calcium, and 
is affected by agents that stimulate G-protein turnover, 
such as GTPtS (Trimmer and Weeks, 1991).
The effect of carbachol can be blocked by atropine, a 
muscarinic antagonist (fig. 13) . This suggests that the 
locust supraoesophageal ganglia contain receptors similar 
to the vertebrate muscarinic receptors, which can function 
through the inositol lipid pathway.
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Figure 7.
Separation of [3H]-inositol labelled water soluble 
products.
Twenty ganglia were preincubated for 90min in 10ml of 
buffer A containing 3mM calcium. After which they were 
transferred to buffer A containing 2mM calcium and 5/LtCi 
[3H]-inositol, and incubated for 30min in presence (open 
inverted triangles) or absence of ImM carbachol (closed 
circles). The twenty ganglia were homogenised in acidified 
chloroform/methanol, and the water soluble metabolites 
were separated on Dowex-1 formate columns using sequential 
elution. The free inositol was washed from the column by 
eluting with 10 x 2ml distilled water. The inositol 
phosphates were separated by eluting with 5mM disodium 
tetraborate/6OmM ammonium formate (5 x 2ml fractions, 
glycerophosphatidylinositol), 0.2M ammonium formate/0.1M
formic acid (10 x 1ml fractions, inositol monophosphates 
(IPl)), 0.5M ammonium formate/0.1M formic acid (10 x 1ml 
fractions, inositol bisphosphates (IP2 )) and 0.8M ammonium 
formate/0.1M formic acid (10 x 1ml fractions, inositol 
trisphosphates (IP3 ))•
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The effect of carbachol on the incorporation of [3H]- 
inositol into the inositol phosphates in the presence of 
EGTA.
Ten ganglia were preincubated for 60min in 10ml of buffer 
A containing 2mM EGTA. The ganglia were split into 5 
groups of 2. In control experiments (n=6) each group was 
incubated in buffer A containing 1/xCi [3H]-inositol, 2mM 
EGTA and lOmM lithium (hatched rising to the right) for 
30min at 25°C. In treated experiments (n=5) lOmM carbachol 
was added (hatched rising to the left). Results from 10 
ganglia were pooled, and the incorporation of [3H]- 
inositol into inositol monophosphate (IP1), inositol 
bisphosphate (IP2), inositol trisphosphate (IP3) and total 
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Figure 9.
Incubations in the absence of calcium, lithium and 
carbachol•
Twenty ganglia were preincubated for 90 min in buffer A 
containing 5/xCi [3H]-inositol. Counts for 10 ganglia (n=8 ) 
were taken immediately after this preincubation period 
(hatched rising to the right). The remaining 10 ganglia 
were transferred into buffer A after being split into 5 
groups of 2, and incubated for 20 min at 25°C (cross 
hatched n=6 ). Groups of 10 ganglia were also incubated for 
llOmin in the preincubation conditions (hatched rising to 
the left n=5) • Each data point represents the mean and 
standard error of mean for n replicates. Comparing 
radioactivities recovered per 10 ganglia after the 90min 
preincubation period and after the subsequent 20min 
incubation period showed significant increases in the 
inositol monophosphate fraction (IP), inositol 
bisphosphate fraction (IP2) and total counts (TOTAL).
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The effect of carbachol in the presence of 0.3mM calcium.
Groups of 20 ganlia were preincubated as described in fig. 
9. In control conditions, 0.3mM calcium was added to 
buffer A during the 20min incubation period (hatched 
rising to the left, n=4). To the agonist treated ganglia, 
lOmM carbachol was added to the incubation buffer (cross 
hatched, n=5). Mean incorporation of [3H]-inositol into 
inositol monophosphate (IP), inositol bisphosphate (IP2), 
inositol trisphosphate (IP3) and total inositol phosphates 
(TOTAL) were determined for n replicates (results obtained 
from pooling of 10 ganglia). The standard error of mean is 
shown for each data point. There were no significant 
differences observed.
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The effect of carbachol in the presence of 0.3mM calcium 
and lOmM lithium.
Groups of 20 ganglia were preincubated for 90 min (fig. 
9). In control conditions 0.3mM calcium and lOmM lithium 
were added to buffer A during the 20min incubation period 
(hatched rising to the left, n-9). Carbachol (lOmM) was 
added to agonist treated ganglia (cross hatched, n=9) . 
Each data point represents mean incorporation of [3H]- 
inositol into the inositol phosphates (results obtained 
from pooling of 10 ganglia) for n replicates and the 
standard error of the mean. There were significant 
increases in the IP fraction, IP2 fraction, and TOTAL 
counts recovered. When carbachol treated ganglia without 
lithium (fig. 10) are compared with carbachol treated 
ganglia in the presence of lOmM lithium there were 
significant increases in the IP1 p<0.01), IP2 (p<0.01) and 
total counts (p<0.05).
* p<0.05, ** p<0.02
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The effect of carbachol in the presence of 3mM calcium.
Groups of 20 ganglia were preincubated for 90min. They 
were then incubated in buffer A containing 3mM calcium for 
20min in the presence (cross hatched, n=5) or absence 
(hatched rising to the left, n-5) of lOmM carbachol. 
Comparing mean incorporation of [3H]-inositol into the 
inositol phosphates (results obtained from pooling of 10 
ganglia for n replicates) showed significant increases in 
the IP1, IP3 and total inositol phosphates.
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Figure 13
The effect of carbachol and atropine in the presence of 
3mM calcium and lOmM lithium.
After a preincubation of 90min, the ganglia were then 
incubated in buffer A containing 3mM calcium and lOmM 
lithium (control results represented by hatched bars 
rising to the right, n=4). The ganglia were treated with 
lOmM carbachol (hatched rising to the left, n=4) or lOmM 
carbachol and O.lmM atropine (cross hatched, n-5). The 
mean incorporation of [3H]-inositol from n replicates 
(results obtained from pooling of 10 ganglia per 
replicate). The error bars represent the standard error of 
mean. Significant increases were observed when comparing 
controls and carbachol treated ganglia in the IP2 fraction 
and total inositol phosphates. Atropine inhibited the 
effect of carbachol. There were significant decreases in 
the IP2 fraction and total inositol phosohates.
* p<0.05, *** p<0.001
0 p<0.05 compared with carbachol treated ganglia.
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CONTROL1 65.8 24.0 10.2 3951
C0NTR0L2 56.9 27.7 15.3 2020
TREATED1 45.9 28.5 25.6 2201
TREATED2 45.7 28.5 26.1 2114
Table 2
The effect of carbachol in single incubations.
Locust ganglia (10) were incubated for 20min in buffer A 
containing 3/iCi of [3H]-inositol (CONTROLS 1 and 2). To 
the agonist treated ganglia (TREATED 1 and 2) carbachol 
(lOmM) and lithium (lOmM) were added. The percentage of 
each inositol phosphate fraction as a function of total 
radioactivity recovered was determined. This showed that 
carbachol increased the proportion of inositol 
incorporated into the inositol trisphosphate (IP3) 
fraction.
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RADIOACTIVITY RECOVERED (C.P.M./10 GANGLIA)
IP1 IP2 IP3
MEAN 1135 278 152
S.E.M. 85 27 42
% OF TOTAL INCORPORATION
MEAN 72.7 18.1 9.2
S.E.M. 2.1 2.2 1.7
Table 3.
The effect of EGTA, a calcium chelator, on control values.
Groups of 10 ganglia were incubated in buffer A containing 
ImM EGTA and 3/xCi [3H]-inositol. The results were obtained 
from 5 separate experiments. The mean incorporation of 
[3H]-inositol into the inositol phosphate fractions and 
the standard error of mean are shown, expressed both as 
the radioactivity recovered from 10 ganlia and the 




Having shown that a muscarinic cholinergic drug, 
carbachol, increased the levels of inositol phosphates in 
the locust ganglia, work could begin on a more rigorous 
characterisation of the muscarinic receptor linked to the 
inositol lipid pathway.
However, many problems existed with the assay system 
employed to determine inositol phosphate turnover. Many 
replicates needed to be performed in order to show an 
increase, due to the variability and the size of the 
response, which required a high agonist concentration to 
be measurable.
Variability could have arisen at many points of the 
assay procedure: handling of the ganglia; losses of
inositol phosphates in the extraction; diffusion of
inositol into the ganglia which could effect its
availability for incorporation into phosphatidylinositol; 
presence of [3H]-inositol radiolytic products, which 
adhere to the dowex resin and elute with the inositol 
phosphates to give high blanks. A protocol was developed 
to minimise the causes of the variability described. It 
was essential to improve the signal further to
characterise the receptor by performing dose response 
curves for the muscarinic ligands.
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Under conditions in which the inositol-lipid cycle is 
turning over rapidly, the phosphatidylinositol pool will 
be labelled first as this is the entry point for the [3H]- 
inositol into the cycle. Thus, for there to be a 
sufficient accumulation of inositol phosphates the 
phosphatidylinositol pool must be adequately labelled; the 
incorporation of [3H]-inositol into phosphatidylinositol 
was assessed by using thin layer chromatography to 
separate the phospholipids and then examining the 
phosphatidylinositol fraction.
3.2). GENERAL METHODS.
3.2.1). THIN LAYER CHROMATOGRAPHY OF PHOSPHOLIPIDS
The incorporation of a radiolabelled tracer into 
phosphatidylinositol was assessed by using t.l.c. to 
separate the phospholipids and examining the PI fraction.
In t.l.c. separations, different components of a 
phospholipid mixture can be resolved, by utilising the 
different degrees to which the lipids are adsorbed onto a 
solid support coating a glass plate, and then eluted by 
the passage of a suitable solvent system. After separation 
the lipids can be easily recovered.
T.l.c. plates (20 X 20cm) were prepared by spreading 
a slurry of a highly porous amorphous silicic acid, silica 
gel G60, onto a glass support using a plate spreading
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apparatus. This gel contained a binder, calcium sulphate, 
to facilitate adhesion. The plates were impregnated with 
1% w/v potassium oxalate to sequester any calcium ions 
which may interfere with the running of the phospholipids.
Slurry mixture:
20g silica gel G60
40mIs water + 1% w/v potassium oxolate
20mls acetone.
With the above mixture up to 5 plates, 0.25mm thick 
could be prepared. Before use the plates were activated in 
an oven at 100°C for 60mins.
The phopholipid extractions were spotted or streaked 
on to the t.l.c. plates using capillary tubes, and dried 
with a cool hair dryer. After equilibrating the tank with 
the solvent mixture for 2 h, the chromatographic plates 
were developed by placing in the tank and letting the 
mobile phase ascend for the required length of time 
(Simpson et al., 1987). To keep the tank saturated it was 







Water 7 (by vol.)
Initially, the polar solvent mixture tended to strip 
off the silica gel at the base causing uneven solvent 
runs. By washing the glass plates with 0.5M HC1 and 
ensuring all the grease was removed by wiping with acetone 
prior to the spreading of the slurry better binding of the 
silica gel was achieved. Also the run time was shortened 
by heating the solvent tank on a hot plate to 45°C during 
the run. The solvent tank was placed on a gauze to 
dissipate the heat.
3.2.2). IDENTIFICATION OF PI IN LOCUST GANGLIA.
Experiments were performed in which the 
phosphatidylinositol in the locust ganglia (Schistocerca 
gregaria) was labelled with [3H]-inositol. The ganglia 
were dissected and incubated as described above.The 
phospholipids were extracted using acidified chloroform/ 
methanol. The lower chloroform phase was washed with 2M 
KC1. High salt solutions prevent the phosphoinositides 
solubilising in the upper aqueous phase.The lipid samples 
were concentrated under vacuum in a freeze drier, aliquots 
of which were streaked on t.l.c. plates and developed as 
described (see above section.)Visualisation of the 
phospholipid spots was achieved by exposure to iodine 
vapour in another tank.
Various phospholipid standards were run with the samples.
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After developing, 5mm bands of silica gel were scraped off
the glass plate, and the radioactivity in each band was
determined. It was found that the appearance of
radioactivity corresponded with the Rf value of the PI 
standard.
Rf value = distance moved by the spot/ distance from the 
origin to the solvent front
When the chromatographs were ran at different 
temperatures and times, the Rf values changed but the
order in which the phospholipids migrated remained 
constant: phosphatidic acid> phosphatidyl-ethanolamine>
phosphatidyl-serine> phosphatidyl-choline> phosphatidyl- 
inositol> lysophosphatidy1-choline. Phosphatidy1-choline 
and phosphatidylinositol ran very close to each other, and 
sometimes did not separate (tables 4a and 4b).
3.2.3) QUANTIFICATION OF PHOSPHOLIPIDS.
By oxidising phospholipids with perchloric acid, 
inorganic phosphates are released, which react with 
ammonium molybdate to form phosphomolybdic acid. Reduction 
of the latter with L-ascorbic acid yields a blue complex 
which was measured spectroscopically (Chen et al., 1956)
3.2.3.1)• ASHING PROCEDURE.
After extracting the phospholipids using acidified
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chloroform/ methanol, the chloroform phase was washed with 
2M KC1 and then dried down using a freeze drier under 
vacuum. The lipids were then resuspended in 200^1 of 
chloroform/ methanol (2:1 by vol.). A 50/il aliquot of this 
sample was oxidised with 300/*l of perchloric acid, first 
by heating over a bunsen flame until the solution turned 
black, then by placing in an oven at 120°C for 4-5 hours 
until the solution went clear.•
With the phospholipid samples which were separated on 
thin layer chromatographic plates, the perchloric acid 
oxidation was carried out in the presence of silica after 
being scraped off. But, prior to the absorbance reading 
(820nm) the silica suspension was centrifuged and the 
supernatant decanted.
3.2.3.2). ANALYSIS OF THE INORGANIC PHOSPHATE
CONTENT.
The ashed sample was made up to a volume of 6mls, and 
then divided into two 3ml portions. To each portion 3mls 
of the assay reagent was added (Chen et al, 1956). The 
tubes containing the reagent and the sample were mixed and 
incubated in a shaking water bath for 90mins at 37°C. The 
absorbance was measured at 820nm, and the phosphate 
concentration calculated by comparision with a standard 
curve prepared from inorganic phosphate (fig. 14).
3.3) MANIPULATION 07 RESULTS.
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3.3.1). [3H]-INOSITOL INCORPORATION INTO THE
INOSITOL PHOSPHATES.
3.3.1.1). DETERMINATION OF RADIOLYTIC DECOMPOSITION 
PRODUCTS.
•> ,
[H]-Inositol breaks down upon storage to release 
ionised decomposition products, which elute from ion 
exchange columns. The stock solution was precleaned on 
Dowex-1 formate before use and stored with approximately 
5mg of the resin in the stock bottle.
Even after being precleaned the [3H]-inositol still 
contained some contamination, the levels of which were 
determined. A known amount of [3H]-inositol was added to a 
Dowex formate column containing 0.2g of wet resin in a 
pasteur pipette. [3H]-Inositol was eluted with distilled 
water, and the decomposition products were eluted with 2M 
ammonium formate/ 0.1M formic acid. All the 2ml fractions 
that were collected were counted, and the amount of 
radiolytic contamination was expressed as a percentage of 
total tritium recovered. Typically, 0.5 to 1% of tritium 
was present as radiolytic products.
To calculate the levels of inositol phosphates 
recovered in the experiments, the [3H]-inositol was eluted 
with distilled water and counted. From this the level of 
contamination was determined and subtracted from the total
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radioactivity eluted with the formate solutions,
3.3.1.2). SEPARATION OF [3H]-INOSITOL LABELLED WATER
SOLUBLE PRODUCTS.
The aqueous phase of the extraction was added to 
Dowex-1 resin in formate form. Free inositol was eluted 
with lOmls of distilled water, and the radioactivity was 
determined. The glycerophosphoinositides were eluted with 
lOmls of 60mM ammonium formate/ 0.1M formic acid and 
discarded.All the [3H]-inositol products were eluted with 
5x2mls of 2M ammonium formate/ 0.1M formic acid. The 
fractions were collected and counted.
Total radioactivity = Inositol phosphates + Radiolytic 
decomposition products
Level of radiolytic decomposition products = [3H]-Inositol 
x % decomposition/ 100
A known fraction of the chloroform phase (1/4) was taken 
and ashed for lipid phosphorus determination. The results 
were expressed as the amount of [3H]-inositol incorporated 
into the inositol phosphates per microgram of total lipid 
phosphorus (d.p.m.//ug P).
3.3.2) . [3H]-INOSITOL INCORPORATION INTO PI
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An aliquot (100/il from a total of 200/xl) of the 
chloroform phase was streaked 2cm from the base of the 
20x2Ocm t.l.c. plate, and dried before developing in a 
solvent tank. The phospholipids separated into four major 
bands as visualised with iodine vapour.
Phosphatidylethanolamine (PE) ascended furthest up 
the plate, well clear of the region in which there was 
[3H]-inositol incorporation. The silica gel in this 
region, corresponding to the Rf value of the PI standard, 
was scraped off. On addition of scintillant the 
radioactivity was determined. Silica gel from other 
regions on the t.l.c. plate were also scraped off and 
counted. It was found that almost all the radioactivity 
recovered was in the PI fraction (fig. 15). Some 
radioactivity was found near the origin of the plate and 
may be explained as [3H]-inositol incorporation into the 
polyphosphoinositides. PE separated completely from PS, 
PC, PI, and thus this lipid could be scraped off and used 
as an internal standard. The results were expressed as the 
amount of [3H]-inositol incorporated into PI per microgram 
of phosphorus in PE (d.p.m./ ng P in PE).
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Figure 14.
Standard curve for inorganic phosphate assay.
Optical densities were measured (82Onm)against reagent 
blanks for known phosphate standards (a standard solution 
of potassium 26mg dihydrogen orthophosphate in 100ml 
distilled water contained 6/Ltg of phosphorus per 0.1ml). 
The results shown are expressed as mean of triplicate 
determinations for each phosphate concentration (from 

















































Separation of known phospholipids on t.l.c. plates.
The Rf values for known phospholipids, visualised by 
iodine vapour, are shown for chromatographic plates 
developed at 60°C for 60 min (table 4a, solvent front = 
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Figure 15.
[^H]-Inositol incorporation into phosphatidylinositol.
The phospholipid samples from incubation of locust ganglia 
with [ ] -inositol were prepared as described (3.2.2). 
Increasing aliquots of the chloroform phase (5pl (open 
circles), 10pl (closed circles) and 50jil (inverted open 
triangles)). The chromatogram was developed at 45^C for 
1hr. The solvent front ascended 130mm from the origin. The 
t.l.c. plate was divided into 5mm bands, and the silica 
gel was scraped off and counted. The radioactivity 
recovered in each band was determined. Identification of 
phosphatidylinositol was achieved by co-chromatography 
with a known standard (Rf value of PI=0.41 (53mm from the
origin), PE=0.69, PS=0.50, PC=0.38).
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3.4). EFFECT OF CARBACHOL AMD PILOCARPINE ON THE
INOSITOL LIPID PATHWAY.
3.4.1) METHOD
Supraoesophageal ganglia from adult locusts were 
incubated in [3H]-inositol as already described. Twenty 
ganglia were preincubated for 90mins at room temperature 
in 5mls of lithium free, calcium free buffer A containing 
2/xCi of [3H]-inositol. The 20 ganglia were split into two 
groups of 10; 5 ganglia were placed in an eppendorf tube 
containing 1ml of buffer A (+10mM lithium, +3mM calcium) 
and 2 n d  of [3H]-inositol, then incubated for 20mins at 
25°C. For treated experiments, 10/il of the agonist was 
added to the buffer to give the required concentration. 
Ten ganglia were pooled to determine the amount of [3H]- 
inositol incorporation into inositol phosphates and PI, by 
using ion exchange chromatography and thin layer 
chromatography respectively.
For each agonist used, pilocarpine or carbachol, the 
results were collected over three separate experiments. In 
each experiment 10 groups of 10 ganglia were used, in 
which the controls and the dose response were performed 
together The mean [3H]-inositol incorporation, into the 
inositol phosphates and phosphatidylinositol, for control 
and ganglia treated with agonist were determined by 
pooling the results from three experiments. From inorganic
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phosphate determinations, total lipid phosphorus and the 
percentage of PE of total lipid phosphorus were 
calculated.
3.4.2). RESULTS.
3.4.2.1). Dose response for pilocarpine.
In the presence of pilocarpine the incorporation of 
[3H]-inositol into the inositol phosphates increased 
significantly at lmM pilocarpine (p<0.002) and O.lmM 
pilocarpine (p<0.05) when compared to control values (fig. 
16) . The level of [3H]-inositol incorporation into the 
phosphoinositides tends to decrease with increasing 
agonist concentration. At O.lmM pilocarpine the 
phosphatidylinositol that is labelled is significantly 
lower than the control (p<0.02) (fig. 17).
3.4.2.2). Dose response for carbachol.
As with pilocarpine, carbachol also increased [3H]- 
inositol incorporation into the insitol phosphates, but 
higher concentrations were required (significant result 
obtained at lOmM carbachol (p<0.05), see fig. 18). [3H]-
inositol incorporation into phosphatidylinositol tended to 
decrease with increasing agonist concentration (fig. 19), 




A more rigorous characterisation of the suggested 
muscarinic receptor linked to the inositol lipid pathway 
required development of an assay system which could define 
agonist potency. Then application of various antagonists 
to the response elicited by the agonist would give an 
indication of the subclass of the receptor involved.
A dose-effect study was carried out on two muscarinic 
agonists: pilocarpine and carbachol. Pilocarpine has been 
claimed to possess selectivity for the muscarinic
receptor (Caulfield and Stabley, 1982). As it is 
postulated that the muscarinic receptor linked to the 
inositol lipid cycle in the locust ganglia is (Duggan, 
1987), the potency of pilocarpine was compared with 
carbachol in stimulating inositol phosphate turnover.
One has to exercise caution in comparing agonist 
potencies in dose-effect studies, which measure the 
physiological response that is the the final outcome of a 
sequence of events , amongst which the binding of the 
agonist to the receptor is the first. Agonist potency is 
determined by two drug dependent parameters: affinity and 
intrinsic efficacy (Kenakin, 1984). Affinity is the 
ability of the agonist to bind to the receptor, and is 
reflected in the dissociation constant of the agonist- 
receptor complex. Intrinsic efficacy relates to the 
ability of the agonist-receptor complex to elicit a
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cellular response, and is determined by the occupancy of 
the receptor for a given response. Many tissues have a 
receptor reserve for muscarinic agonist, that is, only a 
proportion of the total number of receptors need to be 
occupied for a full response. This is because the primary 
signal is amplified to give the final response. Thus, the 
apparent affinity constants obtained from dose-response 
studies are poor indicators of agonist affinity (Ringdahl, 
1984). In tissues which have a high receptor reserve, a 
full cellular response can still occur with an agonist 
with low affinity and high efficacy.
In these studies all the experiments were performed 
on the same tissue, the locust supraoesophageal ganglia. 
Thus, if the agonist were assumed to be acting on the same 
receptor population in this tissue, then the potencies can 
be compared and related to affinity. The response 
investigated was the effect on [3H]-inositol incorporation 
into the inositol phosphates and phosphatidylinositol.
There was a dose dependent stimulation of 
phosphatidylinositol turnover in the presence of 
pilocarpine (fig. 16). In the stimulated state, above 10“ 
5M pilocarpine, the variability of the results increases 
(see S.E.M.) significantly. Thus, before any statistical 
comparisions could be performed, the data had to be 
normalised by performing a log^Q x transformation, and 
then analysed using a students t-test. In comparision with 
the dose-response curve obtained in carbachol treated
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experiments (fig. 18) it was shown that the maximum 
response occurred at 10”3M carbachol. Therefore, the 
ganglia responded at a lower concentration of pilocarpine 
suggesting higher potency. The response itself is 
relatively small, in the stimulated state [3H]-inositol 
incorporation into the inositol phosphates increases 
approximately two fold, this along with the variation 
observed in the responses masked any stimulated states 
between no response and a full response.
In both the carbachol and pilocarpine dose-effect 
curves the [3H]-inositol incorporation into
phosphatidylinositol showed large variations (S.E.M was 
over 30% of the mean at 10~3M pilocarpine (fig. 17)). In 
the presence of both agonists there was a trend of 
decreasing labelled phosphatidylinositol recovered with 
increasing agonist concentration (figs. 17 and 19) . One 
could postulate that the rate at which the 
phosphatidylinositol pool is replenished is slower than 
the loss during receptor activation and inositol phosphate 
accumulation. There are many intermediates between 
formation of the second messengers and their recycling 
into the phosphatidylinositol pool. The kinetics of the 
cycle are therefore very complicated, as there are many 
enzymes involved in the interconversions.
It was interesting to note that the incorporation of 
[3H]-inositol into the phosphatidylinositol pool was 
greater in the experiments performed with carbachol than
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with pilocarpine (see controls in figs. 17 and. 19). This 
may have accounted for the greater accumulation of 
inositol phosphates observed in the carbachol dose 
response experiments (compare figs. 16 and 18). These 
results suggest that the labelling of the 
phosphatidylinositol pool can vary significantly from one 
set of experiments to the next,
This perhaps is not altogether surprising, as the 
phosphatidylinositol pool gets labelled initially from the 
traumatised state of the ganglia during the dissection and 
the period spent in the preincubation buffer. One would 
expect the ganglia to be in different states of trauma 
because dissection of 20 ganglia takes 15 min., hence the 
last ganglion to be dissected has a shorter preincubation 
period than the first ganglion. Variability in the 
labelling of the phosphatidylinositol pool would result in 
variability of the response, as it is from this pool that 
the accumulation of inositol phosphates is obtained.
The stimulation of inositol phosphate turnover in the 
presence of pilocarpine lends further evidence to the 
suggestion that a muscarinic like receptor is present in 
insects which is linked to the inositol lipid cycle. Even 
though pilocarpine seems to be more potent than carbachol 
( the ganglia respond at 1 0“4M pilocarpine, but not at the 
same concentration of carbachol), high concentration of 
this agonist is required for phosphatidylinositol 
hydrolysis. Other doseresponse studies (Fisher and Snider,
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1987) also show high concentration requirements for the 
phosphoinositide response (EC50 for carbachol in the 
guinea pig cerebral cortex is 200/aM) • These results 
suggest that a high degree of receptor occupancy may be 
needed to maximally activate the inositol lipid cycle. 
Also, as the experiments were performed using whole 
ganglia, high concentrations of agonist may have been 
required to overcome diffusion barriers.
The receptor number can be reduced in any tissue by 
irreversible alkylation. After which, the changes in the 
functional response can be assessed. If the muscarinic 
receptors in chick atrial cells are alkylated using 
propylbenzilycholine mustard, Brown and Goldstein (1986) 
demonstrated that carbachol failed to give a maximal 
response, and by increasing the alkylation the magnitude 
of the response decreased progressively. Thus for the 
phosphatidylinositol system there seems to be little 
receptor reserve. In comparison the dose response for the 
inhibition of adenylate cyclase shifts to the right, but 
there is no reduction in the response until up to 95 % of 
the muscarinic receptors are alkylated. Therefore, there 




Effect of increasing doses of pilocarpine on the 
incorporation of [3H]-inositol into the inositol
phosphates.
Twenty ganglia were preincubated for 90min. In control 
experiments the ganglia were transferred into buffer A 
containing lOmM lithium and 3mM calcium for 20min (n=9). 
For agonist treated ganglia, 5 doses of pilocarpine were 
used (10” 7 (n=3), 10” 6 (n=3), 10” 5 (n=4), 10~ 4 (n=3) and 
10~ 3 (n=3)). The upper water soluble phase of the
acidified chloroform/methanol mixture was pooled from 10 
ganglia and added to Dowex-1 formate columns. The results 
were obtained from four separate experiments, and the mean 
incorporation of [3H]-inositol into the inositol
phosphates from n replicates were determined (d.p.m. 
radioactivity recovered per /ug of total lipid phosphorus, 
total lipid phosphorus in 10 ganglia = 20.2 M9 P +/“ 2.5 
(s.d.), n=10). Control value is represented by the dashed 
line (114 d.p.m.//xg P +/- 14.3 (S.E.M.). Agonist treated
ganglia are represented by the filled circles. Fmax test 
for the largest and smallest variances showed that they 
were significantly different (p<0.05, two tailed). The 
results were compared using students t-test after a log10x 
transformation. There were significant increases at O.lmM 
and ImM pilocarpine.
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The effect of increasing doses of pilocarpine on the 
incorporation of [3H]-inositol into phosphatidylinositol 
(PI).
The ganglia were preincubated and incubated as described 
in fig. 16. The phospholipids were prepared from the lower 
chloroform phase of the acidified chloroform / methanol 
mixture, and separated by t.l.c.. Radioactivity recovered 
from the phosphatidylinositol fractipn (see fig.15) of the 
ganglia (10) incubated in control conditions (n=5) and in 
the presence of pilocarpine (n=3 for 10“7, 10”6, 10”5, 10" 
4, 10“ 3 M) was measured. The results were pooled from
three separate experiments, and the mean incorporation of 
[3H]-inositol into PI for n replicates were determined 
(radioactivity in PI (d.p.m.) per /xg phosphorus in 
phosphatidylethanolamine (PE), % PE of total lipid
phosphorus = 16.7% +/- 3.9 (s.d.), n=10). The control
value is represented by a dashed line (3860 d.p.m. / pq V 
in PE +/- 483 (S.E.M.). There was a significant decrease 






































The effect of increasing doses of carbachol on the 
incorporation of [3H]-inositol into the inositol 
phosphates.
For preincubation and incubation conditions see fig. 16. 
The upper water soluble phase of the acidified chloroform 
/methanol mixture was pooled from 10 ganglia Radioactivity 
recovered in [3H]-inositol labelled inositol phosphates 
was determined using anion exchange chromatography for 
control (n=3) and carbachol treated ganglia (n=3 for 10~5, 
10"4, 5xl0”4, 10” 3 and 10” 2 M carbachol). The results
were pooled from three separate experiments, and the mean 
incorporation of [3H]-inositol is shown for n replicates 
(d.p.m. of total radiolabelled inositol phosphates per /xg 
of total lipid phosphorus, total lipid phosphorus per 10 
ganglia = 18/xg P +/- 1.6 (s.d.), n=10). Control value is 
represented by a dashed line (214 d.p.m. //xg P +/- 16
(S.E.M.), n=3). There was a significant increase at lOmM 
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The effect of increasing doses of carbachol on the 
incorporation of [3H]-inositol into phosphatidylinositol 
(PI).
For preincubation and incubation conditions see fig. 16. 
The phospholipids were prepared the chloroform soluble 
phase of the acidified chloroform / methanol extraction 
mixture, and separated by t.l.c.. Radioactivity recovered 
from [3H]-inositol labelled phosphatidylinositol was 
determined from ganglia incubated in control conditions 
(n=3) and those treated with carbachol (10“ 5 (n=3), 10” 4
(n=4), 5 x 1(T4 (n=3), 10“ 3 (n=3), 10“ 2 (n=3) M) . The
results were pooled from three separate experiments, and 
the mean incorporation of [3H]-inositol is shown for n 
replicates (d.p.m. of labelled phosphatidylinositol / /Ltg 
of lipid phosphorus in phosphatidylethanolamine (PE), % PE 
of total lipid phosphorus = 16.7% +/- 3.9 (s.d.), n=10). 
The control value is represented by the dashed line (11 
020 d.p.m. / ng of P in PE) . There was a significant 
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3.5). EFFECT OF REMOVING [3H]-INOSITOL FROM THE
INCUBATION BUFFER.
Experiments were performed in which the radiolabel 
was only present in the preincubation buffer. This would 
determine whether or not the PI pool labelled during the 
preincubation period is utilised to show an increase in 
inositol phosphate turnover. A muscarinic cholinergic 
agonist pilocarpine, was used in the incubation buffer not 
containing the radiolabel.
3.5.1). METHOD.
See general methods for detailed descriptions. Twenty 
ganglia were preincubated for 90mins at room temperature 
in 5mls of buffer A containing 5/xCi of [3H]-inositol. 
Groups of 10 ganglia were taken for determination of [3H]- 
inositol incorporation into PI and inositol phosphates 
(preincubation).
In control experiments, 5 ganglia were placed in 1ml 
of buffer (+10mM lithium, 3mM calcium) without radiolabel 
and incubated for 20mins at 25°C. For agonist treated 
experiments, 10/xl of 0.1M pilocarpine was added to 1ml of 
incubation buffer (to give final concentration of ImM).
The results were obtained for two separate 
experiments. The total lipid phosphorus and the mean
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percentage of phosphatidylethanolamine were determined.
3.5.2). RESULTS
When the ganglia were treated with ImM pilocarpine 
there was no effect on [3H]-inositol incorporation into 
phosphatidylinositol and inositol phosphates in the 
absence of [3H]-inositol in the incubation buffer (figs. 
2 0a and 20b).
3.5.3). DISCUSSION.
Results obtained from experiments in which the 
radiolabel was removed from the incubation buffer (fig. 
20), showed that the incorporation of [3H]-inositol into 
the phosphatidylinositol pool was much less than that 
obtained from the dose response studies. Thus, the 
presence of the radiolabel further labels the 
phosphatidylinositol pool after the preincubation period. 
In experiments with carbachol the appearance of the label 
into the phosphatidylinositol fraction increases by nearly 
ten fold (1256 d.p.m.//xg in PE (fig. 20a) to 11020 
d.p.m.fug in PE (fig. 19)), if one compares the activity 
after the preincubation period and that obtained from 
control experiments, which included a 20 min incubation 
period in the presence of [3H]-inositol.
There was a small but insignificant increase in the 
accumulation of [3H]-inositol phosphates from the labelled
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phosphatidylinositol pool when incubated in the presence 
of lmM pilocarpine (fig. 20b). Thus, in inositol free 
conditions during the incubation period, the label could 
not be chased out of the phosphatidylinositol pool. This 
suggested the presence of an agonist insensitive 
phosphatidylinositol pool. Koreh and Monaco (1986) have 
demonstrated that rat WRK-1 rat mammary tumour cells 
contain at least two distinct pools of 
phosphatidylinositol, only one of which is sensitive to 
hormonal action.
Since a pilocarpine induced response was observed in 
experiments in which [3H]-inositol was added to the 
incubation buffer (fig. 16), one can conclude that much of 
the turnover of the inositol lipid cycle occurs during the 
incubation period. There has to be a large excess of [3H]- 
inositol in the buffer to enable rapid incorporation into 
the phosphatidylinositol pool, in order to observe the 
appearance of the label in the inositol phosphates. 
Studies in the blow fly salivary gland investigating the 
hormonal activation of phosphatidylinositol hydrolysis 
(Fain and Berridge, 1979) indicated that newly synthesised 
[3H]-phosphatidylinositol appears to be preferentially 
hydrolysed following stimulation by the agonist, 5- 
hydroxytryptamine. Results from these experiments on 
locust ganglia show that the phosphatidylinositol pool can 
be further labelled and acted upon by an agonist within 
the 20 min incubation period. Even though the 
phosphatidylinositol pool is labelled during the
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preincubation period, the absence of accumulation of [3H]- 
inositol phosphates in the presence of a muscarinic 
agonist, suggests that this pool is inaccessible to 
agonist action. A small sub-pool has to be constantly 
replenished with labelled phosphatidylinositol to observe 
an accumulation of [3H]-inositol phosphates.
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Figure 20.
The effect of removing [3H]-inositol from the incubation 
buffer.
Groups of 20 ganglia were prelabelled for 90min in 5ml of 
buffer A containing 5/iCi [3H]-inositol. The radioactivity 
incorporated into the inositol phosphates and 
phosphatidylinositol were determined immediately following 
this preincubation period (represented by P in tables 20a 
and b (hatched rising to the right) n=7)). Incubations 
were carried out in the absence of the radiolabel (buffer 
A + lOmM lithium and 3mM calcium). Radioactivity recovered 
from the inositol phosphates and PI after the 20 min 
incubation period were determined for groups of 10 ganglia 
in control conditions ('C* (hatched rising to the left), 
n=6 )and from those treated with ImM pilocarpine (*T* 
(cross hatched), n=6 ). The results were pooled from 2
separate experiments, and the mean (+/- S.E.M.)
incorporation into the inositol phosphates (d.p.m.//Ltg 
total lipid phosphorus, total lipid phosphorus from 10 
ganglia = 16.4/xg P +/- 2.3 (s.d.), n=10), and PI
(d.p.m./^g P in PE, % of PE of total lipid phosphorus = 
24.5% +/- 5.2 (s.d.), n=10).
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3.6). THE EFFECT OF ADDING PHYTATE HYDROSYLATE IN
THE EXTRACTION PROCEDURE.
3.6.1). INTRODUCTION.
The experiments were repeated to investigate the 
effects of pilocarpine, atropine and lithium on the 
incorporation of [3H]-inositol into the inositol 
phosphates and PI. In these experiments the phytate 
hydrosylate was added in the extraction procedure as 
described below. The effect of phytate hydrosylate on the 
recovery of inositol phosphate standards (inositol 1- 
phosphate, inositol 1,4-bisphosphate, inositol 1,4,5- 
trisphosphate) from the extraction procedure and Dowex 
columns was also determined.
3.6.2) PREPARATION OF PHYTATE HYDROSYLATE.
Losses of trace amounts of labelled inositol 
phosphates in the extraction procedure can be reduced by 
the addition of a random mixture of cold inositol 
phosphates (Wreggett et al., 1987). This was prepared by 
dissolving lg of sodium phytate in 5mls of 0.2M sodium 
acetate/ acetic acid, pH 4.0, in a glass stoppered tube 
and heated in a boiling water bath for 8 hours. After 
cooling the solution was desalted by passage through 4ml 
of Amberlite resin (IR-120(H), BDH Chemicals) in a pasteur 
pipette (Wreggett and Irvine, 1987).
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To the stock solutions of 0.5M HC1 and distilled 
water, the phytate prepared above was added in the ratio 
1:100 v/v. Thus, the acidified chloroform/ methanol 
contained 1ml of 1:2 chloroform: methanol, 0.2ml 0.5M HC1 
and 2/il of phytate hydrosylate. The water which was used 
to separate the phases (0 .2mls) also contained 2/il of 
phytate hydrosylate.
3.6.3). THE EFFECT OF ADDING PHYTATE HYDROSYLATE TO
THE EXTRACTION MIXTURE ON THE RECOVERY OF 
INOSITOL PHOSPHATE STANDARDS IN THE
PRESENCE OF LOCUST GANGLIA.
As the losses of inositol phosphates on the Dowex-1 
formate columns were limited (up to 85% recovery) , the 
whole acidified choloform/methanol extraction procedure 
was performed in the presence of the ganglia in order to
determine whether or not the tissue itself binds to the
inositol phosphates. The effect of adding phytate
hydrosylate on the recovery was also determined.
3.6 .3.1). METHOD
Groups of 10 ganglia were homogenised in acidified 
chloroform/methanol (see above) containing a known amount 
of radiolabelled inositol phosphates (approximately 20 000
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d.p.m. of the mixture). This was performed in the. presence 
or absence of phytate hydrosylate, which was added to the 
0.5M HC1 and distilled water. The upper phase of the 
extraction mixture was added to the Dowex-1 formate 
columns and eluted with distilled water and 2M ammonium 
formate/0.1M formic acid. The total inositol phosphates 
recovered was determined by scintillation counting of the 
fractions eluted (see above).
3.6 .3.2). RESULTS
The recovery of inositol phosphates was increased in 
the presence of phytate hydrosylate (from 32.5% to 52.5%, 
n=5), but losses of up to 50% were incurred when the 
extraction was peformed in the presence of locust ganglia 




+PHYTATE 52.5 (5.4) n=5
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3.7). THE EFFECT OF PILOCARPINE, ATROPINE AND
LITHIUM ON [3H]-INOSITOL INCORPORATION INTO 
THE INOSITOL PHOSPHATES AND
PHOSPHATIDYLINOSITOL
3.7.1). METHOD
Groups of 20 ganglia were preincubated for 90 min at 
room temperature in 5mls of buffer containing 5/iCi of 
[3H]-inositol. Groups of 5 ganglia were then placed in 1 
ml of incubation buffer, which included 3mM calcium and 
2/iCi of [3H]-inositol for 20min at 25PC. The reaction was 
stopped on dry ice, and [3H]-inositol incorporation into 
the inositol phosphates and phosphatidylinositol was 
determined for 10 ganglia (2 groups of 5 pooled). The mean 
radioactivity recovered in the inositol phosphate 
fractions (d.p.m./nq total lipid phosphorus) and 
phosphatidylinositol (d.p.m.//ug lipid phosphorus in PE) 
were determined from pooling the results obtained from 
three separate experiments.
The incubations were treated to investigate the 
effects of O.lmM pilocarpine, O.lmM atropine and lOmM 
lithium. Control experiments were performed in the 
presence or absence of lOmM lithium in the incubation 
buffer. To determine the effect of a muscarinic agonist, 
the ganglia were treated with O.lmM pilocarpine in the 
presence or absence of lOmM lithium. The effect of adding 
an antagonist, O.lmM atropine, to ganglia treated with
122
O.lmM pilocarpine was also measured.
3.7.2). RESULTS.
The results show that there was an increase in the 
recovery of inositol phosphates in the presence of phytate 
hydrosylate in the extraction procedure (compare the 
radioactivity recovered when• stimulated with 0.ImM 
pilocarpine in the absence of phytate hydrosylate (fig 
16) , and that obtained from experiments in which phytate 
hydrosylate was added to the extraction mixture (fig. 
21a)). Figure 21a shows an increase in [3H]-inositol 
incorporation into the inositol phosphates in experiments 
treated with O.lmM pilocarpine. On addition of lOmM 
lithium, the accumulation of inositol phosphates, was 
enhanced (fig* 2 1a, p<0.01 when compared with
control+lithium). However, no significant effect of the 
antagonist, atropine, was observed on pilocarpine (O.lmM) 
and lithium (lOmM) treated ganglia. Comparing the effects 
of pilocarpine on the incorporation of [3H]-inositol into 
phosphatidylinositol showed no significant changes (fig. 
21b). When the ganglia were treated with O.lmM 
pilocarpine, 0.1 mM atropine and lOmM lithium there was a 
significant increase (fig. 21b, p<0 .0 2) in the recovery of 
radiolabelled phosphatidylinositol.
Whereas, enhancement of [3H]-inositol phosphate 
accumulation was not observed in the presence of lOmM 
lithium, 3mM calcium and lOmM carbachol, these results
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show that by improving the recovery of inositol phosphates 
and stimulating with a more potent agonist, pilocarpine, 
lithium enhances the effect of pilocarpine. However, 
atropine did not antagonise the effect of the agonist. The 




The effect of adding phytate hydrosylate in the extraction 
procedure.
After 90min preincubation, groups of 10 ganglia were 
incubated for 20 min in buffer A containing 3mM calcium 
and 5/xCi [3H]-inositol. Phytate hydrosylate was added to 
the acidified chloroform / methanol extraction mixture to 
increase the recovery of inositol phosphates. Control 
incubations are represented by 'C' (hatched rising to the 
right, ^ 6 ) and control incubations in the presence of 
lOmM lithium are represented by 'C+LI' (hatched rising to 
the left, n=6 ) • Experiments were performed in which the 
ganglia treated with O.lmM pilocarpine in the absence 
('PlL' (cross hatched), n=4) or presence of lOmM lithium 
('PIL+LI* (vertical lines), n=4). The effect of an 
antagonist, atropine, was measured by treating the ganglia 
with O.lmM pilocarpine, lOmM lithium and O.lmM atropine 
('ANT* (horizontal lines), n=4). The results were pooled 
from three separate experiments, and the mean 
incorporation of [3H]-inositol incorporation into the 
inositol phosphates (fig. 21a) and PI (fig. 21b) were 
determined. In the presence of pilocarpine and lithium, 
there was an increase in the recovery of radiolabelled 
inositol phosphates, when compared with control+lithium. 
Atropine did not antagonise the effect of pilocarpine in 
the presence of lithium (fig* 21a). There was a 
significant increase in the labelling of the PI pool in 
the presence of atropine (fig. 21b).
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A more definitive demonstration that 
phosphatidylinositol breakdown is linked to the 
muscarinic-like receptor activation in the locust ganglia 
may be obtained from using cell free systems. The 5- 
hydroxytrptamine receptor in the blow fly salivary gland 
was first characterised using whole glands, which then led 
to the development of a cell free system to further 
ascertain the effects of receptor activation on G-protein 
and phospholipase C activation.
5-HT receptors in intact blowfly salivary glands 
linked to both cyclic adenosine 3•, 5•-monophosphate
formation and calcium mobilisation (Berridge and Heslop, 
1981) could be distinguished pharmacologically using both 
agonists: 5-methyltryptamine was more potent in
stimulating hydrolysis of phosphatidylinositol and the 
transport of calcium, whist 4- and 5-fluoro-a- 
methyltryptamine was capable of raising cAMP levels and 
stimulating fluid secretion, and antagonists: methysergide 
was a potent inhibitor of phosphatidylinositol hydrolysis, 
whilst cinanserin was far more selective in blocking the 
stimulatory effect of 5-HT on cAMP formation. Such 
pharmacological characterisations of blow fly salivary 
glands were made possible because of the well defined and 
consistent responses to the agonists, both with respect to 
second messenger generation and ' the associated
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physiological responses. This was not found to be. the case 
in our studies using locust ganglia, in which the 
formation of inositol phosphates in response to the 
addition of agonists was variable and dependent on other 
factors such as calcium ion concentrations. Using whole 
tissue preparations the indirect effect of drug action 
remain indetermined. The agonist may act on other 
receptors or second messenger systems which indirectly 
affect the system being studied.
A cell free system to study the effects of receptor 
activation enables characterisation of the G-protein link 
to the effector: adenylate cyclase, guanylate cyclase and 
phospholipase C. Evidence for the presence of G-proteins 
in insects has come from studying the effects of GTP on 
the binding of muscarinic agonists (Whyte and Lunt, 1986), 
the cloning of a Drosophila melanogaster guanine 
nucleotide regulatory protein 6 -subunit gene (Yarfitz et 
al., 1988), and the effects of guanine nucleotide 
analogues in stimulating inositol phosphate formation in 
cell free blow fly salivary glands (Litosch and Fain, 
1985; Litosch et al., 1985).
To demonstrate phospholipase C activity in cell free 
systems the agonist sensitive phosphatidylinositol pool 
must be adequately prelabelled. Initial studies on the 
blowfly salivary gland prelabelled with [3H]-inositol 
(Fain et al., 1983) found that on homogenisation there was 
rapid degradation of labelled phosphatidylinositol. This
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problem was circumvented by performing the studies in the 
presence of EGTA, a calcium ion chelator. Experiments by 
Litosch et al. (1985) on the cell free system, provided 
direct evidence that guanine nucleotides were required for 
the expression of the hormone effect on phosphoinositide 
breakdown. Stable GTP analogues, Gpp(NH)p and GTPrS could 
directly activate inositol phosphate formation, and could 
act synergistically with 5-methyltryptamine, a PI specific 
5-HT receptor agonist. A linear rate of inositol phosphate 
formation was not maintained for more than 15 sec., and a 
decline in the enzymatic rate was readily apparent after 
30sec. This departure from the first order kinetics 
suggested rapid depletion of hormone sensitive lipid 
substrate during incubation of the homogenate at levels 
where the Vmax can no longer be maintained.
In these studies using locust ganglia, the 
phosphatidylinositol pool labelled with [3H]-inositol 
during the preincubation period was found not to be 
sensitive to the action of agonist (fig. 20a and b) . This 
would suggest that development of a cell free preparation 
to investigate phospholipase C activity may be 
impracticable. Labelling of the agonist sensitive 
phosphatidylinositol pool required the presence of the 
agonist: carbachol or pilocarpine, and the extent of
labelling with [3H]-inositol was found to be very variable 
(see figs. 16-19). A better approach may be to add 
exogenous labelled phosphoinositides to the homogenate, 
similar to the studies by Litosch and Fain (1985) on the
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blowfly salivary gland cell free experiments. The 
contribution of the endogenous substrate must be 
considered in such studies, as the exogenous lipid 
substrate may compete poorly with the endogenous lipid 
substrate (Litosch and Fain, 1985). Accessibility of the 
substrate to the catalytic site would require 
optimization.
Cell free systems provide a valuable approach to the 
study of receptor/G-protein/phospholipase C relationships. 
Prelabelling of the agonist sensitive phosphoinositide 
pools prior to experimentation may prove to be 
problematic. Availibility of assays which measure mass 
changes of inositol 1 ,4,5-trisphosphate in stimulated 
conditions may help to counter these problems, as this 
would alleviate the need to prelabel the 
phosphoinositides.
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4). HIGH PRESSURE LIQUID CHROMATOGRAPHY OF
INOSITOL PHOSPHATE ISOMERS.
4.1). INTRODUCTION
Separation and purification of the various inositol 
phosphate isomers can be achieved by the use of an 
h.p.l.c. separation procedure (Batty et al, 1989). 
Although the batch technique using Dowex chromatography 
can be used to separate inositol mono-, bis-, and tris 
phosphates, it does not separate different isomers such as 
inositol 1,3,4-trisphosphate and inositol 1,4,5- 
trisphosphate. Experiments were performed to determine 
whether [3H]-inositol was incorporated into inositol
1,4,5-trisphosphate in the locust ganglia.
Before separation of the inositol phosphates using 
h.p.l.c. a purification procedure was employed using 
Accell QMA ion exchange SEP-PAK columns (Wreggett and 
Irvine, 1987). This offered a rapid, high recovery and 
reproducible method for the separation of the total 
inositol phosphates.
4.2). METHODS.
The dissections, preincubation and incubation 
conditions were essentially the same as already described
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in general methods (see 2 .2 ).
4.2.1). PREINCUBATION.
Groups of 10/20 ganglia were preincubated in 5 mis of 
buffer A (calcium free, lithium free) containing 3/xCi of 
[3H]-inositol, for 90 min at room temperature.
4.2.2). INCUBATION.
The ganglia were split into groups of 5 and placed in
Eppendorf tubes containing 1 ml of buffer A, 3mM calcium
, , , ,and 4/xCi [ H]-inositol. Incubations were performed m  the
presence or absence of 0.5mM carbachol. The agonist 
treated experiments were performed in the presence or 
absence of lOmM lithium. Incorporation of [3H]-inositol 
into the inositol phosphates was determined over a 1 hour 
period at 30°C.
4.2.3). SAMPLE PREPARATION.
The acidified chloroform/methanol extraction 
procedure was applied to groups of 10 ganglia. Further 
purification of the inositol phosphates was achieved by 
loading the upper phase onto Accell QMA SEP-PAK cartridges 
(Waters Associates) in formate form. The free [3H]- 
inositol was eluted with distilled water (2 x 2mls) and 
counted. Radiolabeled inositol phosphates were eluted with 
3mls of 0.5M ammonium formate (see characterisation of
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Accell QMA SEP-PAK columns (see 4.2.4.2). A fraction of 
this eluate (0.5 mis) was taken to be counted, and the 
remainder (2.5 mis) was freeze dried. The inositol 
phosphates were then redissolved in 0.5 mis of distilled 
water, filtered and then freeze dried. The samples were 
then prepared for h.p.l.c. analysis by redissolving in a 
solution containing nucleotides and phytate hydrosylate. 
Nucleotides could then be detected by continuous u.v. 
monitoring of the column eluate at 254nm. Thus, variations 
in retention times between runs or column ageing could be 
routinely measured. These nucleotides were not used as 
absolute markers for inositol phosphates. Inositol 
monophosphates were expected to be eluted at retention 
times intermediate to cyclic adenosine monophosphate 
(cAMP) and guanine monophosphate (GMP), inositol 
bisphosphates between adenosine diphosphate (ADP) and 
guanine diphosphate (GDP), and inositol trisphosphates 
between adenosine triphosphate (ATP) and guanine 
triphosphate (GTP), thus providing a means for 
standardising each run (Batty et al, 1989).
STOCK SOLUTIONS:
Nucleotide mixture: 0.2ml of 5mM cAMP
0.2ml of 5mM GMP 
0.2ml of 5mM GDP 
0.2ml of 5mM ADP 
0.2ml of 5mM ATP 
40/il of Phytate hydrosylate.
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H.p.l.c. sample: 100/xl of the nucleotide mixture added
to the freeze dried sample of 
radiolabelled inositol phosphates.
Standards: 20/xl of [3H]-inositol phosphates




The h.p.l.c. sample (50/xl) and the inositol phosphate 
standards (40/xl) were injected and separated on a Partisil 
10 SAX anion exchange column (see 4.2.5).
4.2.4). SEP-PAK CHROMATOGRAPHY.
4.2.4.1). COLUMN PREPARATION.
Accel1 QMA anion exchange SEP-PAK cartridges (Waters 
Associates) were converted to formate form by washing 
first with 10 mis of a solution of 2M ammonium formate in 
0.1M formic acid (pH 4.75) followed by 20 mis of distilled 
water.
Sample loading and solution delivery were performed 
manually using disposable syringes (with Luer fitting); an 
approximate flow rate of 10-15 ml/min was typically 
maintained. The inositol phosphates could then be eluted
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with increasing concentrations of ammonium formate.
4.2•4•2). CHARACTERISATION OF SEP-PAK CARTRIDGES.
4.2.4.2.1). GRADIENT ELUTION.
The inositol phosphate standard mixture was prepared 
as described and loaded (40/il)’ on to SEP-PAK cartridges 
converted into formate form . The inositol phosphates were 
eluted with 1ml of lOmM increments of ammonium formate/ 
formic acid (pH 4.75)/ 5mM disodium tetraborate (0 to 
300mM). The recovery of inositol 1-phosphate, inositol 
1 ,4-bisphosphate and inositol 1 ,4,5-trisphosphate per 
fraction was determined. Radioactivity was measured by 
liquid scintillation counting (Beckman LS6000 TA, 35-40% 
efficiency for 3H).
4.2.4.2.2). BATCH ELUTION.
The data obtained from the gradient elution were used 
to determine suitable concentrations of ammonium formate 
for batchwise separation of inositol phosphates.
4.2.5). H.P.L.C. OF INOSITOL PHOSPHATES.
Separation of the [3H]-inositol phosphate isomers was 
achieved with a Partisil ( 1 0 / l i M )  SAX anion exchange column 
(HPLC Technology Ltd) (25cm x 4.6cm) equipped with a guard 
column packed with the same resin.
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The samples prepared from the [3H]-inositol 
incorporation experiments were injected (50/il of the 100/xl 
sample prepared from the pooling of 20 ganglia) using an 
auto injector (Shimadzu SIL-6B). After sample injection 
the isomers of inositol phosphates were separated by 
gradient elution from the column. The output volume was 
regulated by two separate pumps (Shimadzu LC-6A) feeding 
into a mixing chamber: pump A contained distilled water, 
and pump B contained 1.7M ammonium formate adjusted to pH 
3.7 with phosphoric acid. The flow rate (1.2 ml/min) and 












The elution of guanine and adenine nucleotides was 
monitored using a u.v. spectrophotometric detector
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(Shimadzu SPD-6AV) set at 254nm. Fractions were collected 
(Gilson fraction controller (0.5 min/fraction, from 10 to 
45 min)) and counted by liquid scintillation using a 
Packard Tri-Carb 460 scintillation counter (background 
approximately 20 d.p.m., 35-40% efficiency for tritium). 
Identification of the inositol phosphates was achieved by 
co-elution with known [3H]-inositol labelled standards 
(Inositol polyphosphate marker set obtained from Amersham 
(0.37KBq//ul) , which contained [3H]-inositol 1-phosphate, 
[3H]-inositol 1,4-bisphosphate, [3H]-inositol 1,4,5- 
trisphosphate).
4.2.6). SEPARATION OF INOSITOL 1,4,5-TRISPHOSPHATE,
INOSITOL 1,3,4-TRISPHOSPHATE AND INOSITOL
1,3,4,5-TETRAKISPHOSPHATE.
4.2.6.1)• SEPARATION OF STANDARDS.
From previous experiments it was shown that at least 
two peaks of [3H]-inositol trisphosphates were resolved 
using high pressure liquid chromatography. The major peak 
did not co-elute with the inositol 1 ,4,5-trisphosphate 
standard, and was postulated to be the inositol 1,3,4- 
trisphosphate isomer.
Inositol 1,4,5-trisphosphate, inositol 1,3,4- 
trisphosphate and inositol 1,3,4,5-tetrakisphosphate 
(obtained from NEN Research Products, 0.37 KBq/fil each) 
were resolved using the Partisil 10 SAX ion exchange
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column.
Nucleotide mixture: 100/Ltl of 5mM cyclic guanine
monophosphate, guanine diphosphate, 
guanine trisphosphate, adenosine 
diphosphate, adenosine triphosphate, 
adenosine tetraphosphate.
10/il of phytate hydrosylate.
Inositol phosphate standards:
300/il of the nucleotide mixture. 
lO/il each of the inositol phosphate 
standards (0.37KBq//xl) .
The inositol phosphate mixture (40/xl) was injected 
onto the h.p.l.c. column and separated by gradient elution 
(1 ml/min., output volume controlled by two pumps: pump A 
contained distilled water and pump B contained 1.5M 










The intermediate components between the pump and the 
fraction collector/u.v. detector have a volume of several 
millilitres. At a flow rate of 1 ml/min an appropriate 
compensation of 8 min was made when superimposing 
gradients on the elution profiles obtained. Fractions were 
collected (0.5 min/fraction) from 30 to 50 min, and the 
radioactivity in each fraction was determined by liquid 
scintillation counting.
4.2.6 .2). SEPARATION OF [3H]-INOSITOL LABELLED
INOSITOL PHOSPHATES IN LOCUST GANGLIA
Groups of 24 ganglia were preincubated for 90 min in 
5 mis of buffer A containing 4/xCi of [3H]-inositol. These 
were split into groups of 6 ganglia, and incubated for 60 
min at 25°C in 1 ml of buffer A containing 4juCi of [3H] — 
inositol, 3mM calcium, lOmM lithium and 0.5mM carbachol. .
The incubation was terminated by placing the ganglia 
on dry ice. The upper phase of the acidified 
chloroform/methanol extraction mixture from the pooling of 
24 ganglia was added to SEP-PAK columns. Radiolabelled 
inositol phosphates were eluted and prepared for h.p.l.c. 
analysis as described above (see sample preparation). The 
freeze dried samples were resuspended in 100/Ltl of the 
nucleotide mixture, and 50/il was injected onto the
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h.p.l.c. column. The elution protocol was as described for 
the separation of the standards. Fractions were collected 
(0.5min/fraction) from 8 min to' 48 min, and the 
radioactivity in each fraction determined by liquid 
scintillation.
4.2.7). SEP-PAK SEPARATION OF INOSITOL TRIS- AND
TETRAKIS PHOSPHATE.
Gradient elution of inositol 1,4,5-trisphosphate 
(IP3 ) and inositol 1,3,4,5-tetrakisphosphate (IP4 ) on SEP- 
PAK cartridges in formate form was performed.
4.2.7.1) RECOVERY OF IP4 FROM SEP-PAK COLUMNS.
The inositol 1,3,4,5-tetrakisphosphate standard (10/xl from 
a mixture containing 10/xl of the standard (0.37 KBq//xl, 
NEN Research Products) , 10/xl phytate hydrosylate and 100/xl 
of distilled water) was added to SEP-PAK columns in 
formate form, and eluted with 1 ml of ammonium formate (pH
4.75 with formic acid) in steps of lOmM (from 150mM to
350mM). Radioactivity per fraction was determined by 
liquid scintillation counting.
4.2.7.2) RESOLUTION OF IP3 AND IP4.
The inositol phosphate mixture (10/xl of a mixture
containing 10/xl IP4 , 10/xl IP3 , 10/xl phytate hydrosylate, 
100/xl distilled water) was added to the SEP-PAK column and
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eluted with ammonium formate (pH 4.75) at lOmM increments 
(1 ml). Fractions (1 ml) were collected, and the 
radioactivity determined by liquid scintillation counting.
4.2.8). TIME COURSE FOR THE PRODUCTION OF INOSITOL
PHOSPHATES
Groups of 20 ganglia were dissected and preincubated 
for 90 min in 5 mis of buffer A containing 5/iCi of [3H]-
inositol. After which, the ganglia were transferred into
, , , , , *> , , 
the incubation buffer containing 4/iCi [ H]-inositol, 3mM
calcium, lOmM lithium in the presence or absence of 0*5mM
carbachol. The ganglia were incubated at 25°C in groups of
5 for 10, 20, 40, 60 and 120 min in control and carbachol
treated conditions. Thus, 50 ganglia were used in each
experiment, and four separate experiments were performed.
The radiolabelled inositol phosphates were recovered 
from the ganglia using the acidified chloroform/methanol 
extraction procedure in the presence of phytate 
hydrosylate. The upper water soluble phase was taken for 
analysis on SEP-PAK columns. Free [3H]-inositol and the 
glycerophosphatidylinositol were eluted with 2x2 mis 
distilled water and 1x2 mis 5mM disodium tetraborate 
respectively. The radiolabelled inositol phosphates were 
eluted with 0.4M ammonium formate (pH 4.75).
The amount of [3H]-inositol incorporated into the 
inositol phosphates per 5 ganglia was determined at each
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incubation time point for control and carbachol treated 
experiments (n=4).
4.3). RESULTS.
The inositol phosphate standards were well resolved 
by gradient elution from SEP-PAK ACELL QMA cartridges 
(fig. 22). The inositol 1-phosphate, inositol 1,4- 
bisphosphate and inositol 1,4,5-trisphosphate peaks 
occurred at 40mM, 140mM and 190mM ammonium formate
respectively. Thus, by elution with 0.5M ammonium formate, 
total radiolabelled inositol phosphates can be determined. 
From the gradient elution profile, a batch elution 
protocol for each of the inositol polyphosphates was 
determined. Inositol mono-, bis- and trisphosphates may be 
resolved by sequential batch elution with 80mM, 150mM and 
240mM ammonium formate respectively. A mixture of inositol 
polyphosphate standards was separated by batch elution as 
shown in figure 23 (% recovery of inositol mono-, bis-,
tris phosphate and total inositol phosphates were 80.8% 
+/- 4.8 (S.E.M.), 103% +/- 10.9 (S.E.M.), 82.7% +/- 6.7
(S.E.M.) and 89.1% +/- 3.5 (S.E.M.), n=4). Using this
protocol upto 90% of the total inositol phosphates could 
be recovered.
The mixture of inositol phosphate standards was also 
separated using h.p.l.c. (fig. 24a). However, using this 
method the recoveries of the inositol trisphospates were 
reduced, especially that of inositol trisphosphate (%
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recovery of inositol (1)-phosphate, inositol (1,4)-bis 
phosphate, inositol (1,4,5)-trisphosphate and total 
inositol phosphates were 82.1% +/- 6.6 (S.E.M.), 68.0 +/- 
1.5 (S.E.M.), 26.1% +/- 4.8 (S.E.M.) and 58.8 +/- 1.0
(S.E.M.) respectively, n=4). Stimulation of locust ganglia 
with carbachol in the presence or the absence of lOmM 
lithium resulted in the incorporation of [3H]-inositol 
into at least two isomers of inositol trisphosphate (fig. 
24b). Highly consistent retention times of the nucleotides 
between different runs (cGMP = 17.4-17.8 min, ADP = 22.7-
22.8 min, GDP = 25.4-25.5 min, ATP = 30.9-31.0 min, GTP = 
36.9-37.2 min, for 4 separate runs), enabled 
identification of one of the inositol tris phosphate 
isomers to be inositol 1 ,4,5-trisphosphate (compare fig 
24a and b). Separation of the higher inositol 
polyphosphoinositides (inositol 1 ,3,4-trisphosphate 
36.5min), inositol 1,4,5-trisphosphate (38.5min) and 
inositol 1,3,4,5-tetrakisphosphate (42.5 min)) was 
achieved using a modified gradient elution with ammonium 
phosphate (fig. 25a). The incorporation of [3H]-inositol 
into the inositol phosphates was very much reduced in 
these experiments, and only one radiolabelled inositol 
tris phosphate peak was resolved (fig. 25b, retention time 
= 36.5 min), which corresponded with the retention time of 
the inositol 1,3,4-trisphosphate standard (fig. 25a). As 
the retention times of the nucleotides were very 
consistent between the 4 succesive runs (cGMP = 7.6-10.1 
min, ADP = 18.4-18.6 min, GDP = 22.6-22.8 min, ATP = 34.5- 
34.6 min, GTP = 40.3-40.5 min, adenosine tetraphosphate =
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45.4-45.5 min.), this inositol trisphosphate peak was 
postulated to be inositol 1 ,3,4-trisphosphate.
Elution of inositol 1,3,4,5-tetrakisphosphate from 
SEP-PAK cartridges (fig. 26) showed that the IP4 peak 
occurred at the 290mM fraction and 92% of the 
radioactivity added was recovered (compare large losses in 
the h.p.l.c. column). The separation of inositol 1,4,5- 
trisphosphate and inositol 1 ,3,4,5-tetrakisphosphate by 
gradient elution is shown in figure 27. The inositol 
trisphosphate peak, at 200mM, and the inositol
tetrakisphosphate peak at 260mM ammonium formate were 
resolved. However, there was too much overlap in the tails 
of the IP3 and the IP4 peaks to allow for the development 
of a batch elution protocol. Substantial amounts of IP3 
and IP4 were eluted together between 200 and 260mM
ammonium formate.
The time course for the incorporation of [3H]—
inositol into the inositol phosphates approached
equilibrium after approximately 60 min in both control and 
carbachol treated ganglia (fig. 28). The incorporation of 
the radiolabel became more variable at 60 and 120 min 
incubation times. In the presence of carbachol there were 
insignificant increases in labelling of inositol 




Locust ganglia were stimulated with carbachol and the 
water soluble [3H]-inositol labelled products analysed 
using high pressure liquid chromatography. Metabolism of 
the various inositol phosphate isomers, such as inositol
1,4,5-trisphosphate and inositol 1,3,4-trisphosphate 
(Irvine et al., 1985), can only be determined if these
isomers are resolved. Results presented here show that
*) , , , , ,
[H]-inositol was incorporated into at least two isomers
of inositol trisphosphates. The method used to separate
the inositol phosphates was developed from that routinely
used in investigating mammalian systems (Batty et al.,
1989; Safrany et al., 1991; Wregget and Irvine, 1987).
In the first series of studies (figs. 24a anb b), the 
major inositol phosphate peak did not co-elute with the 
inositol 1,4,5-trisphosphate standard. Experiments were 
performed in which the two isomers of inositol 
trisphosphates were resolved using standards (fig. 25a) . 
The incorporation of [3H]-inositol into the inositol 
phosphates in these experiments was lower than in the 
previous experiments (compare recovery in figs. 24b and 
25b), and only one inositol trisphosphate peak was 
observed (fig* 25b), which was identified to be the 
inositol 1 ,3,4-trisphosphate isomer.
The rate of appearance and disappearance of the two 
isomers of insitol phosphates has been followed in the rat 
parotid gland (Irvine et al., 1985). Inositol 1,4,5- 
trisphosphate was more rapidly metabolised than inositol
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1,3,4-trisphosphate. This is consistent with the. proposed 
second messenger role of inositol 1,4,5-trisphosphate. The 
levels of inositol 1 ,3,4-trisphosphate rose for several 
minutes after the disappearance of inositol 1,4,5- 
trisphosphate. The kinetics of the 1,3,4-isomer 
corresponded with the kinetics of the inositol 
trisphosphate in studies by Downes and Wusteman (1983). 
These results were consistent with the high levels of 
inositol 1 ,3,4-trisphosphate found in the locust ganglia 
after the 1 hour incubation period (fig. 24b), during 
which the levels of inositol 1,4,5-trisphosphate would 
have declined. Kinetic studies in SH-SY5Y human blastoma 
cells (Safrany et al., 1991) showed that inositol 1,4,5- 
trisphosphate was metabolised to inositol 1,3,4- 
trisphosphate via inositol 1,3,4,5-tetrakisphosphate. 
There was no conclusive demonstration of the presence of 
inositol 1 ,3,4,5-tetrakisphosphate in the locust ganglia, 
this being the probable precursor for the production of 
inositol 1,3,4-trisphosphate.
One of the major reasons for the absence of inositol
1,3,4,5-tetrakisphosphate in our preparation may have been 
the large losses of the higher inositol phosphates 
incurred in the 10 SAX h.p.l.c. column (figs. 24a and 
25a) . Whereas, up to 90% of the inositol phosphates were 
recovered from SEP-PAK columns (figs. 23, 26 and 27), only 
6 6% of the inositol 1,4-bisphosphate (fig. 24a), 21% of
inositol 1,3,4-trisphosphate, 16% of inositol 1,4,5- 
trisphosphate and 2% of the inositol 1,3,4,5-
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tetrakisphosphate (fig. 25a) were recovered from the 
h.p.l.c. column.
Another possibility was that all the inositol
1,3,4,5-tetrakisphosphate was converted to inositol 1,3,4- 
trisphosphate during the 1 hour incubation period. A time 
course for the production of inositol phosphates was 
performed in order to investigate this possibility. 
However, the loss of inositol phosphates in the h.p.l.c. 
column and the reduced incorporation of inositol 
phosphates made identification of the isomers 
impracticable.
The results presented here, using SEP-PAK columns to 
separate the total inositol phosphates (fig 28), showed 
that phosphatidylinositol turnover occurred even in 
control conditions. The labelling of inositol phosphates 
approached a plateau after 60 min. In the presence of 
carbachol stimulation occurred between 10 and at60 min, 
after which the labelling was approximately equivalent to 
control values. This relatively rapid approach to 
equilibrium was similar to that observed in the [32P]-Pi 
labelling of the polyphosphoinositides (chap 4). This 
suggested that the polyphosphoinositides derived from the 
activities of the 4- and 5-kinases were metabolised to 
produce the inositol phosphates. In the stimulated 
conditions the labelling of the inositol phosphates was 
not above that in control conditions when approaching the 
plateau, suggesting that the supply of
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polyphosphoinositides became rate limiting for 
phospholipase C activity. Experiments performed to 
investigate [3H]-inositol (chap.2) and [32P]-Pi (chap.4) 
labelling of the polyphosphoinositide pool have showed 
that this may be a possibility. There was a depletion of 
[32P]-Pi labelled polyphosphoinositides when stimulated 
with carbachol, and very little labelling was observed 
with [3H]-inositol. Between 10 and 60 min carbachol 
increased the amount of radiolabelled inositol phosphates 
suggesting the activation of phospholipase C (fig. 29).
Inositol mono-, bis-, and trisphosphates were well 
resolved using SEP-PAK columns (figs. 22 and 23). Gradient 
elution of inositol tris- and tetrakisphosphates showed a 
substantial overlap between 200 and 260mM ammonium formate 
(fig. 27). Thus a batch elution protocol could not be 
developed to determine the levels of radiolabelled
inositol 1,3,4,5-tetrakisphosphate.
The presence of the two isomers of inositol 
trisphosphate was demonstrated in these studies,
Elucidation of their eventual conversion to inositol will 
require further studies. Development of inositol 1,4,5- 
trisphosphate 5-phosphatase and 3-kinase inhibitors
(Wojcikiewicz et al., 1990; Safrany et al., 1991) will 
greatly facilitate studies aimed at understanding the 
interconversions involved. However, the inhibitors of 5- 
phosphatase and 3-kinase are analogues of inositol 1,4,5- 
trisphosphate (DL-inositol 1,4,5-trisphosphorothioate and
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DL-inositol 1,4-bisphosphate 5-phosphorothioate), and 
hence require preparation of permeabilised cells to study 
their effects. Thus, demonstration of the inositol lipid 
pathway will be required in an insect neuronal cell line 
to enable studies to be made using these inhibitors. 
Alternatively, the enzymes may be isolated in cell free 
preparations and characterised by examining the metabolic 




Gradient elution of [3H]-inositol phosphates from SEP-PAK 
cartridges.
Radiolabelled inositol phosphate standards were loaded 
onto SEP-PAK cartridges (40/*l from a stock containing 20/il 
of a mixture of inositol phosphates (0.37 KBq//Ltl) : [3H]- 
inositol 1-phosphate (IP), [3H]-inositol 1,4-bisphosphate 
(IP2) and [3H]-inositol 1,4,5-trisphosphate (IP3), 2 0 / l i1
phytate hydrosylate and 0.5 ml nucleotide mixture. The 
inositol phosphates were separated by gradient elution 
with 1 ml lOmM increments of ammonium formate (pH 4.75) 
from 10 to 300mM. Inositol mono-, bis- and tris phosphate 
peaks occurred at 40mM (14 393 d.p.m.), 130mM (15 571
d.p.m.) and 190mM (16 426 d.p.m.) respectively.
RADIOACTIVITY RECOVERED PER FRACTION




























Batch elution of [3H]-inositol phosphates from SEP-PAK 
cartriges.
A known amount of a mixture of inositol phosphates 
(approximately 40 000 d.p.m. (0.37 KBg//il) of [3H]-
inositol 1-phosphate (IP), [3H]-inositol 1,4-bisphosphate
(IP2) and [3H]-inositol 1,4,5-trisphosphate (IP3) were 
loaded onto SEP-PAK cartridges. Inositol mono-, bis- and 
trisphosphates were eluted by sequential batch elution 
with 4 x 1 ml fractions of 80mM (fractions 1-4) , 150mM
(fractions 5-8) and 240mM ammonium formate (pH 4.75) 
respectively. The elution profiles from two SEP-PAK 
columns are shown (% recovery for IP = 80.8% +/- 4.8
(S.E.M.), IP2 « 103.7 +/- 10.9 (S.E.M.), IP3 = 82.7 +/- 
6.7 (S.E.M.) and total inositol phosphates = 89.1 +/- 3.51 
(S.E.M.), n=4).
RADIOACTIVITY RECOVERED PER FRACTION
(D.P.M. / 1 ml FRACTION)















Separation of inositol phosphates using high pressure 
liguid chromatography.
Radiolabelled inositol phosphate standards ([3H]-inositol 
1-phosphate (IP^(l)r [3H]-inositol 1,4-bisphosphate 
(IP2 (1 *4 ), and [3H]-inositol 1,4,5-trisphosphate 
(IP3 (1,4,5), (0.37KBq//il)) spiked with nucleotides (cyclic 
guanine monophosphate (cGMP), adenosine diphosphate (ADP), 
guanine diphosphate (GDP), adenosine trisphosphate (ATP) 
and guanine trisphosphate (GTP)) were loaded onto a 
Partisil 10 SAX column (40/ul of stock)• Separation was 
achieved by gradient elution with ammonium formate (1 0 0% 
elution buffer* 1.7M (pH 3.7), flow rate * 1.2 ml/min) 
(fig. 24a). Radioactivity collected from 1 min (1.2ml) 
fractions were determined. The elution profiles for two 
successive separations are shown. Retention times for 
IPl(l), IP2 (1/4) and IP3 (1,4,5) were 20 min, 24 min and 35 
min respectively (% recovery for IP^(l) * 82.1% +/- 6.6 
(S.E.M.), IP2 (1,4) * 68.0% +/- 1.5 (S.E.M.), IP3 (1,4,5) * 
26.1% +/- 4.8 (S.E.M.) and total inositol phosphates =
58.8% +/- 1*0 (S.E.M.), n=4). The samples prepared from
the [3H]-inositol incorporation experiments: ganglia
treated with 0.5mM carbachol in the presence (inverted 
triangles) or the absence of lOmM lithium (filled 
circles), were injected (50/il of the IOOjliI sample prepared 
from the pooling of 20 ganglia) onto the h.p.l.c. column, 
and separated using the same protocol as for the standards 
(fig 24b). Radioactivity per 0.5 min (0.6ml) fraction was 
determined. Inositol 1,4,5-trisphosphate was identified by 
co-elution with the standard. Sucessive runs could be 
directly compared because of very consistent retention 
times obtained from the separation of the nucleotides 
(cGMP = 17.6 min, ADP = 22.7 min, GDP = 25.4 min, ATP =
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Separation of inositol trisphosphate isomers using 
h.p.l.c.
Inositol 1,4,5-trisphosphate (IP3 (1 ,4 ,5 ), inositol 1,3,4- 
trisphosophate (IP3 (1,3,4)) and inositol 1,3,4,5 
tetrakisphosphate (IP4 ) (0.37 KBq//xl, approximately 80 000
d.p.m. added) spiked with nucleotides (cyclic 
monophosphate (cGMP), guanine diphosphate (GDP), guanine 
triphosphate (GTP), adenosine diphosphate (ADP), adenosine 
triphosphate (ATP) and adenosine tetraphosphate (AtetraP)) 
were injected onto a 10SAX column (40/laI from stock). 
Separation was achieved by gradient elution with ammonium 
phosphate (100% elution buffer ■ 1.5M ammonium phosphate 
(pH 3.7), flow rate = 1 ml/min) . Fractions were collected 
from 30-50 min (0.5 min/fraction (0.5ml/fraction)), and 
the radioactivity per fraction determined. The elution 
profiles for successive runs are shown (fig. 25a). 
Retention times for IP3 (1 ,3 ,4 ), IP3 (1 ,4 ,5 ) and
IP4 (1,3,4,5) were 36.5min, 38.5min and 47.5min
respectively (% recovery for IP3 (1,3,4) = 21.2% +/- 1.6
(S.E.M.), IP3(1,4,5) = 16.0% +/- 1.0 (S.E.M.) and
IP4 (1,3,4,5) = 2.1 +/- 0.2 (S.E.M.), n=6 ). Samples
prepared from [3H]-inositol- incorporation experiments: 
ganglia treated with lOmM lithium and 0.5mM carbachol, 
were separated after injection onto the h.p.l.c. column 
(50/xl of the 100/xl sample prepared from the pooling of 24 
ganglia). Fractions were collected from 8min to 48min 
(0.5min/fraction, lml/min)• The elution profiles from two 
separate experiments are shown (from 30-50 min). Inositol
1 ,3,4-trisphosphate was identified by co-elution with a 
known standard (retention time = 36min). Retention times 
for cGMP = 9.3min, ADP = 18.6min, GDP = 22.8min, ATP = 
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Gradient elution of inositol tetrakisphosphate from SEP- 
PAK cartridges.
The inositol 1,3,4,5-tetrakisphosphate standard (25 776
d.p.m., 0.37KBq//xl) was loaded onto a SEP-PAK column in
formate form. The elution profile with increasing 
concentrations of ammonium formate (pH 4.75), from 150mM 
to 350mM in steps of lOmM per fraction, is shown. 
Radioactivity per 1 ml fraction collected was determined 
(92% of the inositol phosphate added was recovered)• The 
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Separation of inositol tris- and tetrakis phosphate using 
gradient elution from SEP-PAK columns.
A mixture of inositol 1,4,5-trisphosphate (IP3 (1,4,5) and 
inositol 1,3,4,5-tetrakisphosphate (IP4 (1 ,3 ,4 ,5 ) (34 604
d.p.m. added, 0.37KBq/jil) were loaded onto a SEP-PAK 
cartridge, and eluted with increasing concentrations of 
ammonium formate (pH 4.75) (from 150mM to 350mM in steps 
of lOmM). Radioactivity per 1 ml fraction collected was 
determined (86.5% of the radioactivity added was 
recovered). The inositol tris- and tetrakisphosphate peaks 
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Time course for the production of inositol phosphates.
After a preincubation period of 90 min, groups of 5 
ganglia were incubated in buffer A containing [3H]- 
inositol, 3mM calcium and lOmM lithium in the presence 
(filled circles) or absence (open circles) of 0.5mM 
carbachol. The ganglia were incubated for 10, 20, 40, 60 
and 120 min. On extraction of the water soluble 
metabolites (upper phase of the chloroform/methanol 
extraction mixture), the total inositol phosphates were 
separated by SEP-PAK chromatography (free inositol was 
eluted with distilled water and the inositol phosphates 
were eluted with 0.4M ammonium formate). The results 
obtained from 2 separate experiments were pooled, and the 
mean incorporation of [3H]-inositol into the inositol 
phosphates (+/- S.E.M.) in control and carbachol treated 
ganglia determined.
Figure 29.
Enhancement of PI turnover in the time course experiments.
The experiments were performed as described in fig. 28. 
The results were pooled from 4 separate experiments, and 
the incorporation of [3H]-inositol into the inositol 
phosphates determined. For each experiment, the percentage 
enhancement at each incubation time point was determined 
(treated/control multiplied by 1 0 0), and the mean 
percentage enhancement (+/“ S.E.M.) for each time point 
from 4 separate experiments was deduced (filled circles). 
The control is shown as a dotted line (100).
TIME 
(MINS)
PERCENTAGE ENHANCEMENT OF PI TURNOVER
TIME 
(MINS)
TOTAL INOSITOL PHOSPHATES (D.P.M / 5  GANGLIA)
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5). [32P]-INORGANIC PHOSPHATE INCORPORATION
INTO THE PHOSPHOLIPIDS.
5.1). INTRODUCTION
The principal substrate in the intact cell for the 
membrane bound phospholipase C is PI(4 ,5 )P2 (Drummond et 
al., 1984). This has some very interesting consequences 
for a receptor transducing mechanism. First of all, the 
polyphosphoinositides represent a very small pool that 
must be constantly replenished (Berridge, 1983), to ensure 
adequate sustrate supply under receptor activation of the 
phospholipase C. Subtle alterations of the kinases or the 
phophomonoesterases will shift the position of equilibrium 
that exists between the polyphosphoinositides, resulting 
in the change of the PIP2 pool. Any reduction in the 
levels of PIP2 will reduce the effectiveness of the 
receptor mechanism (Downes et al., 1983) and could account 
for the phenomenon of desensitisation.
Since the formation of polyphosphoinositides requires 
ATP, the agonist dependent breakdown of PI is sensitive to 
metabolic inhibitors (Downes & Wustemann, 1983). As the 
metabolism of PIP2 is linked to the onset of calcium 
signal (Berridge and Irvine, 1989), it appears that both 
entry and extrusion of calcium from the cytosol require 
energy. The consequence of this would be to prevent the 
cell from overloading itself with calcium when low levels 
of ATP prevent calcium extrusion (Berridge, 1983).
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In mammalian cells, the kinases and the 
phosphomonoesterases play key roles in the regulation of 
substrate supply. The size of the PIP2 pool will determine 
the characteristics of the IP3/Ca2+ response on 
stimulation of phospholipase C by the G/proteins via 
receptor activation. Phospholipase C may hydrolyse other 
phosphoinositides to produce DG without IP3 . Thus the 
relative sizes of the phosphoinositide pools could 
determine which of the signalling pathways predominate in 
a cellular response. Hydrolysis of PIP2 releases inositol 
-1,4,5 trisphosphate (IP3 ) into the cytosol, whilst 
leaving diacylglycerol within the plane of the membrane. 
Together these two limbs of the bifurcating signalling 
pathway provide an exceptionally versatile signalling 
mechanism (Berridge, 1987). Short term cellular responses 
such as contraction, secretion and metabolism are 
controlled by the IP3/Ca2+ limb of the pathway. The other 
limb controlled through DG, stimulates protein kinase C 
which may play a role in long term events such as growth 
and differentiation (Nishizuka, 1986). Hydrolysis of PI 
with phospholipase C would provide a mechanism by which 
1 ,2sn-diacylglycerol is produced without simultaneously 
producing IP3 . Imai and Gershengorn (1986) have shown that 
the hydrolysis of PIP2 is transient, but there is direct 
and persistent hydrolysis of PI in the rat pituitary cells 
stimulated with thyrotrophin releasing hormone.
To accommodate enormous changes in the demand for
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polyphosphoinositides imposed by the stimulation of 
phospholipase C, two types of mechanisms may operate to 
give net synthesis of PIP and PIP2 during receptor 
activation. The first is the rise in the rate of one or 
both of the kinases (PI 4-kinase, PI(4)P 5-kinase). The 
second is the drop in the activity of the 
phosphomonoesterases. This second mechanism assumes that 
substrate cycling is occurring at basal levels, at which 
the activities of the 4-kinase, 5-kinase and the 
phosphomonoesterases are being expressed. Studies using 
human erythrocytes to determine [32P]-Pi flux into the 
monoester phosphates of the polyphosphoinositides most 
clearly demonstrate substrate cycling (Muller et al., 
1986). As these cells lack a hormone linked phospholipase 
C system, the turnover observed can be reasonably 
attributed to the phosphomonoesterases.
An increase in the net synthesis of PIP2 can occur 
during stimulation. The term 'net synthesis' refers to the 
activity of PIP2 kinase minus phosphomonoesterase. 
Cultured hepatocytes stimulated with vasopressin 
demonstrate this phenomenon (Thomas et al.,1983). After
attaining isotopic equilibrium of the phosphoinositides
• , , , . with added [J*P]-Pi, the addition of vasopressin causes a
transient decrease in the levels of radiolabelled PIP2 *
reaching a minimum after 30 sec. If there was no increase
in net synthesis, the levels of [32P]-PIP2 should reach a
new steady state, due to the activity of the phospholipase
C. A mechanism by which this may occur is through the
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activation of PI(4)P -Skinase. Imai and Gershengorn (1986) 
have observed a hormone induced increase in the [32P}- 
specific radioactivity of PIP2 # on exposure of GH3 cells 
to TRH.
The mechanism by which the kinases are activated is 
uncertain. PI(4)P 5-kinase shows product inhibition 
(Downes and MacPhee, 1990), thus the removal of PIP2 could 
raise the kinase activity. Interactions with protein 
kinase C may occur as phorbol esters markedly increase the 
levels of PIP and PIP2 (Taylor et al., 1984). It has also 
been postulated that calcium may stimulate synthesis of 
polyphosphoinositides (Whipps et al., 1987), but the 
mechanism of this action was unresolved.
Substrate supply for the phospholipase C is 
determined by the activities of the kinases, the 
regulation of which will have important consequences for 
the production of second messengers. It seems that 
substrate supply is indeed under active control during 
receptor activation, but how this is achieved is unclear. 
Kinetic analysis performed on a system in which there is a 
rapid equilibration of the gamma labelled phosphate of ATP 
with the tracer, and the design of inhibitors of the 
kinases will help to elucidate the mechanism.
In view of the importance of regulation of 
polyphosphoinositide supply realised in mammalian cells, 
we have performed preliminary experiments to investigate
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the metabolism of the polyphosphoinositides in the insect 
CNS. Previous studies on the locust supraoesophageal 
ganglia (Duggan, 1987) could not demonstrate any effects 
of an acetylcholine receptor agonist, carbachol, on the 
labelling of the polyphosphoinositides with [32P]-Pi. 
Thus, one of the major aims was to show an effect with 
carbachol, in the locust (Shistocerca gregaria) 
supraoesophageal ganglia, by using a [32P]-Pi chase-in 
protocol over a 150 min time course.
5.2). METHODS.
5.2.1) PREINCUBATION.
Adult female locusts (Schistocerca gregaria) in the 
fifth instar were used in all experiments. The insects 
were anaesthetised by cooling and gassing with carbon 
dioxide and then decapitated. The supraoesophageal 
ganglion was exposed by shaving off the cuticle from the 
front of the head. To allow the tissue to recover from the 
trauma of dissection, the ganglia were preincubated for 90 
min, at room temperature in buffer containing 208mM sodium 
chloride, 3.1mM potassium chloride, 5.4mM calcium 
chloride, 2mM sodium hydrogencarbonate, lOmM HEPES, lOmM 
glucose.
5.2.2). INCUBATION.
Batches of 5 ganglia were labelled with carrier free
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[32?]-inorganic phosphate (2MBq) (Amersham International). 
The incubations were performed at room temperature for 0- 
150 mins in the preincubation buffer. In the case of 
experiments involving treatment with agonist, carbachol 
and the [3 2 ]P-inorganic phosphate were added at the same 
time. Incorporation at zero time was determined by the 
addition of 0.2 mis of trichloroacetic acid prior to 
addition of the label. The incubations were terminated by 
the removal of medium and rinsing of ganglia with ice cold 
buffer (preincubation buffer containing 3mM CaCl2 , 8mM 
K2HPO4 , 2mM EGTA but without glucose).
5.2.3). EXTRACTION OF PHOSPHOLIPIDS.
The groups of 5 ganglia were homogenised in 0.5 ml 
acidified chloroform/methanol (1:2 v/v CHC^rC^OH, 0.1 ml 
4M HC1) . After addition of 0.5 ml 4M KCl/chloroform (1:1 
v/v) the phases were separated by centrifugation (500g, 
5min) . Carrier phospholipids (200^ xg of a mixture of 
phosphatidy1-serine, phosphatidy1-inositol, phosphatidyl- 
inositol 4-phosphate, phosphatidyl-inositol 4,5- 
bisphosphate (Sigma Chemical Co.) were added to the 
extraction mixture to reduce the loss of [32P]-labelled 
phospholipids.
5.2.4) T.L.C. SEPARATION OF PHOSPHOLIPIDS.
The lower chloroform phase of the acidified 
chloroform/methanol extraction mixture contained all the
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labelled phospholipids. This phase was dried by 
evaporation under nitrogen, and then resuspended in 2 0 0/xl 
of chloroform/methanol (2:1 by vol.).
The phospholipids were analysed by two-step one­
dimensional thin layer chromatography on silica gel 
according to the method of Medh and Weigel (1989) . The 
chromatograms were developed on aluminium-backed thin 
layer chromatography plates (20 x 20 cm, No.5554, 
Kieselgel F2 5 4 , 0.2mm thickness obtained from Merck
Chemical Company). The plates were activated by heating at 
1 1 0°C for 15 min.The phospholipid extracts were then 
spotted as 8mm wide bands on different lanes 1.5cm from 
the bottom of the plate using a capillary tube. The plates 
were developed by ascending chromatography successively in 
two different solvent systems, which were equilibrated in 
solvent tanks. The first acidic solvent system was
composed of CHCI3-CH3OH-CH3COOH-H2O (55:43:3:4. by vol.). 
The development was stopped when the solvent front reached 
about 0.5 cm from the top of the plate. The plates were 
allowed to air dry before development in a second basic 
solvent composed of CHCI3-CH3OH-NH4OH-H2O (40:70:10:20. by 
vol.). The development in the second solvent system was 
stopped when the solvent front migrated a distance
equivalent to 25 % of the first solvent.
Identification of the phospholipids was achieved by 
developing the chromatograms with known phospholipid 
standards (phosphatidic acid, phosphatidylethanolamine,
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phosphatidylinositol, phosphatidylserine,
phosphatidylcholine, sphingomyelin, phosphatidylinositol 
4-phosphate, phosphatidylinositol 4,5-bisphosphate (Sigma 
Chemical Co.))* The phospholipids were visualised by 
charring at 160°C after spraying with 10 % H2SO4 , in 50% 
ethanol. The radiolabelled phospholipids were located 
using an AMBIS radioanalytic imaging system (Ray Test 
Instruments, Sheffield), which detects B emmisions. 
Identification of the phospholipids was based on co­
chromatography with.known standards.
Quantification of [32P]-Pi incorporation into the 
phospholipids was achieved by determining the 
radioactivity over the required area of the chromatogram. 
Autoradiographs of the chromatograms taken from the AMBIS 
scanner were developed for 3 hours, during which the 
disintegration in counts per min was determined (c.p.m./5 
ganglia). Results from all the incubation times (0, 15,
60, 150 min), in both control and carbachol treated
experiments were obtained from scanning of a single t.l.c. 
plate. Thus, incorporation of [32P]-Pi into the 
phospholipids could be directly compared.
5.3). RESULTS.
An autoradiograph of a chromatogram taken from the 
AMBIS scanner is shown in figure 30. The migration of 
known standards on the t.l.c. plates is reflected in their 
Rf values (fig.30). Identification of the radiolabelled
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phospholipids was based on co-chromatography with known 
standards. This showed the presence of two unidentified 
phospholipids (X, Y). Phosphatidylinositol bisphosphate 
was not adequately resolved from lipid X to allow for it 
to be quantified. The levels of [32P]-Pi incorporation 
into phosphatidylinositol (PIP), phosphatidylinositol 4- 
phosphate (PIP) and phosphatidic acid (PA) were plotted 
against incubation time (fig 31). This showed that the
levels of [32P] associated with PA increased in the
presence of 0.5mM carbachol, throughout the incubation 
period, while that in PIP decreased. The results were 
expressed as the ratio of radioactivity in PIP relative to 
that in PA (table 5) . The extent of labelling of PIP 
relative to PA increased over the 150 min incubation 
period in control conditions. This was not found to be the 
case in carbachol treated experiments, in which the label 
associated with PIP was approximately half that of PA at 
all time points.
5.4). DISCUSSION.
The metabolism of polyphosphoinositides has been 
extensively studied by using radioisotope labelling 
techniques. As with phosphatidylinositol, the
polyphosphoinositides may be labelled to isotopic 
equilibrium using [3H]-inositol or [32P]-Pi, but this can
take upto 3 days in GH3 pituitary tumour cells (MacPhee
and Drummond, 1984). Hence, stable cultured cell lines are 
essential for such studies to allow for equilibration of
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the diester phosphate of phosphatidylinositol with the 
labelled precursors. However, the polyphosphoinositide 
monoester phosphates attain isotopic equilibrium with the 
r-phosphate of adenosine trisphosphate within 70 minutes 
in hepatocytes, when there is very little radioactivity in 
the diester phosphate groups (Palmer et al, 1986; Thomas 
et al,, 1983).
The results presented here show that when the locust 
ganglia were incubated with [32P]-Pi there was a rapid 
appearance of label in the phospholipids involved in the 
inositol lipid signalling cycle (fig. 30). This labelling 
is dependent on the activities of the 4-kinase, 5-kinase 
and diacylglycerol kinase, which phosphorylate 
phosphatidylinositol, phosphatidylinositol 4-phosphate and 
diacylglycerol respectively using [32P]-labelled adenosine 
trisphosphate. There was a rapid appearance of label into 
phosphatidylinositol 4-phosphate and phosphatidic acid 
within the first 15 minutes, which tended to plateau by 
150 minutes (fig. 31). This [32P]-Pi was postulated to be 
associated with the 4 and 5 positions on the inositol ring 
of the polyphosphoinositides. The labelling of the 
monoester phosphate groups from added [32P]-Pi in 
unstimulated hepatocytes was slower than the labelling of 
the r-phosphate of adenosine trisphosphate, the immediate 
metabolic precursor (Palmer et al., 1986). However, the 
time lag which separated the labelling of the adenosine 
trisphosphate and of the phospholipids was only of a few 
minutes, suggesting that the metabolic renewal of the 4-
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and 5-phosphate groups of the hepatic 
polyphosphoinositides at near steady state was no more 
than 5 minutes. Thus, the rapid labelling observed in 
these experiments also suggests that 4- and 5-kinase 
activities are present in the locust ganglia.
Under control conditions the levels of 
phosphatidylinositol 4-phosphate labelling increased 
throughout the 150 min incubation period (fig. 31) . The 
ratio of labelled phosphatidylinositol 4-phosphate to 
phosphatidic acid also increased with time (table 5) . 
Thus, the labelling of phosphatidylinositol 4-phosphate 
due to 4-kinase was greater than the rate of labelling of 
phosphatidic acid from the activity of diacylglycerol 
kinase. This suggested that under these conditions the 
amount of diacylglycerol was rate limiting. In GH3 
pituitary tumour cells (MacPhee and Drummond, 1984) the 
addition of thyrotrophin-releasing hormone resulted in an 
increase in the levels of both diacylglycerol and 
phosphatidic acid, also suggesting that the amount of 
diacylglycerol was rate limiting in resting conditions. 
Hormone stimulated rat pituitary cells (Imai and 
Gershengorn, 1986) and hepatocytes (Thomas et al., 1983) 
showed increases in phosphatidic acid levels presumably 
from the activity of diacylglycerol kinase.
In the presence of 0.5mM carbachol, the level of 
[32p]_pi asSociated with phosphatidylinositol 4-phosphate 
decreased while that in phosphatidic acid increased (fig.
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31). The decrease in [32P]-Pi labelled
phosphatidylinositol 4-phosphate occurred at the earliest 
time point (15 min), hence recently labelled inositol 
lipids can become susceptible to agonist action. Work on 
blow fly salivary glands (Fain and Berridge, 1979) showed 
that there was a preferential breakdown of recently 
labelled [3H]-phosphatidylinositol, which occurred within 
6 min. Longer labelling periods of up to 187 min produced 
only a slight increase in [3H]-phosphatidylinositol 
breakdown. Results from our experiments suggests that 
phospholipase C is activated by the agonist, and that the 
polyphosphoinositides are broken down at a faster rate 
than their formation by phosphorylation. The increase in 
diacylglycerol production will account for the increase in 
the rate of labelling observed in phosphatidic acid. The 
incorporation of [32P]-Pi into phosphatidylinositol 
occurred at a slower rate than into the other 
phospholipids involved in the pathway, and the breakdown 
of [3 2P]-phosphatidylinositol in the presence of carbachol 
was not detected (fig. 31). Labelling of 
phosphatidylinositol with [32P]-Pi in WRK-1 cells (Koreh & 
Monaco, 1986) rat pituitary cells (Imai & Gershengorn, 
1986) and GH3 pituitary tumour cells (MacPhee & Drummond, 
1983) have shown sharp increases in the rate of 
phosphatidylinositol and phosphatidic acid labelling in 
the presence of agonists. It can be postulated that in our 
system the labelled phosphatidic acid serves mainly for 
the production of the large agonist-insensitive 
phosphatidylinositol pool. Experimental support for
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receptors triggering the hydrolysis of a small 
metabolically active inositol lipid has come from studies 
using WRK-1 rat mammary tumour cells lines (Koreh and 
Monaco, 1986. These experiments demonstrated that [32P]-Pi 
incorporation into the 1-phosphate position of the hormone 
sensitive pool of phosphoinositides require, either a long 
term incubation period (8 hours), or the presence of an 
agonist during a short term incubation (2 hours). After 
equilibrium labelling with [32P]-Pi only 15% of the 
phosphatidylinositol pool was hormone sensitive (Monaco, 
1982; Monaco and Woods, 1983). Also, the phosphatidic acid 
pool could be sufficiently large to highly dilute the 
labelled phosphatidic acid. This would lead to the 
production of an agonist sensitive phosphatidylinositol 
pool which is of low specific activity. Any changes in the 
size of this pool will not be detected.
Radiolabel ([32P]-Pi) flux into the monoester 
phosphates of the polyphosphoinositides does not 
conclusively demonstrate phospholipase C activity. Studies 
using human erythrocytes, which lack a hormone linked 
phospholipase C system, have shown that 
polyphosphoinositides undergo a rapid turnover of their 
phosphomonoester groups (Muller et al., 1986). This 
substrate cycling can be reasonably attributed to the 
activities of the 4- and 5-kinases, and the 
phosphatidylinositol 4-phosphate and phosphatidylinositol
4,5-bisphosphate phosphomonoesterases. Thus, any changes 
observed in [32P]-Pi incorporation into the
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polyphosphoinositides may be due to the changes in the 
activities of the kinases and the phosphomonoesterases.
Phospholipase C activity can be demonstrated by 
measuring the flux of [3H]-inositol through the 
phosphoinositides into the inositol phosphates (Downes and 
Wusteman, 1983). Incubation of the ganglia in the presence 
of [3H]-inositol showed that the label was incorporated 
predominantly into phosphatidylinositol. There was little 
or no incorporation into the polyphosphoinositides, as 
they constitute a small fraction of the total 
phosphatidylinositol pool (Thomas et al., 1983). The 
phosphatidylinositol pool that is rapidly turning over 
would be labelled to high specific activity ([3H]-inositol 
added 84 Ci/mmol), enabling detection of any changes in 
pool size. Any breakdown of phosphatidylinositol would 
result in the formation of inositol phosphates, thus 
giving a measure of phosphatidylinositol turnover.
All the experiments were performed in the presence of 
[3H]-inositol in the preincubation buffer. It was found 
that the phosphatidylinositol fraction was labelled, but 
could not be chased out by subsequent addition of agonist 
in inositol free conditions (fig. 20) • This suggests that 
the phosphatidylinositol fraction labelled during the 
preincubation is agonist insensitive. The presence of such 
a pool is consistent with findings from the [32P]-Pi 
labelling experiments (fig. 31).
177
However, with the label present in the incubation 
buffer, there was an increase in the labelling of the 
phosphatidylinositol pool. This can be explained by the 
presence of 3mM calcium, a higher concentration of [3H]- 
inositol and the fact that the incubations were performed 
at 25°C.
In the presence of pilocarpine and carbachol there
• , 7 i •was an agonist dependent accumulation of [H]-inositol 
phosphates (figs. 16 and 18) . The inositol phosphate
isomers were identified by co-elution with known standards
from the h.p.l.c. column. The presence of inositol 1,4,5- 
trisphosphate suggested that phospholipase C activity was 
present in the locust ganglia. There was also a 
corresponding decrease in the [3H]-inositol labelling of 
the phosphatidylinositol pool. A rapid withdrawal of lipid 
from the polyphosphoinositide pool in stimulated ganglia 
could result in the depletion of the phosphatidylinositol 
pool , which serves to replenish phosphatidylinositol 
4,5,-bisphosphate required for phospholipase C activity. 
The production of inositol phosphates would account for 
the loss in [32P]-Pi label in the polyphosphoinositides 
observed (fig. 31). This also suggests the production of 
diacylglycerol which is phosphorylated to phosphatidic 
acid. Preliminary experiments (Chapter 2) have shown that 
the carbachol enhancement of the incorporation of [3H]- 
inositol into the inositol phosphates can be inhibited by 
atropine and augmented by lithium. Myo-inositol 1- 
phosphatase is known to be inhibited by lithium ions
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(Allison et al, 1976; Sherman et al, 1981). Thus, this 
action of lithium can be used as a method for identifying 
receptors that function through the inositol lipid 
pathway, by observing an accumulation of labelled inositol 
phosphates in the presence of an agonist.
The results presented here show that locust ganglia 
will take up and metabolise [3H]-inositol and [32P]- 
labelled inorganic phosphate into acid soluble and lipid 
soluble products. Analysis of these products has 
established the presence of a functional 
phosphatidylinositol signalling cascade. The key enzymes 
involved in the inositol lipid cycle may be exploited as 
potential target sites for the development of pest control 
agents. Both the activation and inhibition of the enzymes 
will disrupt the signalling cascade. Purification of 
phospholipase C , diacylglycerol kinase,
polyphosphoinositide kinases, phosphatidylinositol
synthetase and inositol polyphosphatases from mammalian 
tissues show that each of these key enzymes is present in 
different isoforms (Kanoh et al., 1990; Downes and 
MacPhee, 1990; Rhee et al., 1989). There are at least five 
distinct isoenzymes of phosphoinositide specific 
phospholipase C's (Rhee et al, 1989), which differ from 
one another with respect to their molecular mass, charge, 
divalent cation requirement, substrate specificity and 
form of their released products. Similar purification and 
biochemical characterisation studies could be performed on 
the insect forms of these enzymes. Once these enzymes are
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isolated, potential pesticides may be screened to 
elucidate their mode of action, from which structure- 
activity relationships can be determined and new lead 
structures obtained. In vitro screens are a good indicator 
of bioactivity on a particular system. However, this type 
of data has to be used in conjunction with primary screens 
on whole organisms, as toxicity of compounds also depends 
on other factors such as accessibility. It is also 
possible to increase the selectivity of potential 
pesticides by running parallel in vitro studies based on 
isolated mammalian enzymes. One of the attractions of 
disrupting second messenger systems is that the effect of 
the drug can be amplified if it acts early in the cascade. 
The inositol lipid cycle provides the investigator with 
many potential target enzymes which regulate the supply of 
second messengers such as diacylglycerol and inositol
1,4,5-trisphosphate. This has important implications in 
the development of resistance, as targeting many sites 




The effect of carbachol on the incorporation of [32P]-Pi 
into the phospholipids.
After a preincubation period of 90 min, groups of 5 
ganglia were incubated for the required length of time (0- 
150 min.) in the presence (filled circles) or the absence 
(open circles) of 0.5mM carbachol. Phospholipid samples 
were prepared after extraction and separated by two-step 
one-dimensional thin layer chromatography. The 
radiolabelled \lipids were located and quantified using 
the AMBIS scanner. The results presented here were 
obtained from one of three experiments. Identification was 
achieved by co-chromatography with known standards (O -
origin, Rf values for unknown X = 0.05,
phosphatidylinositol4,5-bisphosphate (PIP2) ® 0.10,
phosphatidylinositol4-phosphate (PIP) 83 0.17,
sphingomyelin — 0.24, unknown Y = 0.26,
phosphatidylcholine (PC) = 0.29, phosphatidylserine (PS) = 
0.55, phosphatidylinositol (PI) = 0.63,






Quantification of [32P]-Pi incorporation into PI, PIP and 
PA.
Total radioactivity in each phospholipid band was 
determined (c.p.m. per 5 ganglia). The radiolabelled 
phospholipids from all the incubations were spotted and 
counted on a single t.l.c. plate, so that the 























50 100 150 200
TIME (MIN)
184
RATIO [32P]-Pi IN PIP V. PA
TIME (min) CONTROL CARBACHOL




Results presented as the ratio of radioactivity in PIP to 
that in PA.
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6) MUSCARINIC RECEPTORS IN INSECT NERVOUS
TISSUES
6.1) INTRODUCTION
6.1.1) ELECTROPHYS10LOGICAL EVIDENCE FOR
MUSCARINIC RECEPTORS
One source of evidence for the presence of
muscarinic-like receptors in insect nervous tissue has 
come from electrophysiplogical assay systems. Nicotinic 
and muscarinic responses could be distinguished
pharmacologically in isolated somata of locust (Locusta 
migratoria) thoracic neurones, maintained under voltage 
clamp (Benson, 1988). Muscarinic evoked responses were 
blocked by muscarinic antagonists; QNB > scopolamine > 
atropine > 4-DAMP, pirenzepine, HHSiD, (Benson, 1992). 
QNB, scopolamine and atropine are not known to be
selective for any subtype of receptor (Buckley et al, 
1989). Gallamine, methoctramine and AFDX116 are all 
thought to be M2 selective muscarinic antagonists but are 
inactive at the locust somata. These results suggest that 
these receptors have a pharmacological profile unlike that 
in vertebrates, in which pirenzepine is expected to show 
M^ selectivity and HHSiD is expected to show M3 
selectivity. Muscarinic drugs were also able to antagonise 
nicotinic responses (EC5q<1)liM) . This is not a mixed 
receptor as alpha-bungarotoxin, a nicotinic antagonist,
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has no effect. Other muscarinic agonist . such as
oxotremorine, muscarine, pilocarpine and arecoline could 
evoke an electrophysiological response. McN-A-343, thought 
to be an selective agonist (Hammer and Giachetti, 1982) 
was found to be inactive.
Other studies using dorsal unpaired median neurones 
(DUM) in adult cockroaches, Periplanata americana, for 
patch clamp recordings indicated the presence of mixed 
nicotinic/muscarinic receptors (Lapied et al., 1990). In 
these cells there was a nicotine induced biphasic 
response. This was composed of an initial fast
depolarisation followed by a slow depolarising second 
phase. The fast response was not affected by alpha- 
bungarotoxin or atropine, however the slow depolarising 
response could be blocked by both muscarinic (gallamine 
and pirenzepine) and nicotinic antagonists (d-tubocurare 
and alpha-bungarotoxin). Application of a muscarinic 
agonist, McN-A-343 (Lapied et al., 1992), produced a 
biphasic response. The fast hyperpolarisation was 
suppressed by lOnM gallamine. The slow depolarising
response was antagonised by lOnM pirenzepine, which is a 
Mi muscarinic antagonist. These results suggest that the 
pharmacological properties of the DUM neurone ACh
receptors are complex, and the functional significance of 
this is yet to be elucidated.
It has been suggested that the muscarinic-like 
receptors in insects may be involved in the negative
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feedback regulation of acetylcholine release (Breer and 
Knipper, 1984; Knipper and Breer, 1989). In these studies 
it was shown that muscarinic agonists; muscarine (10/iM) 
and oxotremorine (ImM), reduced tritiated aetylcholine 
release from insect synaptosomes from adult locusts 
(Locusta migratoria migratorioides). A muscarinic 
antagonist, atropine, enhanced ACh release. Activation of 
these muscarinic-like autoreceptors was found to decrease 
cAMP levels leading to a decrease in ACh release. Stable 
analogues of cAMP (8-bromoadenosine cAMP, butrylyladenine 
cAMP) facilitated synaptosomal release and antagonised the 
inhibitory effects of agonists. Binding studies in 
subcellular fractions showed striking differences in 
affinities for pirenzepine for the synaptosomes and cell 
bodies (Knipper and Breer, 1988). These observatons
suggested that the cell bodies contained M^-like receptors 
(high affinity for pirenzepine) and the nerve terminals 
contained M2~like receptors; on the basis that 
oxotremorine, which has a high preference for M2 
receptors, induced a reduction in cAMP levels. A more 
definitive characterisation of this presynaptic
muscarinic-like autoreceptor would require the use of 
other selective ligands such as methoctramine (M2 ),
AFDX116 (M2 ), AFDX384 (M2 ), hexahydrosilafenidol (M3 ) and 
4-DAMP (M3 ). The differences in the pharmacological
profile of the locust receptor and the vertebrate receptor 
can then be determined.
Electrophysiological studies have also suggested that
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the Insect muscarinic-like receptor may be involved in 
negative modulation of ACh release (Trimmer and Weeks, 
1989; LeCorronc and Hue, 1991). The sixth abdominal (A6) 
ganglion of the cockroach has provided a suitable
preparation for the characterisation of the presynaptic 
muscarinic-like receptor (LeCorronc and Hue, 1991). This 
preparation included a cercus, the cereal nerve XI and the
isolated giant interneurone 2 for stimulation and single
fibre recordings. It was found that an excitatory post 
synaptic potential (EPSP) could be evoked either by
elecrical stimulation of the cereal nerve XI or by 
micropressure injection of 1/M carbachol. Bath application 
of lpM arecoline, a muscarinic agonist, had no effect on 
carbachol induced potentials. Hence, arecoline does not 
act postsynaptically. However, muscarinic agonists were 
able to inhibit EPSP's evoked by presynaptic stimulation 
of the cereal nerve XI. This suggests the presence of 
muscarinic-like autoreceptors which can regulate ACh 
release, as the EPSP's evoked by the stimulation of the 
cereal nerve is thought to occur by the action of ACh on 
postsynaptic nicotinic receptors. Muscarininc M2 selective 
antagonists (lOOnM AFDX116 and lOOnM methoctramine) 
antagonised the inhibition of the EPSP's induced by 
arecoline. 4-DAMP and pirenzepine had no effect. Thus, 
this muscarinic autoreceptor shares the pharmacological 
properties of the vertebrate M2 subtype of receptor 
(LeCorronc et al., 1991).
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6.1.2). RADIOLIGAND BINDING ASSAYS IN INSECT TISSUES
Binding of radiolabelled ligands has been used 
extensively to pharmacologically characterise receptors. 
The binding of high affinity, specific, saturable
radiolabelled drugs such as quinuclidinylbenzilate (QNB) 
and N-methyl scopolamine (NMS) has been used to
characterise muscarinic receptors in the mammalian nervous 
system. Binding of [3H]-QNB has been shown to occur in the 
particulate fractions of many insects, including fruitfly 
heads (Dudai and Benbarak, 1977), housefly heads (Shaker 
and Eldefrawi, 1981), cockroach ventral nerve cords
(Lummis and Satelle, 1985) and supraoesophageal ganglia 
from two different species of locust (Breer, 1981; Aguilar 
and Lunt 1984).
Locust mAChR is found to be different from the rat 
muscarinic receptor in pharmacological properties, thermal 
stability, hydrophobic properties (Aguilar and Lunt, 1984; 
Aguilar et al, 1984; Duggan, 1987) and sensitivity to 
disulphide reducing agents (Fonseca et al., 1991). further 
investigation into the differences of the muscarinic 
receptors in insects and mammals with respect to their 
biochemical properties, may prove the receptor to be a 
potential target site for the development of pest control 
agents.
Binding of [3H]-QNB to the supraoesophageal ganglia 
of locusts, Schistocerca gregaria, has been used to
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further characterise the muscarinic-like receptor. The 
kinetic analysis of [3H]-QNB binding revealed at least two 
binding sites (Aguilar and Lunt, 1984). Duggan (1987) 
attempted to more fully characterise the muscarinic 
receptor in the locust ganglia, by performing similar 
studies to those of Aguilar and Lunt (1984), using known 
muscarinic antagonists in competition assays. Pirenzepine, 
an selective antagonist, and AFDX116, an M2 selective 
antagonist showed low affinity (Ki's in the micromolar 
range) in competition with [3H]-QNB. The assays were 
performed at InM [3H]-QNB, a concentration at which both 
the high affinity and low affinity sites would be occupied 
(Aguilar and Lunt, 1984) . This may explain the low Hill 
numbers for the antagonists used in these studies.
Recent studies (Abdullah et al, 1991) have found 
consistent differences between the affinities of 
pirenzepine, AFDX116 and 4-DAMP in various insect brains 
and mammalian brains. Binding of [3H]-QNB to the heads of 
honey bee (Apis mellifera), housefly (Musca domestica) and 
the american cockroach (Periplanata americana) showed a 
single high affinity binding site (0.47nM in honey bees, 
0.17nM in houseflies and 0.13nM in cockroach). However, 
the saturation curve was obtained using a narrow 
concentration range of [3H]-QNB (0-6nM in the cockroach 
brain, compared with 0-3OnM used in locust brain (Aguilar 
and Lunt, 1984)), and hence Abdullah et al (1991) may not 
have shown binding of [3H]-QNB to the second low affinity 
component. The three insect brain receptors showed lower
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affinity for pirenzepine and 4-DAMP, an M3 selective 
muscarinic receptor antagonist, than did the mammalian 
brain receptors (27-50 fold lower affinity for
pirenzepine, and 9-27 fold lower affinity for 4-DAMP). It
had been postulated that the cloned muscarinic receptor 
from Drosophila was the M^ subtype, based on its
activation of phosphoinositide turnover (Shapiro et al, 
1989). The studies on the insect brains including that in 
Drosophila suggested that there was a predominance of this 
subtype of muscarinic-like receptors, and that it is 
unlike the mammalian M^ subtype (mammalian M^ has a Ki of 
16nM (Buckley et al, 1989), and insects have Ki*s ranging 
from 484—900nM). The higher affinities of the insect
muscarinic receptors for 4-DAMP than pirenzepine, 
suggested that the this subtype is more like the mammalian 
M3 than M^.
We have used the supraoesophageal ganglia of the 
locust Schistocerca gregaria for studies that re-examined 
[3H]-QNB binding. In these studies competition assays were 
performed against [3H]-QNB using subtype selective 
muscarinic antagonists; 4-DAMP, AFDX116, pirenzepine and 
methoctramine. The experiments performed were similar to 
that of Aguilar and Lunt (1984) and Duggan (1987), but the 
competition assays were peformed at a concentration of 
[3H]-QNB which was approximately equivalent to the Kd of 
the high affinity site. This was to ensure that the 
binding of [3H]-QNB was predominantly to this site. 
Assuming that the competing ligand binds to a single class
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of sites, and that the radiolabelled ligand binds to two 
classes of sites, then at high concentrations of [3H]-QNB 
the competing ligand will appear to recognise two sites, 
but at low concentrations of [3H]-QNB (where binding of 
the radiolabelled ligand occurs predominantly to the high 
affinity site) the competing ligand will appear to 
recognise just one site. Duggan (1987) found that at InM 
[3H]-QNB, pirenzepine gave a statistically better two site 
fit. In our experiments, we tested whether at lower 
concentrations of [3H]-QNB, inhibition of binding with 
pirenzepine showed a higher Hill number, suggesting 
recognition of a single site. If the non-linear Scatchard 
plotfor [3H]-QNB binding (Aguilar and Lunt, 1984) was due 
to negative cooperativity, then pirenzepine would 
recognise two sites irrespective of the [3H]-QNB 
concentration at which the competition assay is performed.
6.2). METHODS FOR RECEPTOR BINDING STUDIES.
6.2.1). TISSUE PREPARATION.
Supraoesophageal ganglia were used in all 
experiments. Typically one hundred ganglia were dissected 
to obtain enough tissue for binding experiments. On 
removing the optic lobes and rinsing the ganglia with cold 
phosphate buffer (50mM disodium hydrogen orthophosphate, 
2mM EDTA, pH 7.2), the ganglia could be stored at -20°C.
6.2.2) . MEMBRANE PREPARATION.
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Purified membrane fractions (P2) were prepared from 
the 100 ganglia for binding experiments. Crude supernatant 
(SI) was obtained by homogenisation of the ganglia in 
approximately 5mls of 50mM phosphate buffer using a hand 
held homogeniser, and then in a Teflon-glass motorised 
Potter-Elvejhem homogeniser (radial clearance of 0.15mm, 
20 strokes at 500revs/min). After low speed centrifugation 
(500g, lOmins, the SI was decanted and the PI fraction was 
washed three times with ice cold buffer. The combined SI 
fractions were made upto 20ml with phosphate buffer. The 
P2 fraction was prepared by high speed centrifugation of 
the Si fraction by centrifigation (Beckman L5-50B, SW 50.1 
rotor) at 80 OOOg for 60mins. This P2 pellet was 
resuspended in lOmls of buffer, and could be stored at - 
20°C. 100 ganglia provided approximately 10-12mg of




obtained from Amersham International was used to 
characterise the muscarinic like receptors in the locust 
ganglia. Samples of membrane preparations (1ml, 100-250/xg 
protein) in phosphate buffer were incubated in the 
presence of different concentrations of [3H]-QNB for 2 
hours at 25°C. Enough protein was obtained from 100 
ganglia to perform 48 incubations. Thus, a range of 12
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concentrations of [3H]-QNB could be performed. At each 
concentration, duplicates of non-specific and total 
binding were determined. The non-specific binding was 
taken as the amount of [3H]-QNB bound in the presence of 
lmM atropine. Binding was terminated by the addition of 
cold PBS (lGmM phosphate, 140mM sodium chloride, pH 7.4). 
The samples were filtered under reduced pressure through 
glass fibre filters (type A/E, Gelman Sciences) in a 
Brandel Cell Harvester. After washing 3 times with 5mls of 
buffer, the filters were placed in scintillation vials. 
Radioactivity was determined by the addition of 5mls of 
scintillant (optiphase safe) and counting in a Packard 
scintillation spectrometer (counting efficiency 30-35%).
In competition experiments binding of [3H]-QNB to 
locust ganglia was inhibited by various muscarinic 
agonists; carbachol, muscarine, pilocarpine and 
methacholine (Sigma Chemical Co.), and antagonists; N- 
methyl scopolamine, AFDX116, methoctramine, 4-DAMP, 
pirenzepine. The radioligand concentration was kept 
constant and competed with increasing concentrations of 
unlabeled drug. As with the saturation experiments, a P2 
membrane preparation was used. The binding assays were 
performed in 1ml of buffer A containing the resuspended 
membrane preparation (100-250 ng of protein) and 0.4nM 
[3H]-QNB. Total binding was determined in the absence of 
the competing ligand. Non-specific binding was determined 
in the presence of O.lmM atropine. Incubations were 
performed at 30°C for 2 hours in a water bath. Binding was
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terminated by the addition of 5mls of cold PBS, and a 
filtration assay was performed (see above). Dissection of 
100 ganglia provided enough tissue for duplicate 
determinations of total binding, non-specific binding and 
binding at 22 concentrations of competing drugs (2-4 
drugs) per experiment.
6.2.4). DATA ANALYSIS.
6 .2.4.1)• SATURATION STUDIES.
The binding data were analysed using a computer 
assisted non-linear curve-fitting technique. The raw data 
were formatted using an EBDA program (developed by 
McPherson (1985)). Initial estimates for dissociation 
constants (Kd's), inhibition constants (Ki*s) and receptor 
concentrations (Bmax's) were obtained for analysis using 
LIGAND (Munson and Rodbard, 1980)• Estimates for multiple 
sites were made from Hill plots and Eadie-Hoftsee plots by 
a linear interpolation method.
All the curves were fitted using an iterative method. 
After the first set of estimates for the multiple sites is 
made, the actual amount of binding predicted for each 
independent site is calculated. The sets of figures are 
then added for each concentration of free ligand. Finally, 
the resultant calculated curve is compared with the actual 
data for "goodness of fit".
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In equilibrium binding experiments a model was used 
that described the binding of a single ligand to a 
heterogenous population of sites given by the equation:
Bt = (Bml*F)/(F+Kdl) + (Bm2*F)/(F+Kd2) .... + N*F
Bt = Total bound
Bm = Total number of binding sites 
F = Free ligand concentration 
Kd = Dissociation constant.
N = Non-specific binding.
As EBDA produces two SCAFIT files: one in which the 
non-specific binding is subtracted from the total binding; 
and one in which only the total binding is used, the 
theoretical non-specific binding can be determined using 
LIGAND and compared with that obtained experimentally. The 
estimate of N is based on the formal definition that N is 
the ratio of Bound/Free at infinite free concentration of 
ligand. This can be derived from expressing total binding 
as a function of the free ligand concentration, and then 
determining the non-specific binding component from the 
asymptote of the curved plot using the Scatchard 
transformation. If the non-specific binding is determined 
correctly, then the parameters estimated with and without 
the empirical non-specific bound should not differ 
significantly.
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LIGAND allows for the simultaneous analysis of 
multiple experiments, by calculation of a correction 
factor (C) for each experiment relative to the first. This 
method of calculation is used when insufficient 
information from any one experiment is obtained for 
determination of parameters for multiple sites: if only 10 
points are obtained to fit 5 parameters of a two classes 
of sites model, then the estimates of the parameters are 
essentially statistically indeterminate. However, if the 
Scatchard plots obtained from multiple experiments differ 
only in terms of their intercepts with both the horizontal 
and vertical axis, then the correction factor can be used. 
This pattern of congruent curves would be expected if Kl, 
K2 and the ratios of R1:R2:N are the same for all 
experiments, suggesting that these experiments are 
qualitatively similar, but only differ in the total amount 
of receptor present.
6.2.4.2)• COMPETITION STUDIES.
For competition analysis, the free ligand 
concentration is usually held constant while the 
concentration of the unlabeled competitor becomes the 
independent variable.
For a given concentration of the competitive 
inhibitor (I) and the free ligand (F), the occupancy 
equation is simply the extension B = (Bm*F)/ (F+Kd), where 
the Kd of the ligand is modified by the concentration of
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the competitor and its particular affinity for the 
particular binding site.
(1) Bt = (Bm*F)/(F+Kd(l+I/Ki)).
For more than one independent site,
(2) Bt = (Bml*F)/(F+Kdl(1+I/Kil))
+ (Bm2*F)/ (F+Kd2(1+I/Kd2))
Bt = Amount bound at [F]
F = free ligand concentration.
Bml = Total number of binding sites (site 1)
Bm2 = Total number of binding sites (site 2)
Kdl, Kd2 = Dissociation constants for sites 1 and 2.
Kil, Ki2 = Inhibition constants for sites 1 and 2.
The occupancy equation allows for the testing of 
various binding models. The simplest case assumes that 
both the nonlabelled and labelled drug bind to a single 
independent site, and the parameters for this model (Ki, 
Kd. Bmax and non-specific binding) can be calculated by 
goodness of fit to binding predicted in equation (1 ).
In all curve fits the saturation data for [3H]-QNB
(HOT experiments) were co-analysed with the competition 
data from each unlabeled drug (DRUG experiments). This 
multiexperiment analysis required determination of 
additional correction factors, which reduced the degrees
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of freedom but increased the data set from which better 
determinations of the parameters could be obtained. The 
residual sum of squares for each binding model was 
obtained and tested for significance using the F-test. 
More complicated models used equation (2) to determine the 
parameters.
Binding models:
1) The labelled drug and the unlabeled drug bound to an 
independent single site.
2) The labelled drug bound to two classes of sites, whilst 
the unlabeled drug bound to a single class of sites (K21 
and K22 were shared parameters).
3) Both the labelled and unlabeled drugs bound to two 
classes of sites.
6 .2.4.3). TESTING FOR SIGNIFICANCE OF EXTRA
PARAMETERS (F-TEST).
When testing between single and multiple sites, 
additional parameters are added to the model and the 
goodness of fit will tend to improve. The sum of squares 
will decrease simply because of the added flexibility of 
the model. Ultimately if there are as many parameters as 
there are data points, then the curve can theoretically 
run exactly through each point.
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There is a statistical test of whether the increase 
in the goodness of fit for a model with additional
parameters is significantly more than expected by chance 
alone. It is based on the "extra sum of squares
principle".
F = ((SS1-SS2)/(dfl-df2))/(SS2/df2)
SSI and SS2 are residual sum of squares of the deviations 
of the points to the fitted curve and dfl, df2 are the 
associated degrees of freedom (data points - parameters) 
for the original model and the model with additional 
parameters, respectively. The calculated F ratio is then 
compared to the tabulated value for the F statistic with 
(dfl - df2 ) and df2 degrees of freedom.
6.3). RESULTS.
6.3.1). [3H]-QNB SATURATION.
The specific binding isotherm at equilibrium for the 
P2 membrane fractions (fig 32) showed a consistent 
tendency to reach saturation in the range 2-5 nM [3H]-QNB. 
At higher concentrations of the radioligand (upto 50nM) a 
second binding site was observed, the saturation of which 
was not achieved, probably due to the limitations of the 
filtration assay (Bennett and Yamamura, 1985)•
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The equilibrium binding data were then analysed using 
models for a single and two class population of non­
interacting binding sites using LIGAND (fig. 33a and b) . 
Results were co-analysed from four separate experiments, 
each with twelve data points (see methods for the use of 
correction factors). There was a statistically significant 
better fit of the experimental data for the two site model 
Data obtained from the saturation curve (fig. 33a) were 
transformed and presented as a Scatchard plot (fig. 33b) . 
The dissociation constants were 0.36nM for the high 
affinity site and 39.8nM for the low affinity site. The 
estimation for the low affinity site was found to be more 
variable.
The saturation binding data from three experiments, 
which had the lowest sum of squares, were used for co­
analysis with the competition data. Statistical analysis 
of the five binding models are shown in table 6 . One and 
two site fits with non-specific binding set to zero (Nl), 
as SCAFIT files with non-specific binding subtracted 
(models 1 and 2 ) were analysed, again showed a highly 
significant difference (p<0.0001). To test whether the low 
affinity site was obtained from an incorrect determination 
of non-specific binding, a one site fit with a floating Nl 
parameter (model 3) was compared with the two site model 
with Nl fixed to zero (model 2). This showed that model 2 
was significantly different from model 3 (p<0.001), hence 
the second site was not due to non-specific binding. 
Further evidence that the non-specific binding was
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correctly determined came from comparing the theoretical 
value of Nl by analysis of SCAFIT files without non­
specific binding subtracted (fig. 34, theoretical value = 
4% +/- 0.36 (S.E.M.), n=3) , with the experimental
empirical value (fig. 32, empirical value = 3% +/- 0.80 
(S.E.M.), n=4). The theoretical value for non-specific
binding was obtained for a one site fit for [3H]-QNB 
binding with a dissociation constant of 0.25nM, a receptor 
concentration of 233 fmol/mg protein, this suggested that 
the second site and the non-specific component could not 
be distinguished in this Scatchard analysis of toal 
binding (fig. 34) . A two site model with a floating Nl 
(model 4) did not significantly differ from the two site 
model with Nl fixed to zero (model 2) , but was 
significantly different from the one site model with a 
floating Nl (model 3) (p<0.002).
The use of correction factors was justified as shown 
in table 6 . In the fifth binding model (2 sites), the 
correction factors; Cl, C2 and C3, for the three 
experiments were set to 1. When compared to model 2 (two 
site model with floating parameters Cl, C2 and C3, the F- 
test showed a highly significant difference (p<0 .0 0 0 1).
6.3.2). COMPETITION ASSAYS.
The pharmacological characteristics of the binding 
sites were investigated in experiments in which the
• • • . . . . 3effects of muscarinic ligands on the inhibition of [ H]-
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QNB binding at equilibrium were measured (tables 7 and 8 ). 
A typical inhibition curve is shown in figure 35. For each 
competitive ligand, three binding models were tested (see 
methods), and the fitted curve in this example (fig. 35) 
was obtained from co-analysis of seven experiments for a 
two site model for [3H]-QNB binding (3 experiments) and a 
two site model for 4-DAMP binding (4 experiments) (model
3) . The results shown were obtained from one of the four 
4-DAMP competition experiments co-analysed.
Displacement of [3H]-QNB binding to locust ganglia by 
five muscarinic cholinergic antagonists gave a rank order 
of potency of N-methylscopolamine > 4-DAMP > pirenzepine > 
methoctramine > AFDX116 (table 7) . For all the ligands 
tested, including the agonists (tables 7 and 8 ), model 2 
(two sites for QNB binding, one site for the competing 
ligand) was significantly different from the first binding 
model. The third binding model was not tested for N- 
methylscopolamine and methoctramine, as the iteration 
process failed using these data for such a complex model. 
However, the two site model for the unlabelled ligand, 4- 
DAMP, was shown to be significantly different from the one 
site model (Ki for the low affinity site was 120nM and Ki 
for the high affinity site was 24nM). Two site binding 
models (model 3) for pirenzepine and AFDX116 were not 
significantly different from the one site binding models 
(model 2). The Hill coefficient for pirenzepine was close 
to one (0.92 +/- 0.105 (s.e.m.), n=6 ), suggesting a single 
binding site for this ligand.
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The inhibition constants for the four muscarinic 
agonists showed lower affinities than the antagonists, the 
rank order of potency being pilocarpine > muscarine > 
carbachol > methacholine. The two site fit for muscarine 
(model 3) was significantly different from the one site 
fit (model 2, p=0.015, Ki for the low affinity site =
500/iM, Ki for the high affinity site = 37jiM) • The fitted 
curve for the two sites for muscarine binding is shown in 
figure 36. The data points were obtained from one of three 
experiments•
6.4). DISCUSSION.
Insect muscarinic-like receptor subtypes have been 
identified by their specific ligand binding properties. 
Results presented here show that [3H]-QNB binds with high 
affinity to membranes from the supraoesophageal ganglia of 
the locust.
The data analysis was performed using a curve fitting 
technique, as this method has many advantages over 
graphical methods. Scatchard plots and Eadie-Hoftsee plots 
are useful in that transformation of data from single non­
interacting sites are linear, and hence useful for initial 
estimates of the binding parameters (Munson and Rodbard, 
1980). However, using these graphical methods, small 
errors in the amount bound are propagated to both the x 
and y-axis (Bylund, 1986). Also, the magnitude of the
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error increases with increasing free radioligand 
concentration (Scatchard plot) and decreasing competing 
ligand concentration (Eadie-Hoftsee plot), which makes 
statistical analysis difficult.
Evidence for muscarinic receptor heterogeneity in 
insect tissues has come from both binding (Aguilar and 
Lunt, 1984; Duggan, 1987; Abdullah et al., 1991) and 
functional studies (Knipper and Breer, 1988; Duggan 1987). 
Functional characterisation using electrophysiological 
studies in DUM neurones of the cockroach, Periplanata 
americana, (Hue et al., 1989; LeCorronc and Hue, 1991), 
has shown the receptor to be similar to the mammalian M2 
subtype. Duggan (1987) showed that carbachol enhanced 
phosphatidylinositol turnover was inhibited by an 
subtype selective antagonist, pirenzepine. A cloned 
Drosophila receptor expressed in Y1 cells (Shapiro et al., 
1989) stimulates phospholipase C activity, this and its 
sequence similarity to the mammalian ml, m3 and m5 
receptor subtypes suggested the existence of a functional 
muscarinic-like receptor in insects.
Similar results were found in [3H]-QNB binding 
studies (fig. 33) to those obtained by Aguilar and Lunt 
(1984), in that [3H]-QNB recognised at least two classes 
of binding sites. Heterogeneity of binding sites was also 
suggested by findings that Hill coefficients of the 
various cholinergic ligands were less than one 
(scopolamine = 0.38, gallamine = 0.76, carbachol = 0.46,
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acetylcholine - 0.43 from Aguilar and Lunt, 1984). The 
data obtained from dissociation kinetics were also in 
keeping with the two populations of sites model. As the 
competition experiments were performed at 1.5nM [3H]-QNB, 
one would have expected low Hill numbers as at this 
concentration of radioligand both the low and high 
affinity sites would be occupied. Duggan (1987) showed 
that pirenzepine recognised at least two sites with 
inhibition constants of 0.15/xM and 7.5/xM, when competition 
was performed at InM [3H]-QNB (from the Hill plot Ki = 1.9 
+/— 1.1 /xM, Hill coefficient = 0.5 +/- 0.04). In our
studies performed at 0.4nM [3H]-QNB, where a higher
proportion of high affinity sites are expected to be 
labelled, pirenzepine only recognised one site (two site 
model did not give a better fit, see table 7) of 2.8/xM 
(Hill coefficient = 0.92 +/- 0.105).
Muscarinic receptor heterogeneity could also explain 
the discrepancies between Hill numbers obtained from 
studies by Abdullah et al. (1991) and those of Duggan 
(1987). In these studies Abdullah et al. 1991 argued that 
[3H]-QNB bound to one site. The competition experiments 
were performed at concentrations of the radioligand 
approximately corresponding to its Kd value, which was 
consistent with the dissociation constant of our high 
affinity site. Furthermore, the similarity of the 
inhibition constants obtained from our experiments and 
those from studies by Abdullah et al. (1991), suggest that 
the high affinity site in the locust ganglia is similar to
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the site characterised in the brains of honey bees, 
houseflies and american cockroaches (Ki's for AFDX116 
range from 1,6 to 5/iM in the insect species, table 7 
showed that the locust ganglia had a Ki value of 14/iM. 
Ki's for pirenzepine range from 0.48/xM to 0.9/uM in the 
insect brains whilst in the locust ganglia was 2.84/iM) . 
Studies on the locust brain (fig. 32; Aguilar and Lunt, 
1984) showed there was a tendency for the high affinity 
site to saturate between 2-5nM [3H]-QNB. Higher
concentrations of radioligand were required to show the 
existence of the second site. As Abdullah et al. (1991)
, , , o
obtained the binding parameters from 0-6nM [JH]-QNB, the 
establishment of the second site in these insect species 
will require further saturation at higher radioligand 
concentrations. The low affinities for pirenzepine, an M^ 
antagonist, methoctramine and AFDX116, M2 antagonists, 
suggested that the insect muscarinic receptor was unlike 
the mammalian M^ subtype. There seems to be a predominance 
of this characteristic in insects, as similar results were 
also found by Shapiro et al. (1989) in a cloned Drosophila 
receptor expressed in Y1 cells (Ki for pirenzepine = 
570nM).
The most potent of the muscarinic subtype selective 
ligands for the [3H]-QNB labelled site was shown to be 4- 
DAMP, an M3 muscarinic antagonist (Doods et al., 1987; 
Lazareno et al., 1990). This ligand recognised two sites 
(Ki of the high affinity site = 24nM, Ki of the low 
affinity site = 120nM). The high affinity site was similar
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to that described by Abdullah et al. (1991) in the three 
insect brains tested (Ki1s ranged from 19-57nM). In the 
rat sub-maxillary gland, which has a predominance of M3 
receptors, 4-DAMP binds with higher affinity (Ki 0.37nM). 
Thus, the insect muscarinic receptor appears to bind with 
lower affinities to all the ligands tested when compared 
to the mammalian muscarinic subtypes, but the order of 
potency suggests that the insect receptor is more like the 
mammalian M3 than the M^ subtype. Unlike the studies by 
Abdullah et al. (1991), our studies have shown the 
presence of another 4-DAMP binding site with a Ki of 120nM 
(fig. 35), as well as the presence of another [3H]-QNB 
binding site (fig. 33) . Therefore it seems reasonable to 
postulate that the insect species may include more than 
one muscarinic subtype, similar to the multiple subtypes 
found in the mammalian brains.
An alternative explanation for the curvi-linear 
Scatchard plots for [3H]-QNB binding is that there is a 
single population of binding sites which induce negative 
cooperative interactions. More extensive binding studies, 
such as those performed on the rat adenohypophysis (Henis 
and Sokolovsky, 1983), can help to elucidate the nature of 
the interaction. In this approach, the binding of the
labelled ligand in the presence or absence of the
unlabeled competing ligand can be predicted if the sites
show heterogeneity. The binding parameters of the both the 
labelled and unlabeled ligands have to accurately
determined. As 4-DAMP and QNB bind to the locust ganglia
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with high affinity to heterogenous sites, the above 
approach to test this may be used if the binding 
parameters of labelled 4-DAMP are elucidated in the 
absence of any competing ligand. Other experiments which 
investigate the effect on dissociation kinetics 
(Waelbroeck et al., 1986), and the effects of irreversibly 
alkylating the receptors to disrupt cooperative 
interactions (Hulme et al., 1978) can also be used. 
Dissociation kinetics from the locust ganglia suggest site 
heterogeneity of [3H]-QNB binding sites Aguilar and Lunt, 
1984).
There have been reports that [3H]-QNB, a hydrophobic 
ligand, may label more sites than [3H]-N-methylscopolamine 
(NMS), a hydrophillic ligand (Brown and Goldstein, 1986). 
[3H]-N-methylscopolamine bound to a uniform number of 
sites with affinities agreeing with those observed in 
functional studies. However, [3H]-QNB bound to 
approximately 80% more sites, and labelled the same sites 
as [3H]-NMS sites but also labelled additional sites. The 
possibility in our preparation that [3H]-QNB may label 
additional non-functional sites has to be investigated by 
comparing binding affinities using [3H]-NMS.
One of the main aims of binding studies is to compare 
affinities with functional assays. Correlations between 
structure and function may prove to be useful in 
rationally designing drugs which selectively act with high 
efficacy on target effectors (cAMP pathway, inositol lipid
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pathway, ion channels etc.)* Our attempts to functionally 
characterise the receptor by stimulating
phosphatidylinositol turnover were fraught with 
difficulties. High concentrations of agonists, pilocarpine 
and carbachol, were required to show a response and the 
variability and the size of the response made a complete 
pharmacological study impracticable.
Advantages of radioligand binding assays over in vivo 
assays include minimisation of the problems of access of 
drugs to their binding site, and their removal by uptake 
or chemical/enzymic degradation. Since the event being 
examined is the initial interaction of the ligand with the 
receptor, effects of the drug distal to the receptor are 
eliminated. In addition, compensatory effects mediated 
through other receptors or cellular processes do not occur 
in radioligand binding assays. Furthermore, quantitative 
comparisons of the affinities of various drugs in 
different tissues is relatively straightforward. 
Radioligand binding assays can be useful in determining 
classification of receptor subtypes. On the other hand, it 
is important to recognise that most organs contain a 
variety of cell types, and that different subtypes can 
mediate the same physiological response.
Inhibition of [3H]-QNB binding by muscarinic agonists 
showed low affinities relative to the antagonists (table 
8 ). This is consistent with findings from other studies 
using insects (Dudai and Ben-Barak, 1977; Aguilar and
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Lunt, 1984; Abdullah et a l . ,  1991). Binding of agonists to 
the muscarinic receptor shows complexity in their 
interactions (Birdsall et a l . ,  1978; Birdsall et a l . ,  
1980). The receptor can exist in three interconvertible 
states, the proportions of which depends upon nucleotide 
and magnesium ion concentrations (Birdsall et a l . ,  1984). 
The dissociation constants for the super high, high and 
low binding sites for carbachol in the rat cerebral cortex 
were 77nM, 1.7/xM and 125^nM respectively (Birdsall et a l . ,  
1980). Of the agonists tested only muscarine showed 
recognition of two sites (fig. 36, Ki low affinity = 
500/iM, Ki high affinity = 37.5/iM). Pilocarpine showed the 
highest potency in inhibiting [3H]-QNB binding (Ki 
19.1/zM). This was consistent with the finding from 
functional studies, in which pilocarpine was more potent 
than carbachol in stimulating phosphatidylinositol 
turnover. Thus, the receptor characterised using the 
ligand binding studies may be the same receptor which 
stimulated phosphatidylinositol turnover (see chapter 3) . 
The low affinities of the agonists for the receptor may be 
due to the absence of any super high or high affinity 
states of the receptor in the conditions employed in these 
assays. In the rat cortex (Birdsall et al., 1980), [3H]-
oxotremorine-M was found to almost exclusively bind to the 
highest affinity states of the muscarinic receptor. 
Measurement of its displacement by unlabeled 
oxotremorine-M gave the affinity and the abundance of the 
superhigh sites. Moreover, by the use of [ H]- 
oxotremorine-M to label the high affinity state of the
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cerebral cortex muscarinic receptors and . [3H]-N-
methylscopolamine to label predominantly the low affinity 
state, it is possible to get an approximate affinity of 
any ligand for either state of the receptor. The ratio of 
affinities of these compounds in these assays appears to 
correlate with the ability of compounds to stimulate 
phosphatidylinositol turnover (Freedman et al., 1990). 
This has led to the development of highly efficacious and 
potent muscarinic agonists such as L-670,207, a novel non­
quaternary oxadiazole (EC50 in stimulating
phosphatidylinositol turnover = 0.18/liM, carbachol = 220/xM, 
pilocarpine = 13/uM) . Similar studies could be undertaken 
with the receptor in the locust ganglia.
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Figure 32.
[3H]-QNB binding to locust ganglia.
Locust membranes (P2) were suspended in 1 ml of buffer 
(protein - 0.224 gm/ml) and incubated for 2hr at 25°C with 
[3H]-QNB (duplicates from 0-50nM). Binding was determined 
by filteration using a Brandell Cell Harvester. Total 
binding (filled inverted triangles) and non-specific 
binding in the presence of O.lmM atropine (open circles) 
at each [3H]-QNB concentration are shown. The percentage 
of non-specific binding was determined by regression 
analysis (4.8% (r=0. 98)). The data were obtained from one 
of four experiments (mean non-specific binding = 3.0% +/- 





























Specific binding of [3H]-QNB to locust ganglia.
The saturation curve for specific binding (total minus 
non-specific from fig. 32) is shown in figure 33a. The 
data, from one of four experiments, were tranformed and 
represented as a Scatchard plot (fig. 33b). Results 
obtained from these four experiments were co-analysed 
using a computer assisted non-linear least-squares curve- 
fitting technique (LIGAND). A two site fit (Kdl = 0.36nM, 
Kd2 = 39.8nM, Bmaxl - 300 fmoles/mg, Bmax2 = 5411
fmoles/mg) gave a significantly better fit (p < 0 .0 0 1, 
using the F-test) than a one site fit (Kd 4.3nM, Bmax = 
3550 fmoles/mg.). Two site and one site curve fits are 
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Figure 34
Theoretical determination of non-specific binding.
A Scatchard transformation of the total binding of [3H]- 
QNB to locust P2 (from fig. 32) is shown. The non-specific 
binding component was determined from the asymptote of the 
curved plot. The dashed line represents the curve fit for 
one of the experiments (Kd = 0.25nM, Bmax = 233 fmoles/mg, 
% non-specific binding - 6.4%), and the solid line
represents the curve obtained from the co-analysis of 
three experiments (Kd - 0.25nM, Bmax = 233 fmoles/mg, % 
non-specific - 4.0 +/- 0.4 (S.E.M.)).




































Inhibition by 4-DAMP of total [3H]-QNB binding.
Binding of 0.4nM [3H]-QNB to locust purified P2 membranes 
(0.143 mg of protein/ml incubation buffer) was displaced 
by increasing concentrations of 4-DAMP (O.lnM to 1/xM) • The 
binding (duplicates) from one of four experiments is 
shown. The fitted curve was obtained from co-analysis of 
three [3H]-QNB saturation and four 4-DAMP competition 
assays (two sites for [3H]-QNB (Kdl * 0.28nM, Kd2 =
13.3nM, Bmaxl = 145 fmol/mg, Bmax2 - 2905 fmol/mg) and two 
sites for 4-DAMP (Kil = 120nM, Ki2 = 24nM)).












Inhibition by muscarine of total [3H]-QNB binding.
Binding of 0.4nM [3H]-QNB to P2 membranes (0.181 mg 
protein/ml incubation buffer) was displaced with 
increasing concentrations of muscarine (ljxM to ImM) • The 
fitted curve was obtained from co-analysis of three [3H]- 
QNB saturation and three competition assays (two sites for 
[3H]-QNB (Kdl « 0.23nM, Kd2 = 8 .8nM, Bmaxl - 73 fmol/mg, 
Bmax2 = 1326 fmol/mg) and two sites for muscarine (Kil = 
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LIGAND analysis of [3H]-QNB binding to locust P2.
Specific binding of [3H]-QNB obtained from three 
experiments were tested using 5 binding models:
One site for the ligand, non-specific binding (Nl) fixed 
at 0 (model 1 ).
Two sites for the ligand, Nl fixed at 0 (model 2).
One site for the ligand, Nl floated (model3).
Two sites for the ligand, Nl floated (model4)
Two sites for the ligand, the correction factors (C2 and 
C3) and Nl fixed (model 5).
The residual sum of squares for each binding model was 
determined. Significantly better fits were obtained for 
the two site models (p < 0.0001 between models 1 and 2 
and p < 0.002 between models 3 and 4). There were no 
significant differences between models 1 and 3 and between 
models 2 and 4. This suggested that the second site was 
not part of the non-specific component. Model 5 was 
significantly different from.model 2 (p < 0 .0 0 0 1), thus 












C2 C3 SUM OF 
SQUARES
MODEL1 4.40 ---- 1707 ---- 0 2.18 1 .35 26428
MODEL2 0.38 20.0 173 3124 0 1 .82 1 .09 12660
MODEL3 1 .40 ---- 657 ---- 0.90 1 .87 1.13 18813
MODEL4 0.37 17.0 168 2746 0.16 1 .82 1 .09 12400
MODELS 0.39 69.4 229 11417 0 1 1 34350
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Table 7.
Inhibition of total [3H]-QNB binding by muscarinic 
antagonists.
Binding of 0.4nM [3H]-QNB to locust P2 membranes
(approximately 0.2 mg protein per 1 ml incubation buffer) 
was displaced by N-methyl scopolamine (NMS), 4-DAMP, 
pirenzepine (PIREN), AFDX116 and methoctramine (METHOC)
for 'n* experiments. For each drug the competition data 
were co-analysed with three [3H]-QNB saturation curves 
(dissociation constant and receptor concentration for the 
high affinity site (Kd(H), Bmax(H), and the low affinity 
site (Kd(L), Bmax(L) are shown) . From using a curve
fitting technique to obtain the least residual sum of 
squares for each binding model, the inhibition constants 
were determined for one and two sites (Ki (L), Ki (H)).
Significance was tested using the F-test (F-ratio obtained 
against a defined model »****•). Significantly better 
curve fits were obtained for two [3H]-QNB sites (compare 
models 1 and 2 for all drugs (p = 0.006-0.00001)). 4-DAMP 
recognised two sites (compare models 2 and 3 (F-ratio = 













NMS 1 1 .30 0.007 ---- 570 ----
(n=2 ) 2 0.003 2.2 0.006 0.006 5 774 5.8
3 ---- ---- ---- ---- ---- ----
4-DAMP 1 2.50 0.094 ---- 875 ---- 12.6
(n=4) 2 0.25 12.3 0.076 0.076 93 1898 5.8
3 0.28 13.3 0.120 0.024 102 2015 ****
PIREN 1 2.79 3.80 ---- 1079 ---- 10.9
(n=6 ) 2 0.30 13.3 2.84 2.84 122 2145 2.1
3 0.34 14.5 3.97 1 .25 152 2422 ****
AFDXII6 1 1 .30 ---- 12.60 ---- 596 ---- 7.0
(n=3) 2 0.29 9.9 14.1 14.1 113 1640 0
3 0.38 22.6 32.0 4.3 159 3380 ****
METHOC 1 1 .90 ---- 2.79 ---- 613 ---- 42.4
(n=5) 2 0.25 247 3.87 3.87 108 32190
3 ---- ---- ---- ---- ---- ----
Table 8.
Inhibition of total [3H]-QNB binding by muscarinic agonists.
Binding of 0.4nM [3H]-QNB was inhibited by muscarine (MUSC), 
carbachol (CARB), pilocarpine (PILO) and methacholine 
(METHA) • The results were analysed using LIGAND as for the 
antagonists (see table 7). Two site fits for [3H]-QNB (model
2 ) were significantly better than one site fits (model 1 ) (p 
ranged from 0.005 to 0.00001). When comparing models 2 and 

















MUSC 1 1.26 -- - 160 --- 712 --- 8.02
(n-3) 2 0.24 7.89 155 155 121 1766 4r * * *
3 0.23 8.77 500 37.5 113 2064 6.4
CARB 1 1.07 -- - 565 ---- 640 --- 4fk ic K
(n=2 ) 2 0.24 7.4 834 834 124 1719 6.1
3 ---- ---- ---- ---- ---- ---- ----
PILO 1 2.71 ---- 21.7 ---- 1125 ----
(n=3) 2 0.47 22.1 19.1 19.1 198 3098 26.6
3 ---- ---- ---- ---- ---- ---- ----
METHA 1 1.4 ---- 725 ---- 644 ---- *** *
(n=3) 2 0.32 10.2 770 770 133 1620 5.5
3 0.33 10.6 870 618 136 1687 0
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